Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
1Abbreviated Title: antiPDL1, antiCTLA4 & Radiation
CC Protocol: 15-C-0027 IVersion Date: 08/24/2018NCT number: [STUDY_ID_REMOVED]
Title: A Pilot Study of Immune Checkpoint Inhibition (Durvalumab with or without
Tremelimumab) in Combination with Radiation Therapy in Patients with Unresectable Pancreatic Cancer.
NCI Principal Investigator: Tim Greten, MD
Thoracic & GI Malignancies BranchCenter for Cancer ResearchNational Cancer InstituteBuilding 10, Room 3B439000 Rockville PikeBethesda, MD 20892
Phone: 240-760-6114
E-mail:tim.greten@nih.gov
Investigational Agents:    
Drug Name: Tremelimumab Durvalumab (MEDI4736)
IND Number: 123518 123518
Sponsor: Center for Cancer Research, National 
Cancer InstituteCenter for Cancer Research, National 
Cancer Institute
Manufacturer: MedImmune, Inc. MedImmune, Inc.
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
2PRÃ‰CIS
Background: 
xTremelimumab is a monoclonal antibody agai nst CTLA4. Anti-CTLA4 therapy has been 
shown to enhance anti-tumor immunity by blocking tumor-induced immune suppression of 
cytotoxic T cells. 
xDurvalumab is a human monoclona l antibody directed against PD-L1. Blockage of ligation 
between PD-L1 and PD1 induces local immune activ ation and prevent anergy and exhaustion 
of effectors T-cells. 
xSeveral studies have documented an increase in peripheral antitumor immunity following 
radiation. This effect is evidently too weak to be clinically relevant, but has the potential to 
be boosted by immune modulation.
xThe underlying hypothesis of this study is that  the effect of Immune Checkpoint inhibitor 
(Durvalumab with or without Tremelimumab) treatment can be  enhanced by radiation in 
patients with advanced pancreatic carcinoma.
Objective:
xTo determine the safety, to lerability and feasibility of immune checkpoint inhibition 
[comprising either Durvalumab alone, or combined Durvalumab and Tremelimumab] in 
combination with stereotactic body radiation therapy (SBRT) in patients with unresectable pancreatic cancer.
Eligibility:
xHistologically confirmed metastatic pancreatic cancer with primary in-situ (or locally-
recurrent) with at least 1 measurable metastatic lesion by RECIST 1.1 criteria and accessible for biopsy. There is no limit to the number of prior chemotherapy regimens received.
x3DWLHQWVPXVWEHÂ•\HDUVRID JHDQGKDYHDSHUIRUPDQFHVWDWX V(&2*Â” 1
xLife expectancy of greater than 3 months.
xAcceptable organ and bone marrow function.
xPatients must not have had standa rd of care chemotherapy, radiotherapy, or major surgery 
within the last 2 weeks prior to entering the study. For recent experimental therapies, a 28 day period of time must have elapsed before commencing protocol treatment.
xNo active or prior documented autoimmune or inflammatory disorders (including 
inflammatory bowel disease, diverticulitis with the exception of diverticulosis, celiac disease, irritable bowel disease; Wegner syndrome ; Hashimoto syndrome;  Gravesâ€™ disease; 
rheumatoid arthritis, hypophysitis, uveitis, etc.) within the past 3 years prior to the start of treatment. 
xNo active or history of inflammatory bowel di sease (colitis, Crohnâ€™s), irritable bowel disease, 
celiac disease, or other serious, chronic, gastrointestinal conditi ons associated with diarrhea. 
No active or history of systemic lupus erythematosus, Wegenerâ€™s granulomatosis.
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
3Design:
xSubjects will be assigned to 4 arms:
Anti-PDL1 (Durvalumab) in combination with radiation (8 Gy in 1 fraction)
Anti-PDL1 (Durvalumab) in combination with radiation (5 Gy in 5 fractions)
Anti-PDL1 (Durvalumab) and anti-CTLA4 (Tremelimumab) in combination with 
radiation (8 Gy in 1 fraction)
Anti-PDL1 (Durvalumab) and anti-CTLA4 (Tremelimumab) in combination with r a d i a t i o n( 5G y  i n  5f r a c t i o n s ) .
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
4TABLE OF CONTENTS
PRÃ‰CIS......................................................................................................................... .................. 2  
TABLE OF CONTENTS................................................................................................................ 4  
1 INTRODUCTION ........................................................................................................ 9  
1.1 Study Objectives ........................................................................................................... 9  
1.1.1  Primary...................................................................................................................... 9  
1.1.2  Secondary.................................................................................................................. 9  
1.1.3  Exploratory ............................................................................................................... 9  
1.2 Background and Rationale............................................................................................ 9  
1.2.1  Pancreatic cancer and the curr ent therapeutic paradigm........................................... 9  
1.2.2  Radiation treatment in pancreatic cancer:............................................................... 10  
1.2.3  Recent advances in immune-based approa ches in solid tumor malignancies......... 12  
1.2.4  Immune response following radiation, m echanism and rationale for combination 
with immune checkpoint inhibition: ..................................................................................... 13  
1.2.5  Tremelimumab........................................................................................................ 14  
1.2.6  Anti-CTLA4 therapy in pancreatic cancer.............................................................. 16  
1.2.7  Durvalumab............................................................................................................. 16  
1.2.8  Anti-CTLA4 in combination with anti-PD1/PD-L1............................................... 18  
1.2.9  Justification for dose and schedule ......................................................................... 20  
1.2.10  Rationale for study popul ation and schedule:......................................................... 23  
1.2.11  Justification for Tumor Biopsies............................................................................. 24  
1.2.12  Justification for accrual increase in Arm C2 with Amendment I ........................... 24  
2 ELIGIBILITY ASSESSMENT AND ENROLLMENT............................................. 25  
2.1 Eligibility Criteria ....................................................................................................... 25  
2.1.1  Inclusion Criteria .................................................................................................... 25  
2.1.2  Exclusion Criteria ................................................................................................... 26  
2.1.3  Recruitment Strategies............................................................................................ 28  
2.2 Screening evaluation................................................................................................... 28  
2.3 Registration Procedures .............................................................................................. 28  
2.3.1  Treatment Assignment Procedures: ........................................................................ 29  
2.4 Baseline Studies.......................................................................................................... 29  
3 STUDY IMPLEMENTATION .................................................................................. 30  
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
53.1 Study Design............................................................................................................... 30  
3.1.1  Arms A1 and A2 ..................................................................................................... 31  
3.1.2  Arms C1 and C2...................................................................................................... 33  
3.1.3  Protocol Stopping Rules ......................................................................................... 34  
3.1.4  Re-treatment............................................................................................................ 34  
3.2 Dose Limiting Toxicities ............................................................................................ 34  
3.2.1  Definition of Dose-limiting Toxicities (DLTs): ..................................................... 34  
3.2.2  Definition of Dose-limiting Toxicities (DLTs) excludes the following conditions:
35 
3.2.3  Investigational Drug Administration ...................................................................... 35  
3.2.4  Durvalumab Drug Administration .......................................................................... 36  
3.2.5  Tremelimumab Dose Administration: .................................................................... 36  
3.2.6  Monitoring of Dose Administration........................................................................ 36  
3.3 Dosing Delays............................................................................................................. 37  
3.3.1  Immune-mediated AEs (imAEs)............................................................................. 37  
3.3.2  Adverse Events of Special Interest ......................................................................... 37  
3.4 Specific Procedures for Stereotactic  Body Radiation Therapy (SBRT)..................... 38  
3.4.1  Radiotherapy administration................................................................................... 38  
3.5 Study Calendar............................................................................................................ 40  
3.6 Criteria for Removal from Protocol Therapy and Off Study Criteria......................... 44  
3.6.1  Criteria for removal from protocol therapy ............................................................ 44  
3.6.2  Criteria for Removal from Study............................................................................ 44  
3.6.3  Off Protocol Therapy and Off Study Procedure ..................................................... 45  
4 CONCOMITANT MEDICATIONS/MEASURES.................................................... 45  
4.1 Prohibited Concomita nt Medications ......................................................................... 45  
5 BIOSPECIMEN COLLECTION................................................................................ 46  
5.1 CORRELATIVE STUDIES FOR RESEARCH/PHARMACOKINETIC STUDIES 46  
5.2 NCI correlative studies ............................................................................................... 48  
5.2.1  Immune monitoring (all arms)................................................................................ 48  
5.2.2  Liver autoantibody panel for autoimmune hepatitis (AIH) .................................... 48  
5.2.3  Mandatory tumor biopsy......................................................................................... 48  
5.2.4  Details of Planned Tumor Analysis ........................................................................ 49  
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
65.3 MedImmune Planned Studies ..................................................................................... 49  
5.3.1  Pharmacokinetics .................................................................................................... 50  
5.3.2  Immunogenicity ...................................................................................................... 50  
5.3.3  T CELL Activation/ICOS expression..................................................................... 50  
5.3.4  Plasma-based assays for circulating receptors/ligands e.g. PDL1.......................... 50  
5.4 Sample Storage, Tracking and Disposition................................................................. 51  
5.4.1  Samples Managed by Dr. Figgâ€™s Blood Processing Core (BPC)............................ 51  
5.4.2  Procedures for Storage of Tissue Specime ns in the Laboratory of Pathology ....... 52  
5.4.3  Protocol Completion/Sa mple Destruction .............................................................. 52  
6 DATA COLLECTION AND EVALUATION........................................................... 52  
6.1 Data Collection ........................................................................................................... 52  
6.2 DATA SHARING PLANS......................................................................................... 53  
6.2.1  Human Data Sharing Plan....................................................................................... 53  
6.3 Response Criteria........................................................................................................ 53  
6.3.1  Definitions............................................................................................................... 54  
6.3.2  Disease Parameters ................................................................................................. 54  
6.3.3  Methods for Evaluation of Measurable Disease ..................................................... 56  
6.3.4  Response Criteria.................................................................................................... 57  
6.3.5  Duration of Response.............................................................................................. 60  
6.4 Modified immune-related re sponse criteria (irRC)..................................................... 60  
6.4.1  The modified irRC based on RECIST 1.1: ............................................................. 60  
6.5 Toxicity Criteria.......................................................................................................... 61  
7 SAFETY REPORTING REQUIREMENTS/DATA AND SAFETY MONITORING 
PLAN 61  
7.1 Definitions................................................................................................................... 61  
7.1.1  Adverse Ev ent......................................................................................................... 61  
7.1.2  Suspected advers e reaction ..................................................................................... 61  
7.1.3  Unexpected adve rse reaction .................................................................................. 61  
7.1.4  Serious..................................................................................................................... 62  
7.1.5  Serious Adverse Event............................................................................................ 62  
7.1.6  Disability................................................................................................................. 62  
7.1.7  Life-threatening adverse drug expe rience............................................................... 62  
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
77.1.8  Protocol Deviation (NIH Definition)...................................................................... 62  
7.1.9  Non-compliance (NIH Definition).......................................................................... 62  
7.1.10  Unanticipated Problem............................................................................................ 62  
7.2 NCI-IRB and Clinical Director Reporting.................................................................. 63  
7.2.1  NCI-IRB and NCI CD Expedited Reporting of Unanticipated Problems and Deaths
63 
7.2.2  NCI-IRB Requirements for PI Reporting at Continuing Review ........................... 63  
7.2.3  NCI-IRB Reporting of IND Safety Reports............................................................ 63  
7.3 IND Sponsor Reporting Criteria ................................................................................. 64  
7.3.1  Reporting Pregnancy............................................................................................... 64  
7.4 Safety Reporting CRITERIA TO THE PHARMACEUTICAL COLLABORATORS
65 
7.4.1  Reporting of serious adverse events ....................................................................... 65  
7.4.2  Overdose ................................................................................................................. 66  
7.4.3  Hepatic function abnormality ................................................................................. 66  
7.4.4  Reporting Removal from  Protocol Therapy and Off Study.................................... 66  
7.5 Data and Safety Monitoring Plan................................................................................ 66  
7.5.1  Principal Investigator/Research Team .................................................................... 66  
7.5.2  Sponsor Monitoring Plan ........................................................................................ 67  
8 STATISTICAL CONSIDERATIONS........................................................................ 67  
8.1 Cross-arm comparison ................................................................................................ 68  
8.2 Duration of radiation................................................................................................... 69  
8.3 Analysis of Immunogenicity....................................................................................... 69  
8.4 Analysis of Pharmacokinetics..................................................................................... 69  
9 COLLABORATIVE AGREEMENTS ....................................................................... 70  
9.1 Agreement Type.......................................................................................................... 70  
10 HUMAN SUBJECTS PROTECTIONS ..................................................................... 70  
10.1  Rationale For Subject Selection.................................................................................. 70  
10.2  Participation of Children............................................................................................. 70  
10.3  Participation of Subjects Unable to Give Consent...................................................... 70  
10.4  Evaluation of Benefits and Risks/Di scomforts for all participants............................. 70  
10.4.1  Risks of exposure to ionizing radiation .................................................................. 70  
10.4.2  Risk of baseline biopsy ........................................................................................... 71  
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
810.4.3  Other risks/benefits ................................................................................................. 71  
10.5  Risks/Benefits Analysis .............................................................................................. 71  
10.6  Consent Process and Documentation.......................................................................... 71  
10.6.1  Reconsent via Telephone ........................................................................................ 71  
10.6.2  Informed Consent of non-English Speaking Subjects ............................................ 72  
11 PHARMACEUTICAL INFORMATION................................................................... 72  
11.1  Tremelimumab............................................................................................................ 72  
11.1.1  Source ..................................................................................................................... 72  
11.1.2  Formulation and Preparation................................................................................... 72  
11.1.3  Stability and Storage............................................................................................... 73  
11.1.4  Administration procedures...................................................................................... 73  
11.1.5  Dose Calculation..................................................................................................... 73  
11.2  Durvalumab................................................................................................................. 74  
11.2.1  Source ..................................................................................................................... 74  
11.2.2  Formulation and Preparation................................................................................... 74  
11.2.3  Stability................................................................................................................... 75  
11.2.4  Storage .................................................................................................................... 75  
11.2.5  Administration procedures...................................................................................... 75  
11.2.6  Durvalumab Dose Preparation Steps ...................................................................... 76  
11.3  Investigational Product Preparation steps................................................................... 77  
11.4  Investigational Product Inspection.............................................................................. 77  
11.5  Investigational Pr oduct Accountability....................................................................... 77  
11.5.1  Reporting Product Complaints................................................................................ 77  
12 REFERENCES ........................................................................................................... 79  
13 APPENDICES ............................................................................................................ 83  
13.1  Appendix A:  Performance Status Criteria ................................................................. 83  
13.2  Appendix B: MedImmune Sample Prepar ation Procedures Serum- SST Tube ......... 84  
13.3  Appendix C: Modified immune-rela ted response criteria (irRC)............................... 85  
13.4  Appendix D: Dosing Modification and To xicity Management Guidelines for 
Immune-Mediated, Infusion-Related, a nd Non-Immuneâ€“Mediated Reactions 
(MEDI4736 Monotherapy or Combination Therapy With Tremelimumab or 
Tremelimumab Monotherapy) 1 November 2017 Version ........................................ 87  
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
91 INTRODUCTION
1.1 S TUDY OBJECTIVES
1.1.1 Primary
xTo determine the safety, to lerability and feasibility of immune checkpoint inhibition 
comprising either Durvalumab alone or combined Durvalumab and Tremelimumab in 
combination with stereotactic body radiation therapy (SBRT) in patients with unresectable pancreatic cancer.
1.1.2 Secondary 
xTo characterize the plasma pharmacokinetic  (PK) parameters of immune checkpoint 
inhibition in combination with stereotactic body radiation therapy (SBRT) in patients with pancreatic cancer.
xTo evaluate the 6-month overall survival rate and overall survival in patients with unresectable pancreatic cancer treated with  immune checkpoint inhibition and radiation 
therapy relative to (1) the type of immune  checkpoint inhibition and (2) quantity of 
radiation administered.
xTo estimate overall response rate (ORR) and progression free survival (PFS) by modified 
immune-related Response criteria (irRC) and Response evaluation criteria in solid tumors 
RECIST 1.1.
xTo estimate median time to progression as calculated by irRC and RECIST 1.1 in patients who progress, and duration of response in pa tients with unresectable pancreatic cancer 
during and following treatment with immune checkpoint inhibition in combination with 
stereotactic body radiation therapy (SBRT).
xTo evaluate the 6-month, 12 month and overa ll survival in patients with unresectable
pancreatic cancer treated w ith immune checkpoint inhibiti on and 5x5 radiation therapy 
(Arm C2).
1.1.3 Exploratory 
xTo measure changes in immune parameters in  the peripheral blood and tumors in patients 
with advanced pancreatic cancer treated w ith immune checkpoint inhibition and radiation 
therapy relative to (1) the type of immune  checkpoint inhibition and (2) quantity of 
radiation administered.
1.2 B
ACKGROUND AND RATIONALE
1.2.1 Pancreatic cancer and the current therapeutic paradigm 
Gemcitabine was establis hed as a cornerstone drug in pancreatic cancer in 1997 following a 
phase III study which demonstrated an improvement  in clinical benefit - a composite measure of 
clinical improvement based on th ree factors: pain, performance st atus, and weight change - and 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
10survival (a secondary endpoint in the study) co mpared to 5-fluorouracil (5-FU) in patients with 
advanced untreated pancreatic cancer. More  patients treated with gemcitabine had an 
improvement in clinical benef it response compared to those tr eated with 5-FU (23.8% versus 
4.8%; P = 0.0022). There were also (modest) gains in survival (median survival 5.65 versus 4.41; 
P = 0.0025 and 1-year survival 18% versus 2% in favor of gemcitabine). No confirmed objective 
tumor responses were observed. Once gemcitabine became the dr ug of choice in this disease,
various agents were combined with it in an attempt to build on its modest efficacy. Cytotoxic combinations of gemcitabine with capecitabine a nd platinum agents do appear to offer a small 
benefit, particularly in  patients with good performance status but this benefit has not been shown 
to be statistically significant. 
The first trial to show a survival benefit for any combination therapy in pancreas cancer and 
which led to FDA approval of this combination in the front-line treatment of pancreas cancer in 2005 was a study by Moore et al., in which 569 patients with untreated locally advanced or 
metastatic pancreas cancer were randomized to receive gemcitabine with either erlotinib or 
placebo[ 1]. There was a very modest but statistically  significant improvement in progression-free 
(HR .77, 95% CI, .64-.92; P=.004), one-year surviv al (23% v 17%; P=.023) and median overall 
survival (6.24 months v 5.91 months, HR .82, 95% CI, .69-.99; P=.038) favoring the erlotinib 
arm.
In 2011 the standard of care initial management  for patients with good performance status 
changed with the publication of a phase III tr ial comparing gemcitabine  with an intensive 
polychemotherapy regimen combining oxaliplatin, irinotecan and 5-FU/leucovorin 
(FOLFIRINOX). Although there was increased toxicity with the experimental regimen it was associated with an impressive response rate (31.6% v 9.4%) and survival advantage (11.1 v 6.8 
months) compared with gemcitabine. Despite this development there remains an unmet need for effective treatments in this disease. 
1.2.2 Radiation treatment in pancreatic cancer:
Traditionally, radiation has been employed in the management of all stages  of pancreatic cancer 
â€“ adjuvant, locally advanced (LAPC) and metastatic. The efficacy of radiation in each situation 
is a matter of controversy given an increasing awareness of the systemic biology and the efficacy data are summarized below. Neve rtheless, issues related to lo cally recurrent or progressive 
disease are a very common occurrence in pancreatic cancer given its location and an important cause of morbidity. Patients who have pain related to the loco-regional extent of their disease, derive a definite palliative benefit with the use of chemoradiation[ 2].
The foothold of chemoradiation for LAPC â€“ perha ps the setting in which it is most commonly 
used â€“ was established on the basis of a number of small clinical trials stretching back to the 1960â€™s. Two of these studies demonstrated a survival benefit for (5-fluorouracil based) 
chemoradiation compared to radiotherapy alone[ 3,4]. Two other studies from the same era 
compared chemotherapy alone to chemoradia tion. In a trial by the GITSG a benefit was 
demonstrated for chemoradiation plus chemotherapy compared to chemotherapy alone[ 5]. The 
chemotherapy consisted of streptozocin, mitomycin and 5-FU and the 1-year survival benefit was 41% compared to 19%. The other trial, by the Eastern Cooperative Oncology Group 
(ECOG), compared 5FU-chemoradiation with ch emotherapy alone, failing to demonstrate a 
survival benefit[ 6]. The value of chemoradiation in LAPC has not been quantified in the modern 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
11clinical trial era. In an attempt to address this question in the era of gemcitabine a phase III study 
was performed by the FFCD â€“ SFRO (FÃ©dÃ©rati on Francophone de CancÃ©rologie Digestive -
SociÃ©tÃ© FranÃ§aise de RadiothÃ©rapie Oncologique) in France[ 7,8]. In this study, the first for 
nearly 20 years to address this question, 119 pa tients (of a planned 176) were randomized to 
undergo induction chemoradiation (with 5-FU 300 mg/m2/24 h as a continuous infusion, day 1â€“5
every week and cisplatin, 20 mg/m2/d, day 1â€“5 at week 1 and 5) followed by gemcitabine, or 
straight to chemotherapy with  gemcitabine. The study was stopped prior to its full enrollment 
due to an inferior survival in the chemorad iation group (median survival 8.6 v 13 months, p = 
0.014). Although this study is not a definitive an swer to the question of chemoradiation, it does 
add to the growing body of opinion that the benef it of chemoradiation in LAPC is most likely 
confined to a carefully selected subgroup. R ecently a similar study was presented comparing 
gemcitabine alone (1,000 mg/m2weekly x 3 every 4 weeks for 7 cycles) to chemoradiation (RT 
50.4 GY in 28 fractions plus gemcitabine 600 mg/m2weekly x 6) followed by 5 cycles of 
gemcitabine alone (1,000 mg/m2weekly x 3 every 4 wks.)[ 9]. The trial was stopped early due to 
slow accrual (N = 74, out of a planned 316). The me dian survivals were 9.2 months (95% CI 7.8 
- 11.4) and 11.0 months (95% CI 8.4 - 15.5) for the two arms respectively (p=0.044). 
In an interesting attempt to tease out the be nefit of chemoradiation, investigators from the 
Groupe Coordinateur Multidisciplinaire en On cologie (GERCOR) perf ormed a retrospective 
analysis of 181 patients with locally advanced PAC who had been entered on prior prospective 
GERCOR studies and who had been offered chemoradiation (at the discretion of the 
investigator), but only if they had rema ined metastasis-free after a 3-month period[ 10]. For those 
patients who were metastasis-free after initial chemotherapy, there was a survival advantage if they proceeded to chemoradiation compared to those who continued with  chemotherapy alone 
(median OS 15.0 and 11.7 months, respectively; P= .0009). These data suggest that radiation 
may offer a survival benefit in selected patients who have disease that is proven to be localized after a test of time. This is an attractive concept as it allows patients to be selected for chemoradiation whilst receiving systemic therapy for their disease and also gives time for the logistics of the chemoradiation to be organize d. The underlying principle is that patients who 
progress systemically prior to chemoradiation woul d in all likelihood not have derived a survival 
benefit from chemoradiation anyway and is in ma nner analogous to patients who develop disease 
progression during neoadjuvant therapy for resect able disease, who would presumably not have 
benefitted from surgery had it gone ahead. 
The same investigators have performed a prospective phase II study based on the same concept, 
i.e. induction chemotherapy (with gemcitabine and oxaliplatin) for a 2-month period, followed 
by chemoradiation if the patient has remained metastasis-free[11]. In this study fifteen percent of 
patients did not go on to receive chemoradiation, which is lower than the 29% rate described in 
their earlier report. The authors speculate that this may have been due to the shorter period of induction (2 v 3 months) and the lower amount of chemotherapy administered. The median 
overall survival achieved in this study was 12.2 mont hs which is in the upper level of the survival 
rate range reported for patients with LAPC. Of course, this attractive concept needs to be assessed definitively and a phase III randomized st udy is currently being performed by the same 
group.
In our proposed study, we are proposing the us e of radiation in a patient population who 
(metastatic pancreatic cancer) who may not othe rwise receive it. Given the proportion of patients 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
12with this disease who go on to develop local symptoms we believe that this alone justifies its 
inclusion as part of the therapeutic regimen. Whilst the traditional RT schedule for this disease has been over a prolonged course and in comb ination with a chemotherapeutic (5FU or 
gemcitabine) as radiosensitizer, modern RT techniques allow for a hypofractionated course without chemotherapy. This will minimize the dur ation of RT and will make it easier to combine 
with anti-CTLA4 treatment. Stereotactic body radi ation therapy (SBRT) has been shown to be 
safe and effective in locally-advanced pancreatic cancer[ 12].
1.2.3 Recent advances in immune-based appr oaches in solid tumor malignancies
The past two years have seen progress for immune-based approaches in solid tumor malignancies, with FDA approvals for these approaches in prostate cancer and melanoma[ 13-
15]. In melanoma, anti-CTLA4 therapy has been s hown to demonstrate a median survival benefit 
in two separate phases 3 studies, both of which were associated w ith long-term disease control in 
approximately one-fifth of patie nts. More recently, anti-PD-L1 therapy has demonstrated a 
similar degree of clinical activity not only in melanoma and kidney canc er but also in lung 
cancer, a disease type previously thought to be refractory to an immune approach[ 16].
Appreciation of the role in developing tumors of immune-evasion has also been evidenced by its inclusion as one of the (updated) hallmarks of cancer[ 17].
Both anti-PD-L1 and anti-CTLA4 therapy enhance anti-tumor immunity by blocking tumor induced immune suppression of cytotoxic T ce lls and therefore exaggerating the immune 
activation that must first occur of its own accord and is thought to be the result of tumor neo-antigens formed as a tumor progresses. The role of CTLA4 and anti-PD-L1 in inhibiting T-cell activation is represented in the schematic in Figure 1 below. 

Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
13Figure 1 CTLA-4 and PD-1/PD-L1 are negative regulators of T cell activity in lymphoid tissues and tumor 
microenvironment respectivel y. Anti-CTLA-4 antibodies, such as ipilimumab and tremelimumab, block 
CTLA4 and, thereby, results in acti vation of T-cells. Blockade with antibodies of PD-1 or PD-L1 (e.g., 
nivolumab and Durvalumab) augments immune response in peripheral tissues. (Gelao. Toxins 2014[ 18])
CTLA4-mediated immune checkpoint is induced in T cells at the time of their initial response to 
antigen. The level of CTLA4 induction depends on the amplitude of the initial T cell receptor 
(TCR)-mediated signaling. After the TCR is triggered by antigen encounter, CTLA4 is 
transported to the cell surface. The stronger the stimulation through the TCR (and CD28), the 
greater the amount of CTLA4 that is deposited on the T cell surface. Therefore, CTLA4 functions as a signal dampener to maintain a consistent level of T cell activation in the face of widely varying concentrations and affinities of ligand for the TCR. The PD-1/PD-L1 inhibitory receptor pathway plays an important role in  modulating T-cell activity in the tumor 
microenvironment during the effector phase of immune response. PD-1 is a surface receptor 
member of the B7-CD28 superfamily. The liga tion of PD-1 with PD-L1 causes the negative 
regulation of T-cells resulting in anergy, exhaustion and death of effector T-cells. Blockade with antibodies of PD-1 or PD-L1 (e.g., nivolumab and Durvalumab) results in the continuing activation of T-cells and enhances anti-tum or immune activity. 
While these studies demonstrate the potential for anti-CTLA4 or anti PD1/PD-L1 therapy to enhance the anti-tumor immune response already in  process, it clearly does not work in the 
majority of patients. The question is whether the initial immune activation stage can be enhanced. The potential for this was intriguingly de monstrated in a recent publication by Postow 
et al who reported a case of the so-called abscopal effect in a patient with melanoma treated with ipilimumab and radiotherapy[ 19]. Temporal associations were  noted between tumor shrinkage 
and antibody responses to the cancer-testis an tigen NY-ESO-1 in addition to changes in 
peripheral-blood immune cells, and increases in antibody responses to other antigens after a patient being treated with anti-CTLA4 was then treated with external beam radiotherapy. The enhanced effect from anti-CTLA4 seen after radia tion appears to have been due to a boost effect 
of tumor cell death and immune stimulation following deliverance of a tumor antigen load. It is this enhanced effect we wish to study in the context of radiation treatme nt for pancreatic cancer.
1.2.4 Immune response following radiation, mech anism and rationale for combination with 
immune checkpoint inhibition:
Several studies have documented an increase in peripheral antitumor immunity following radiation. It may even be the cas e that an intact immune system is critical for RT to exert its 
maximal antitumor effect. This was suggested by a mouse model of melanoma in which single-fraction RT slowed the growth of small tumors  in immune-competent but  not immune-deficient 
mice[ 20]. The same authors also showed that in an animal model of breast cancer ablative RT of 
a primary tumor prevented the growth of metastatic tumor colonies in the lung, an effect that was dependent on the presence of CD8+ T cells. Ot her animal models have  likewise displayed 
augmentation of systemic antitumor immunity following local RT[ 21-23].
The underlying mechanism appears to be that RT-induced necrosis results in the exposure of tumor antigens, thereby increasing the pool of intracellular peptides for cross-presentation[ 24].
Radiation has been shown to augment MHC-I expr ession by tumors, which is critical for antigen 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
14recognition by cognate CD8+ TCRs and which is known to be diminished in tumors as one of 
their escape mechanisms[ 25]. Tumor antigen processing and presentation on MHC-I molecules 
is dependent on expression of a protein called high mobility group box 1 (HMGB-1), a â€œdanger 
signalâ€ which binds toll-like receptor 4 (TLR4) on dendritic cells. In a pivotal study Apetoh et al. demonstrated that RT causes dying tumor cells to release HMGB-1[ 26]. Intriguingly these 
authors also reported that in breast cancer patie nts undergoing radiation and chemotherapy the 
presence of a polymorphism in TLR4 â€“ and by implication a less immunogenic drug-induced cell death â€“ was associated with an inferior prognosis. Similarly, in esophageal cancer patients preoperative chemoradiation has been shown to increase cancer-specific T cell responses and serum levels of HMGB-1, the latter of which correlated with overall survival[ 27].
Despite this, only a few cases of spontaneous de crease of metastases following radiation â€“ the 
so-called abscopal effect â€“ have been reported[ 28-30]. This is presumably because the immune 
response by itself is too weak to be clinically significant. A number of studies have tried to boost 
this anti-tumor immune response following ablation by combining with an immunomodulatory agent: 
-Zeng et al. tested the combination of anti-PD-1 immunotherapy with stereotactic 
radiosurgery in a glioblastoma model. Im proved survival was demonstrated with the
combination treatment compared with either modality alone. Long-term survival was seen only in the combined treatment arm, with a fraction (15%-40%) of animals alive at day 180+ after treatment. There was also increa sed tumor infiltration by cytotoxic T cells 
and decreased regulatory T cells in the co mbined treatment group compared with the 
single modality arms[ 31].
-Dewan et al. evaluated RT in combination with anti-CTLA-4 antibody in two separate 
mouse models of breast and colorectal carcinoma[ 32]. The authors found that the 
combination of anti-CTLA4 and RT achieved enhanced tumor response at the primary 
site (compared to either modality alone). in addition to an abscopal effect. (Interestingly 
this only occurred in fractionated versus sing le-dose RT). The frequency of CD8+ T cells 
showing tumor-specific IFN-gamma production was proportional to the abscopal effect. 
-Demaria et al. tested the combination of RT  with CTLA-4 blockade in a breast cancer 
model (4T1) known to be poorly immunogenic[ 33]. Anti-CTLA4 alone did not have any 
effect on primary tumor growth or survival. RT was able to delay the growth of the 
primary irradiated tumor, but in the absence of anti-CTLA4 survival was similar to that of control mice. In contrast, mice treated with RT + anti-CTLA4 had a statistically significant survival advantage. The increased survival correlated with inhibition of lung metastases formation and required CD8+.
1.2.5 Tremelimumab
Tremelimumab (formerly CP-675,206) is a human IgG2 mAb directed against CTLA-4. Upon T 
cell activation, CTLA-4 expressi on acts to dampen immune responses by CTLA-4 relocation to 
the cell surface in order to modulate and eventually switch off T cell activation.
Tremelimumab blocks the inhibitory effect of CTLA-4, and therefore enhances T cell activation. 
The binding of CTLA-4 to its target ligands (B7.1 [CD80] and B7.2 [CD86]) provides a negative regulatory signal, which limits T cell activation. Blockade of B7 binding to CTLA-4 by anti-
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
15CTLA-4 antibodies also results in markedly enhanced T cell activation and antitumor activity in 
animal models, including killing of  established murine solid tumo rs and induction of protective 
antitumor immunity. Tremelimumab is specific for human CTLA-4, with no cross-reactivity to related human proteins.
Anti-CTLA-4 therapy has recently been shown to be a validated approach to cancer treatment by 
the approval of the mAb ipilimumab in 2011 for the treatment of patie nts with metastatic 
melanoma, based on 2 Phase III studies that dem onstrated a significant improvement on OS in 
the first- and second-line settings. In general, tumor response rates to anti-CTLA-4 therapy are low; approximately 10%, but th e durable response or stable di sease seen in a proportion of 
patients can lead to a significant prolongati on of OS. In a large, single-arm Phase II
Tremelimumab trial in patients with advanced refractory and/or relapsed melanoma, objective responses (primary endpoint) following Trem elimumab 15 mg/kg Q3M were observed in 16 of
241 (6.6%) patients (9 &,>@5HVSRQVHVZHUHGXUDEOHSUHVHQWDWÂ•PR QWKVIURP
enrollment) in all 16 responders. A Phase III , open-label, randomized study comparing
Tremelimumab 15 mg/kg Q3M (Arm A) to either dacarbazine or temozolomide (Arm B) in patients with advanced melanoma was terminated following a pre-specified interim futility analysis. At the time of databa se lock, the median OS (prima ry endpoint) was 12.58 months in 
Arm A and 10.71 months in  Arm B (HR=1.1416, p=0.1272).
The efficacy data for tremelimumab are consistent with those of the related â€“ and FDA-approved- anti-CTLA-4 antibody ipilimumab: tumor response rates are generally low 
(approximately 10%) but the responses obser ved are generally durable. The ipilimumab 
melanoma data clearly demonstrat e that a small proportion of patie nts with an objective response 
and a small impact on PFS rates can lead to a significant prolongation of OS, and support 
development of this class of agent in other tu mors. Although Phase II and Phase III studies of 
tremelimumab in metasta tic melanoma failed to meet the primary endpoints of response rate and 
OS, respectively, the data clearly indicate activ ity of tremelimumab in melanoma, with response
rates and median OS similar to those observed in the ipilimumab trials.
Tremelimumab has been evaluated in a number of  clinical studies â€“ and over 1000 patients â€“ and 
demonstrated manageable toxicities[ 34,35]. The efficacy data for Tremelimumab are consistent 
with those of the related anti-CTLA-4 antibod y ipilimumab: tumor response rates are generally 
low (approximately 10%) but the responses observed are generally durable. The ipilimumab 
melanoma data clearly demonstrat e that a small proportion of patie nts with an objective response 
and a small impact on PFS rates can lead to a significant prolongation of OS, and support 
development of this class of agent in other tu mors. Although Phase II and Phase III studies of 
Tremelimumab in metast atic melanoma fa iled to meet the primary endpoints of response rate and 
OS, respectively, the data clearly indicate acti vity of Tremelimumab in melanoma, with response 
rates and median OS similar to those observed in the ipilimumab trials.
The AE profile of Tremelimumab is consistent with that of ipilimumab, and with the 
pharmacology of the target. To date, no tumor type or stage appears to be associated with unique AEs (except for vitiligo, which appears to be confined to patients with melanoma). Events reported at a frequency RIÂ•DQGDVVHVVHGE\WKHLQYHVWLJDWRUDVUHODWHGWRWUHDWPHQW OLVWHGLQ
descending order of frequency) were diarrhea, rash, pruritus, fatigue, nausea, vomiting, anorexia, headache, abdominal pain, and colitis.
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
161.2.6 Anti-CTLA4 therapy in pancreatic cancer
A small number of studies have evaluated the stra tegy of anti-CTLA4 treatment in pancreatic 
cancer, though not in combination with radiation. Recently, Le et al evaluated ipilimumab in 
combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in patients with previously trea ted pancreatic cancer[ 36]. Three patients treated with the combination had 
evidence of prolonged disease stabilization (3 1, 71, and 81 wk.) and 7 patients experienced 
CA19-9 declines. In 2 of these patients, disease stabilization occurred after an initial period of progression. The median overall survival (OS)  (3.6 vs. 5.7 mo., hazards ratio: 0.51, P = 0.072) 
and 1 year OS (7 vs. 27%) favored the combinati on of vaccine plus anti-CTLA4. Similar to prior 
ipilimumab studies, 20% of patients in each arm had grade 3/4 immune-related adverse events. 
Among patients with OS > 4.3 months, there was an  increase in the peak mesothelin-specific T 
cells (P = 0.014) and enhancement of the T-cell re pertoire (P = 0.031) all of which suggested that 
checkpoint blockade in combination with GVAX has the potential for clinical benefit.
Investigators within NCI performed a phase II trial evaluating the efficacy of Ipilimumab for 
advanced pancreatic cancer. In that study subjects with locally advanced or metastatic pancreas 
adenocarcinoma with measurable  disease, good performance stat us, and minimal comorbidities 
were treated with Ipilimumab (3.0 mg/kg every 3 wk.; 4 doses/course) for a maximum of 2 
courses. Twenty-seven subjects were enrolled (metastatic disease: 20 and locally advanced: 7) with median age of 55 years (27 to 68 y) an d good performance status (26 with Eastern 
Cooperative Oncology Group performance st DWXV WR7KUHHVXEMHFWVH[SHULHQFHGÂ•JUDGH
immune-mediated adverse events (colitis:1, encephalitis:1, hypohysitis:1). There were no responders by response evaluation criteria in solid  tumors criteria but one subject experienced a 
delayed response after initial progressive disease. In this subject, new metastases after 2 doses of Ipilimumab established progressive disease, but continued administration of the agent per protocol resulted in signific ant delayed regression of the primary lesion and 20 hepatic 
metastases. This was reflected in tumor markers normalization, and clinically significant improvement in performance status. Overall the experience in this study suggests that while single agent Ipilimumab at low, (3 mg/kg) dose was ineffective for the treatment of advanced pancreas cancer the activity hinted at in the one  patient who experienced a significant delayed 
response suggests that this approach deserved fu rther exploration, for example by increasing 
dose or combining with other immune-stimulatory approaches.
1.2.7 Durvalumab
Durvalumab is a human monoclonal antib RG\ RI WKH LPPXQRJOREXOLQ * NDSSD ,J*È›
subclass. The fragment crystallize (Fc) domain of Durvalumab contains a triple mutation in the 
constant domain of the IgG1 heavy chain that reduces binding to the complement component 
C1q and the Fc gamma receptors responsible fo r mediating antibody dependent cell mediated 
cytotoxicity[ 37]. Durvalumab inhibits binding of programmed cell death ligand 1 (PD-L1) to 
programmed cell death 1 (PD- 1) and CD80. Programmed death ligand 1 (PD-L1) is a
transmembrane immunoreceptor which controls peripheral tolerance by inhibiting effectorfunctions of T lymphocytes trough engagement with PD-1 receptor on antigen presenting cell. 
Anti-PD-L1 antibodies directly target tumor cells and expected to have less adverse events in 
comparison with anti-PD-1 antibodies that target  effector T-cells in tumor microenvironment.).
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
17Blockade of PD-L1 with Durvalumab expected to  relieve PD-L1-mediated  suppression of human 
T-cell activation within tumors. In a xenograf t model, Durvalumab inhibited human tumor 
growth via a T-cell-dependent mechanism. PD-L1 is upregulated in a broad range of cancers 
with a high frequency, with up to 88% expression in some indications. In a pancreatic cancer, the 
tumor cell expression of PD-L1 is associated with reduced survival and an unfavorable 
prognosis. In the preclinical studies effect of  Durvalumab on the growth of human pancreatic 
adenocarcinoma tumor cell lines in mice was investigated. Durvalumab significantly inhibited growth of the pancreatic adenocarcinoma cell line, HPAC, by up to 74% as compared to the isotype-control antibody. 
In the clinical studies to date more than 220 s ubjects have been enrolled and treated. Currently 
Durvalumab investigated in 5 ongoing clinical studies (2 employing Durvalumab as 
monotherapy and 3 as combination therapy). The majority of the clinical data are from Study 
CD-ON-Durvalumab-1108, which has the greatest number of enrolled subjects. This is a Phase 
1, multicenter study in adult subjects with advanced solid tumors refractory to standard therapy 
(N = 198 subjects). Partial efficacy data av ailable for CD-ON-Durvalumab-1108 based on 
Response Evaluation Criteria in Solid Tumors  (RECIST). Of the 177 subjects treated with 
Durvalumab 10 mg/kg Q2W, 77 have had at leas t one post-baseline dis ease assessment. Four 
subjects (5.2%) had a best response of PR. In addition, 36 subjects (46.8 %) had stable disease.
Of the 177 subjects treated with 10 mg/kg Q2W,  121 subjects (71.8%) had at least 1 treatment-
emergent AE (Table 5.3.1.3- RIFXUUHQW,%HGLWLRQ7KHPRVWIUHTXHQWO\UHSRUWHGÂ• RI
subjects) TEAEs (all grades) were fatigue, dysp nea, nausea, constipati on, and decreased appetite. 
The majority of these TEAEs were Grades 1 to 2 in severity and manageable by the general 
treatment guidelines as described in the current  Durvalumab study protocols. Grade 3 or higher 
TEAEs were noted in 44/177 subjects (24.9%). These events occurring in more than 1 subject included dyspnea (9 subjects); dehydration (4 subjects); abdominal pain, fatigue, sepsis, 
increased aspartate aminotransferase, and increased gamma-glutamyltransferase (3 subjects); and hyperbilirubinemia, back pain, pulmonary embolism, respiratory failure, and hypotension (2 subjects each). The Grade 3 or higher TEAEs that were considered by the investigator to be related to Durvalumab were increased aspa rtate aminotransferase  (2 subjects), and 
hypothyroidism, vomiting, fatigue, infusion -related reaction, troponin, dehydration, and 
arthralgia (1 subject each). Treatment-related, TEAEs were reported for 52/177 subjects (29.4%). The most frequently reported (2 or more subjects) treatment-related TEAEs (all grades) were fatigue (11.3%); nausea (5.6%); dyspnea (4.0%); diarrhea, vomiting, and pyrexia (3.4% each); 
myalgia (2.8%); hypothyroidism, decreased appet ite, dizziness, cough, pr uritus, and rash (2.3% 
each), abdominal pain, increased aspartate aminotransferase, and arthralgia (1.7% each); and 
asthenia, influenza-like illness, edema peripheral, increased alanine aminotransferase, headache, and dry skin (1.1% each). No DLTs have be en reported. The SAEs reported for 3 or more 
subjects were dyspnea, dehydration, abdominal pain, and sepsis. Three subjects had treatment-
related SAEs: arthralgia (1 subject); pleural effusion and pneumonitis (both in the same subject); and muscular weakness and â€œrule out cord compressionâ€ (verbatim term) (both in the same subject). For the entire study population, none of the deaths or TEAEs resulting in discontinuation of Durvalumab in this study were  considered related to Durvalumab treatment. 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
181.2.8 Anti-CTLA4 in combination with anti-PD1/PD-L1.
Durvalumab and tremelimumab data: There is a sound rationale fo r evaluating the combination 
of Durvalumab and tremelimumab for the treatment of advanced malignancies. The mechanisms 
of activation of known activity sites for CTLA-4 and PD-L1 are non-redundant, suggesting that 
targeting both pathways may have additive or synergistic activity[ 38].
The Combination therapy (dual targeting of PD -L1 and CTLA-4) has been shown in preclinical 
studies with a mouse model to cause tumor regression of colorectal cancer. To date, 2 clinical 
trials employing Durvalumab as combination therapy with tremelimumab in adults with advanced non-small cell lung cancer (NSCLC) a nd advanced solid tumors was initiated with 
preliminary efficacy data for combination still pending. Nivolumab plus ipilimumab clinical data: Results of nivolumab administered in combination with ipilimumab for stage III or IV measurable, unresectable melanoma have recently been reported. At the maximum tolerated combination doseâ€”1mg/kg anti-PD1 plus 3 mg/kg ipilimumab every three weeks administered concurrently, 53% of patients ha d an objective response, all w ith tumor reduction of 80% or 
more. Adverse effects occurred in 53% of patients and were similar in quality and intensity to those observed with ipilimumab monotherapy. Se quential administration resulted in a lower 
response rate and lower toxicity rate. With rega rd to biomarkers previously associated with 
responses to anti-CTLA4 or anti-PD1, investigat ors evaluated PD-L1 expression in tumors and 
absolute lymphocyte counts and looked for relati onships with response.  In patients treated 
concurrently, 6/13 patients with  PD-L1+ tumors responded whereas 9/22 patients with PD-L1â€“
tumors responded (P>0.99 by Fisherâ€™s exact). In terestingly however, in the sequential group, 4/8 
patients whose tumors were PD-L1+ responde d 6 whereas only 1/13 who had PD-L1- tumors 
responded. Absolute lymphocyte counts at weeks 5-7 were not associated with response in this 
study.
In the ongoing Tremelimumab + Durvaluma b combination study D4190C00006 in advanced
NSCLC patients, preliminary AE data as of 18Feb2014 available for 7 subjects treated with 
Durvalumab (3 or 10 mg/kg) and tremelimumab (1 mg/kg) in this study showed that the only 
TEAE reported for more than 1 subject was fatigue  (3 subjects). All TEAEs were Grade 1 or 2 
with the exception of one Grade 3 event of increased aspartate aminotransferase. None were considered by the investigator to be related to treatment with the exception of one event of increased amylase (Grade 2), one event of increased aspartate aminotransferase (Grade 3), and one event of increased alanine aminotransferase (Grade 2), which were all deemed related to 
both Durvalumab and tremelimumab. No DLTs have been reported in this study.
Updated information for combination of durvalumab and tremelimumab:Study D4190C00006 is a Phase Ib dose-escalation study to establish safety, PK/PDx, and 
preliminary anti-tumor activity of durvalumab + tremelimumab combination therapy in patients 
with advanced NSCLC. The dosing schedule utilized is durvalumab every 2 weeks (q2w) or every 4 weeks (q4w) up to Week 50 and 48 (12 months), combined with tremelimumab q4w up to Week 24 for 7 doses then every 12 weeks fo r 2 additional doses for up to 12 months. The 
study is ongoing and continues to accrue. 
Study D4190C00006: As of 20Feb2015, durvalumab PK  (n = 55) and tremelimumab PK (n = 
26) data were available from 10 cohorts (1a, 2a, 3a, 3b, 4, 4a, 5, 5a, 8, and 9) following 
durvalumab every 4 weeks (Q4W) or Q2W dosing in combination with tremelimumab Q4W 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
19regimens. An approximately dose-proportional increase in PK exposure (Cmax and area under 
the concentration-time curve from 0 to 28 days [AUC0 28]) of both durvalumab and 
tremelimumab was observed over the dose range of 3 to 15 mg/kg durvalumab Q4W and 1 to 10mg/kg tremelimumab Q4W. Exposures following multiple doses demonstrated accumulation consistent with PK parameters estimated from the first dose. It is to be noted that steady state PK parameters are based on limited numbers of subjects. The observed PK exposures of durvalumab and tremelimumab following combin ation were consistent with respective monotherapy data, 
indicating no PK interaction between these 2 agents.
As of February 20, 2015, ADA data were ava ilable from 60 subjects for durvalumab and 53 
subjects for tremelimumab in Study D4190C00006. Four of 60 subjects were ADA positive for 
anti durvalumab antibodies pos t treatment. One of 53 subjects were ADA positive for anti 
tremelimumab antibodies post treatment. There wa s no clear relationship between ADA and the 
dose of either durvalumab or  tremelimumab, and no obvious association between ADA and 
safety or efficacy.
The durvalumab + tremelimumab doses and regimen selected for this study were based on the 
goal of selecting an optimal combination dose of durvalumab and tremelimumab that would yield sustained target suppression (sPD-L1), de monstrate promising efficacy, and have an 
acceptable safety profile.
In order to reduce the dosing frequency of durvalumab to align with the q4w dosing of 
tremelimumab, while ensuring an acceptable PK/PDx , safety, and efficacy profile, cohorts were 
narrowed to 15 and 20 mg/kg durvalumab q4w. PK simulations from the durvalumab 
monotherapy data indicated that a similar area und er the plasma drug concentration-time curve at
steady state (AUCss; 4 weeks) was expected fo llowing both 10 mg/kg q2w and 20 mg/kg q4w 
durvalumab. The observed durvalu mab PK data from the D4190C 00006 study were well in line 
with the predicted monotherapy  PK data develope d preclinically. This demonstrates similar 
exposure of durvalumab 20 mg/kg q4w and 10 mg/kg q2w, with no alterations in PK when durvalumab and tremelimumab (doses ranging from 1 to 3 mg/kg) are dosed together. While the median Cmax at steady state (Cmax,ss) is expected to be higher with 20 mg/kg q4w (approximately 1.5-fold) and medi an trough concentration at steady state (Ctrough,ss) is 
expected to be higher with 10 mg/kg q2w (approximately 1.25-fold), this is not expected to impact the overall safety and efficacy profile, ba sed on existing preclinical and clinical data.
Monotonic increases in PDx activity were obser ved with increasing doses of tremelimumab 
relative to the activity observed in patients treated with durvalumab monotherapy. There was evidence of augmented PDx activity relative to durvalumab monotherapy with combination 
doses containing 1 mg/kg tremelimumab, inclusive of both the 15 and 20 mg/kg durvalumab plus 1 mg/kg tremelimumab combinations. 
Patients treated with doses of tremelimumab above 1 mg/kg had a higher rate of adverse events 
(AEs), including discontinuations due to AEs, serious AEs (SAEs), and severe AEs. Between the 
10 mg/kg durvalumab + 1 mg/kg tremelimumab and 10 mg/kg durvalumab + 3 mg/kg tremelimumab cohorts treated at  the q2w schedule, the number of patients reporting any AE, 
Grade 3 AEs, SAEs, and treatment-related AE s was higher in the 10 mg/kg durvalumab + 3 
mg/kg tremelimumab cohort than the 10 mg/kg durvalumab + 1 mg/kg tremelimumab cohort. Asimilar pattern was noted in the q4w regimens, suggesting that, as the dose of tremelimumab increased above 1 mg/kg, a higher rate of treatment-related events may be anticipated. Further, 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
20the SAEs frequently attributed to immunotherapy, pneumonitis and colitis, were more commonly 
seen in cohorts using either 3 or 10 mg/kg of tremelimumab compared to the 1-mg/kg dose cohorts. Together, these data suggest that a co mbination using a tremelimumab dose of 1 mg/kg 
appeared to minimize the rate of toxicity when combined with durvalumab. As a result, all combination doses utilizing either the 3 or 10 mg/kg doses of tremelimumab were eliminated in the final dose selection.
In contrast, cohorts assessing higher doses of durvalumab with a constant dose of tremelimumab 
did not show an increase in the rate of AE s. The data suggested that increasing doses of 
durvalumab may not impact the safety of the combination as much as the tremelimumab dose.Further, safety data between the 10-mg/kg and 20-m g/kg cohorts were similar, with no change in 
safety events with increasing dose of durvalumab. 
In Study D4190C00006, of all treatme nt cohorts, the cohort of 11 patients treated in the 20 
PJNJGXUYDOXPDEPJNJWUHP HOLPXPDEJURXSKDGWKHIHZHVW$( V*UDGHÂ•$(V6$(V
and treatment discon tinuations due to AEs, but still showed  strong evidence of clinical activity.
This cohort had a lowe r number of treatment-UHODWHG*UDGHÂ•$(VRUWUHDWPHQWUHODWHG6$(V
No dose-limiting toxicities were reported.Preliminary clinical activity of the durvalumab and tremelimumab combination did not appear to 
change with increasing doses of tremelimumab. The 15- and 20-mg/kg durvalumab q4w cohorts demonstrated objective responses at all doses  of tremelimumab, and increasing doses of 
tremelimumab did not provide deep er or more rapid responses.
Efficacy data suggested that the 20 mg/kg durvalumab + 1 mg/kg tremelimumab dose cohort 
may demonstrate equivalent clinical activity to other dose combinations. A total of 5 of 11 patients in the 20 mg/kg durvalumab + 1 mg/k g tremelimumab cohort were evaluable for 
efficacy with at least 8 weeks of follow-up. Of these, there were 2 patients (40%) with partial response (PR), 1 patient (20%) with stable dise ase (SD), and 1 patient (20%) with progressive 
disease (PD). (The fi fth patient had only a single scan, which was conducted outside the window 
for these evaluations.)
Additionally, of all cohorts, the 20 mg/kg durv alumab + 1 mg/kg tremelimumab dose cohort had 
the feweVW$(V*UDGHÂ•$(V6$(VDQG WUHDWPHQWGLVFRQWLQXDWLRQVGXH WR$(VEXWVWLOO
showed some evidence of clinical activity. Altogether, the data suggested that a 20 mg/kg 
durvalumab + 1 mg/kg tremelimu mab dose combination should be selected for further 
development.
1.2.9 Justification for dose and schedule
1.2.9.1 Tremelimumab
The proposed dose and schedule is informed by PK, safety, and efficacy  data on tremelimumab. 
In an early small Phase II study (A3671002), 2 dosing regimens of tremelimumab were 
compared in subjects with melanoma: 15 mg /kg Q3M (N=45) and 10 mg/kg QM (N=44). 
Comparable efficacy and overall AE rates were  observed in both arms; however, the rate of 
treatment-related CTCAE Grade 3 or 4 AEs was higher in the 10 mg/kg QM arm (27%) 
compared to the 15 mg/kg Q3M arm (13%). Subsequently, 2 pivotal tremelimumab studies (Phase II Study A3671008 and Phase III Study A3671009) in patients with melanoma used the 
regimen 15 mg/kg Q3M. Although neither study met its primary endpoint, the observed response 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
21rate and OS clearly indicate activity of tremelimumab in melanoma. Retrospective exposure-
survival analyses of these studies suggest better OS in subjects with higher tremelimumab exposure. In the Phase III trial, there was no difference LQWKHLQFLGHQFHRI*UDGHÂ• AEs 
between low and high exposure groups of trem elimumab. Tremelimumab at a concentration of 
ÈJP/HQKDQFHG,/ -2 release (in vitro) and showed antitumor activity (in vivo), and was 
consequently identified as the target concentration. PK simulations indicate that following a dose of 10 mg/kg QM for 6 months, approximately 90% of patients are expected to be above the 
WDUJHWOHYHORIÈJP/GXULQJWKHLQGXFWLRQSKDVH,QWKH3KD VH,,,PHODQRPDWULDOZLWKOHVV
frequent dosing of 15 mg/kg Q3M, only approx imately 50% of the patients treated with 
tremelimumab were above the target concentr ation, for only half of the dosing interval. 
Tremelimumab at a dose of 10 mg/kg QM for 6 months followed by 10 mg/kg Q3M is expected to yield PK exposures similar to those of the related anti-CTLA-4 mAb ipilimumab at a dose of 10 mg/kg every 3-weeks followed by 10 mg/kg Q3M, the dosing regimen that was tested in the pivotal first-line melanoma trial[ 15]. The ipilimumab data suggest that the long-term benefits of 
anti-CTLA-4 therapy may be sustained with a re duced frequency of dosing in patients who are 
benefiting from therapy. Based on these data, we will use a tremelimumab dose of 10 mg/kg QM for 6 months of treatment. Following the first 6 months of dosing, in the absence of confirmed 
disease progression, the interval will be increased  to Q3M. Treatment will be continued for up to 
one year as long as the patient co ntinues to derive clinical benefit.
1.2.9.2 Durvalumab
Preclinical toxicities studies with Durvalumab in cynomolgus monkeys, showed that repeated
dosing of Durvalumab was not associated with any adverse effects. Therefore, the NOAEL(no-
observed-adverse-effect) level of Durvalumab in all the general toxicity preclinical studies was considered to be 100 mg/kg, the highest dose tested  in these studies. The majority of the clinical 
safety data for Durvalumab from Study CD-O N-Durvalumab-1108, Phase 1, first-time-in-human 
(FTIH), multicenter, open-label, dose-escalation, and dose-expansion study to determine the maximum tolerated dose (MTD) or  optimal biologic dose (OBD), safety, PK, immunogenicity, 
and antitumor activity of Durvalumab in adult subjects with advanced solid tumors. A total of 198 subjects have been enrolled in Study CD- ON-Durvalumab-1108 and 177 of these subjects 
have received Durvalumab at 10 mg/kg Q2W (either in the dose-escalation or dose-expansion phase of the study). No DLTs have been report ed. The SAEs reported fo r 3 or more subjects 
were dyspnea, dehydration, abdominal pain, a nd sepsis. Durvalumab PK/pharmacodynamic data 
were evaluated for 32 subjects in the FTIH stud y (4 subjects in each of the 0.1 and 0.3 mg/kg 
groups, 3 subjects in each of the 1 and 3 mg/kg groups, and 18 subjects in the 10 mg/kg group).Results suggest that Durvalumab exhibits nonlinear PK likely due to saturable target-mediated clearance, resulting in faster rate of Durvalumab elimination at lower doses compared with high doses. The Michaelis constant (Km) describing half maximum capacity for nonlinear clearance ZDVaÈJP/%DVHGRQPHDQ.PYDOXH > 99% target saturation (both soluble and membrane 
ERXQGLVH[SHFWHGDWÂ•ÈJP/ concentration of Durvalumab. Hence, this concentration was 
identified as target trough concentration during dose selection. Pharmacokinetic simulations indicate that following 10 mg/kg Q2W dose of Durvalumab, > 90% of subjects are expected to PDLQWDLQ 3. H[SRVXUH Â•  ÈJP/ WKURXJKRXW WKH GRVLQJ interval. Near complete target
saturation, membrane bound and soluble PD-L1 (sPD-L1) is expected at a Â•3.0 mg/kg Q2W 
dose of Durvalumab. Exposures following multiple doses (currently data available up to a maximum of 20 doses) demonstrated accumulation c onsistent with the half-lives estimated from 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
22the first dose in each group. Significant target engagement, as measured by sPD-L1 suppression, 
was observed in all individuals following dosing.
Samples from 31 subjects were available for ADA (antidrug antibody) testing. Of these subjects, 
3 (1 subject each in the 0.1, 1.0, and 3.0 mg/kg Q2W cohorts) were ADA positive following dosing. Low ADA titers of 2 and 4 were observe d in ADA-positive samples in 1 subject from 
both the 0.1 and 1.0 mg/kg Q2W cohorts, respectivel y, with no obvious impact on either PK or 
pharmacodynamics. In 1 subject in the 3.0 mg/kg Q2W cohort, the ADA titer increased from 128 to 4096 in sequential ADA positive samples. Lower than expected PK exposure and suppression 
of sPD-L1 were observed in this subject lik ely as a consequence of this ADA response. 
1.2.9.3 Tremelimumab in combination with Durvalumab
Preliminary safety data as of are available for N=7 subjects treated in the ongoing study evaluating the combination of Durvalumab and tremelimumab. Three subjects were enrolled in each of the first 2 dose cohorts. Thereafter, dose escalation proceeded simultaneously to 
Durvalumab 15 mg/kg with 1 mg/kg tremelimumab and Durvalumab 10 mg/kg with 3 mg/kg 
tremelimumab, with 1 subject enrolled in the latte r cohort as of the cutoff date. The only AE 
reported for more than 1 subject was fatigue (3 subjects). All AEs were Grade 1 or 2 with the 
exception of one Grade 3 event of increased aspartate aminotransferase. One subject in this study (Durvalumab 3 mg/kg with 1 mg /kg tremelimumab) was disconti nued from treatment because of 
an SAE of disease progression. No DLTs or deaths have been reported in this study.
The safety profile of durvalumab and treme limumab combination therapy in the 102 subjects 
with advanced NSCLC in Study D4190C00006 is gene rally consistent with that observed across 
177 subjects treated with durvalumab and treme limumab combination therapy (not including 
subjects treated with blinded investigational pr oduct). As of April 15, 2015, 95 of 102 subjects 
(93.1%) reported at least 1 AE. All subjects in  the tremelimumab 3 and 10 mg/kg dose cohorts 
experienced AEs; subjects in the durvalumab 20 mg/kg and tremelimumab 1 mg/kg Q4W cohort 
experienced the lowest AE rate (77.8%). Tr eatment-related AEs were reported in 74 of 102 
subjects (72.6%), with events occurring in > 10 % of subjects being diarrhea (27.5%), fatigue 
(22.5%), increased amylase and pruritus (14.7%  each), rash (12.7%), colitis (11.8%), and 
increased lipase (10.8%). Treatment-UHODWHGÂ•*UDGH$(VUHSRUWHGLQÂ•RIVXEMHFWVZHUHcolitis (8.8%), diarrhea (7.8%), and increased lipase (5.9%). Five subjects reported treatment-related Grade 4 events (sepsis, increased ALT, and increased AST in 1 subject; increased amylase in 2 subjects; myasthenia gravis in 1 s ubject; and pericardial effusion in 1 subject) and 2 
subjects had treatment-related Grade 5 events (polymyositis and an uncoded event of neuromuscular disorder [VT]); the Grade 4 event of myasthenia gravis and Grade 5 polymyositis occurred in 1 subject. There were 2 subjects (both in the durvalumab 20 mg/kg + tremelimumab 3 mg/kg Q4W cohort) with dose-limiting toxicities (DLTs): 1 subject with Grade 3 increased 
AST, and 1 subject with Grade 3 increased amylase and Grade 4 increased lipase. Fifty-six subjects (54.9%) reported SAEs, with events occurring in > 5% of subjects being colitis (9.8%) and diarrhea (7.8%). Thirty-six subjects (35.3%) experienced treatment-related SAEs. Twenty-seven subjects (26.5%) permanently discontinued tr eatment due to AEs. Treatment-related AEs 
UHVXOWLQJLQGLVFRQWLQXDWLRQLQÂ•VXEMHFWVZHUHFROLWLVVX EMHFWVSQHXPRQLWLVVXbjects), 
diarrhea (3 subjects), and increased AST (2 s ubjects). Additional safety results from this study 
are presented in Section 1.2.8 and the durvalumab IB.
1.2.9.4 Fixed Dosing for durvalumab and tremelimumab 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
23A population PK model was devel oped for durvalumab using monot herapy data from a Phase 1 
study (study 1108; N=292; doses= 0.1 to 10 mg/kg Q2W or 15 mg/kg Q3W; solid tumors). 
Population PK analysis indicated only minor imp act of body weight (WT) on PK of durvalumab 
FRHIILFLHQWRIÂ”7KHLPSDFWRIERG\:7 -based (10 mg/kg Q2W) and fixed dosing (750 mg 
Q2W) of durvalumab was evaluated by comparing predicted steady state PK concentrations (5th, median and 95th percentiles) using the population PK model. A fixed dose of 750 mg was selected to approximate 10 mg/kg (based on median body WT of ~75 kg). A total of 1000 patients were simulated using body WT di stribution of 40â€“120 kg. Simulation results 
demonstrate that body WT-based and fixed dosin g regimens yield similar median steady state 
PK concentrations with slightly less overall between-subject variability with fixed dosing regimen.
Similarly, a population PK model was developed for tremelimumab using data from Phase 1 
through Phase 3 (N=654; doses= 0.01 to 15 mg /kg Q4W or Q90D; me tastatic melanoma)[ 39].
Population PK model indicated minor impact of body WT on PK of trem elimumab (coefficient 
RIÂ”7KH:7 -based (1 mg/kg Q4W) and fixed dosing (75 mg/kg Q4W; based on median 
body WT of ~75 kg) regimens were compared us ing predicted PK concentrations (5th, median 
and 95th percentiles) using popula tion PK model in a simulated population of 1000 patients with 
body weight distribution of 40 to 120 kg. Similar to durvalumab, simulations  indicated that both 
body WT-based and fixed dosing regimens of tremelimumab yield similar median steady state 
PK concentrations with slightly less between-subject variability with fixed dosing regimen. 
Similar findings have been reported by others[ 40, 41],[42],[43 ]. Wang and colleagues 
investigated 12 monoclonal antibodies and found that fixed and body size-based dosing perform 
similarly, with fixed dosing being better for 7 of  12 antibodies. In addition, they investigated 18 
therapeutic proteins and peptides and showed th at fixed dosing performed better for 12 of 18 in 
terms of reducing the between-subject variability in pharmacokinetic/pharmacodynamics 
parameters[ 42].
A fixed dosing approach is preferred by the prescribing community due to ease of use and reduced dosing errors. Given expectation of similar pharmacokinetic exposure and variability, we considered it feasible to switch to fixed dosing regimens. Based on average body WT of 75 kg, a fixed dose of 750 mg Q2W durvalumab (e quivalent to 10 mg/kg Q2W), 1500 mg Q4W 
durvalumab (equivalent to 20 mg/kg Q4W) and 75 mg Q4W tremelimumab (equivalent to 1 mg/kg Q4W) is included in the current study. 
Fixed dosing of durvalumab and tremelimumab is recommended only for subjects with > 30kg 
body weight due to endotoxin exposure. Patients w ith a body weight less than or equal to 30 kg 
should be dosed using a weight-based dosing schedule.
1.2.10 Rationale for study population and schedule:
RT is part of the standard trea tment for advanced pancreatic canc er both in the locally advanced 
setting and in the context of metastatic disease where patients frequently develop symptoms from 
the primary tumor. The vast majority of patients with pancreatic cancer have a primary or locally recurrent tumor in-situ for which RT is an acceptable treatment. This allows for a fairly homogenous patient population a nd radiation schedule. Whilst th e traditional RT schedule for 
this disease has been over a prolonged course an d in combination with a chemotherapeutic (5FU 
or gemcitabine) as radiosensitizer, modern RT techniques allow for a hypofractionated course 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
24without chemotherapy. This will minimize the dur ation of RT and will make it easier to combine 
with Immune Checkpoint inhibitors (Tremelimum ab and Durvalumab) treatment. Stereotactic 
body radiation therapy (SBRT) has been shown to  be safe and effective in locally-advanced 
pancreatic cancer[ 12]. Because it is unclear what th e optimal schedule of Tremelimumab and 
Durvalumab treatment with regard to RT is, we intend to employ two separate schedules to 
evaluate this in an exploratory manner.
1.2.11 Justification for Tumor Biopsies
Whilst the preclinical data suggest important imm une-regulatory effects of radiation treatment on 
tumors, with potential for amplification with imm une checkpoint therapy, the effect on humans 
is really unknown. Given that this is essentiall y a small pilot study evaluating feasibility and
safety whose next step in development â€“ if safe  and feasible as per the primary endpoint â€“ will 
most likely be a larger randomized study, it is scientifically important to obtain as much 
information about the treatment effect. This may l ead to altered and improved design of the next 
study. The best strategy for doing this is with tumor biopsies in order to evaluated immune cell 
infiltration (CD4/8 T-cells, MDSC). As pointed out by Deng et al. administration of antiâ€“PD-L1 
enhanced the efficacy of radiation throug h a cytotoxic T cellâ€“dependent mechanism. 
Concomitant with radiation-mediated tumor re gression, they observed that radiation and antiâ€“
PD-L1 synergistically reduced the local accu mulation of tumor-infiltrating MDSCs, which 
suppress T cells and alter the tumor immune microenvironment. It would be important to 
replicate this observation â€“ or disprove it â€“ in hu mans and would be rele vant knowledge whether 
the clinical data (response, PFS etc.) was either positive or negative. Given this, the historical difficulty with obtaining tissue in stroma-rich pancr eatic tumors and the fact that in order for the 
biopsy material from any single patient to be re levant and worthwhile in  the context of small 
patient numbers we would really  require participation from all or almost all of the patients.
However, if a patient has technically biopsiabl e disease but the interventional radiologist has 
concerns that pursuing the biopsy increases the ri sk to above average, or if pursuing the biopsy 
creates additional logistical complications (availability, pre-anesthesia requirements etc.) which causes delays or inconvenience to an unreasonable degree, we will forgo at investigator discretion.
1.2.11.1 Details of Planned Tumor Analysis
We will attempt to perform immunohi stochemically and gene analysis of all tumor biopsies. No 
non-tumor tissue will be analyzed. Analysis w ill be focused and confined to IHC and RNA 
characterization of specific immune cell populations - T-cell, MDSC, NK cells, macrophages- as well as markers of importance in the micro environment such as PD-L1/2 expression. 
RNA analysis will be performed as follows: RNA will be extracted and sent to Cell Processing Section at DTM for microarray analysis using a standard Affymetrix array. Genetic analysis will be on tumor tissue only. No germ line analysis is planned or will be performed without study 
amendment and IRB approval.
1.2.12 Justification for accrual increase in Arm C2 with Amendment I
The primary purpose of this amendment is to increase enrollment in treatment Arm C2 as we 
enrolled already 10 patients. There are two patie nts among 10 patients (20%) treated in Arm C2, 
who had been treated with current protocol over one year and obtained durable partial response 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
25(>12 months). This outcome is inspiring given the benefit of available c linical trials involved 
with immune checkpoint inhibitors in pancreatic cancer has been de cimal. It will be desirable to 
have additional patients enrolled in Arm C2 to more precisely estimate its efficacy. Thus, with 
Amendment I, we would like to double the accrua l number of Arm C2 from 10 to a total of 20 
evaluable patients to provide a more precise estimate of the treatment efficacy in this arm.
2 ELIGIBILITY ASSESSMENT AND ENROLLMENT 
2.1 E LIGIBILITY CRITERIA
2.1.1 Inclusion Criteria
2.1.1.1 Patients must have histopathological conf irmation of pancreatic  adenocarcinoma prior 
to entering this study by the Laboratory of Pathology of the NCI prior to entering this 
study
2.1.1.2 Patients must have disease that is not amenable to potentially curative resection.
Either primary in-situ (or locally-recurrent) tumor must be present and, in the opinion of radiation oncology, be amenable to radia tion therapy as planned in the protocol or 
an extra pancreatic lesion which in the opini on of the radiation oncologist is amenable 
to radiation. Each case will be discussed at GI tumor board with multidisciplinary team.
2.1.1.3 Patients must have at leas t 1 measurable metastatic lesion by RECIST1.1 criteria.
2.1.1.4 There is no limit to the number of prior chemotherapy regimens received. Patients 
must have received at least one line of pr ior systemic chemotherapy for advanced 
unresectable and/or metastatic disease.
2.1.1.5 Age >18 years 
2.1.1.6 Life expectancy of greater than 3 months.
2.1.1.7 ECOG performance status 0-1 (see Appendix A )
2.1.1.8 Patients must have nor mal organ and marrow function as defined below:
absolute neutrophil count > 1,000/ Î¼L
Platelets Â•100,000/Î¼L
total bilirubin %LOLVKRXOGEHÂ”[ ULN (patients 
with Gilbert's Syndrome must have a 
total bilirubin less than 3.0 mg/dL)
serum albumin Â•2.5 g/dL
Patients are eligible with ALT or AST up to 3 x ULN. (up to 5 xULN if liver metastases present)
Creatinine <2X instituti on upper limit of normal
OR
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
26creatinine clearance >45 mL/min/1.73 m2, for patients with 
creatinine levels above institutional 
normal
2.1.1.9 Patients must have recovered from any acute toxicity related to prior therapy, 
including surgery.  Toxicity should be Â”grade 1 or returned to baseline.
2.1.1.10 Patient must be able to  understand and willing to sign  a written informed consent 
document.
2.1.2 Exclusion Criteria
2.1.2.1 Malignant ascites that is clinically detectable by physical examination or is 
symptomatic. Evidence of radiographic ascites that is not clinically significant will not be an 
exclusion criterion.
2.1.2.2$Q\SULRU*UDGHÂ• imAE while receiving immunotherapy, including anti-CTLA4 
treatment, or any unresolved imAE > Grade 1. Note: Active or history of vitiligo will not be a basis for exclusion. 
2.1.2.3 Patients must not have had standard of care chemotherapy, radiotherapy, or major 
surgery within the last 2 weeks prior to entering the study. Note: Local surgeries for isolated lesions for palliative intent are a cceptable. For recent experimental therapies,
a 28-day period of time must have elapsed before commencing protocol treatment. 
2.1.2.4 Patients with known brain meta stases will be excluded from th is clinical trial because 
of their poor prognosis and because they  often develop progressive neurologic 
dysfunction that would confound the evaluation of neurologic and other adverse events.
2.1.2.5 Uncontrolled intercurrent illness, including, but not limited to, ongoing or active 
infection, current pneumonitis, symptomatic  congestive heart failure, uncontrolled 
hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of  incurring adverse events from Durvalumab
or tremelimumab, or compromise the ability of the subject to give written informed consent.
2.1.2.6 Active or prior documented autoimmune or inflammatory disorders (including 
inflammatory bowel disease, diverticulitis with the exception of diverticulosis, celiac disease, irritable bowel disease; Wegner syndrome; Hashimoto syndrome; Gravesâ€™ disease; rheumatoid arthritis, hypophysitis, uve itis, etc.) within the past 3 years prior 
to the start of treatment. The following are exceptions to this criterion:
xSubjects with vitiligo or alopecia
xRequirement for intermittent  use of bronchodilators or  local steroid injections
xSubjects with hypothyroidism (e.g., following Hashimoto syndrome) stable on 
hormone replacement, or psoriasi s not requiring systemic treatment
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
272.1.2.7 History of primary immunodeficiency or hi story of active tuberculosis. Note: Latent 
tuberculosis will not be a basis for exclusion.
2.1.2.8 Diverticulitis (either active or history o f) within the past 2 years. Note that 
diverticulosis is permitted. 
2.1.2.9 Dementia or significantly altered mental status that would prohibit the understanding 
or rendering of Information and Consent a nd compliance with the requirements of the 
protocol.
2.1.2.10 True positive test results for hepatitis A (IgM positive). Subjects with a history of 
hepatitis A with IgG blood test are not excl uded. True positive test results hepatitis B, 
or C infection. 
2.1.2.11 Active or history of inflammatory bowel  disease (colitis, Crohnâ€™s), irritable bowel
disease, celiac disease, or other serious, ch ronic, gastrointestinal conditions associated 
with diarrhea. Active or history of systemic lupus erythematosus or Wegenerâ€™s 
granulomatosis.
2.1.2.12 Current or prior use of imm unosuppressive medication within  14 days before the first 
dose of Durvalumab and tremelimumab. The following are exceptions to this criterion:
xIntranasal, inhaled, and topical steroids
xSystemic corticosteroids at physiologic doses not to exceed 10 mg/day of 
prednisone or equivalent
xSteroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)
2.1.2.13 History of sarcoidosis syndrome.
2.1.2.14 Patients should not be vaccinated with liv e attenuated vaccines within 1 month of 
starting Tremelimumab and Durvalumab treatme nt. Subjects, if enrolled, should not 
receive live vaccine during the study and 180 days after the last dose of both drugs.
2.1.2.15 HIV-positive patients receiving anti-retrovi ral therapy are excluded from this study 
due to the possibility of pharmacokinetic interactions between antiretroviral 
medications and Tremelimumab or Durvalumab. HIV positive patients not receiving antiretroviral therapy are excluded due to the possibility that Tremelimumab or Durvalumab may worsen their condition a nd the likelihood that the underlying 
condition may obscure the attr ibution of adverse events.
2.1.2.16 History of hypersensitivity reaction to human or mouse antibody products.
2.1.2.17 Pregnancy and breast feeding are exclus ion factors. The effects of Tremelimumab and 
Durvalumab on the developing human fetus are unknown. Enrolled patients must 
agree to use adequate contraception (horm onal or barrier met hod of birth control; 
abstinence) prior to study entry, the duration of study participation and 180 days (female patients) or 90 days (male patients) after the end of the treatment. In addition,
male patients must refrain from sperm dona tion for 90 days after the final dose of 
investigational product. Fema le patients must refrain from egg cell donation for 180 
days after the final dose of investigati onal product. Should a woman become pregnant 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
28or suspect she is pregnant while she or her partner is participating in this study, she 
should inform her treating physician immediately.
2.1.2.18 Any condition that, in the opinion of the i nvestigator, would interfere with evaluation 
of the investigational produc t or interpretation of subject  safety or study results.
2.1.3 Recruitment Strategies
The study will be posted on the CCR website and on clinicaltrials.gov.
2.2 S CREENING EVALUATION 
Studies should be done within 28 days prior to enrollment.
xLabs may be performed outside of NIH. Comp lete history (including prior hormone use) 
and physical examination (including height, weight, vital signs, EKG, and performance 
status).
xLaboratory Evaluation
oHematological profile: CBC with differential and platelet count, PT, INR, aPTT, 
fibrinogen.
oBiochemical profile: electrolytes, BUN, creatinine, AST, ALT, total and direct bilirubin, calcium, phosphorus, albumin, magnesium, uric acid, amylase.
oHepatitis A, B, C serological testing.
oSerum or urine pregnancy test for female participants of childbearing age (in the absence of prior hysterectomy).
xImaging studies 
oCT scan of chest, abdomen and pelvis
oAnd/or MRI abdomen
xHistologic confirmation by labor atory of Pathology of the NCI (at any time point prior to 
commencement). A block or unstained slides of primary or metastatic tumor tissue will 
be required from each partic ipant to confirm diagnosis.
2.3 R
EGISTRATION PROCEDURES
Authorized staff must register an eligible candidate with NCI Central Registration Office (CRO) within 24 hours of signing consent. A registration Eligibility Checklist from the web site (http://home.ccr.cancer.gov/intra/eligibility/welcome.htm ) must be completed and sent via 
encrypted email to: NCI Central Registration Office ncicentralregistration-l@mail.nih.gov .A f t e r  
confirmation of eligibility at Central Registration Office, CRO staff will call pharmacy to advise them of the acceptance of the patient on the protocol prior to the release of any investigational agents. Verification of Registration will be forwarded electronically via e-mail to the research team. A recorder is available during non-working hours.
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
292.3.1 Treatment Assignment Procedures:
Cohorts
Number Name Description
1 Cohort 1 Subjects with unresectable pancreatic cancer 
Arms
Number Name Description
1 A1 Durvalumab +8 Gy in 1 fraction
2 A2 Durvalumab +5 Gy in 5 fractions
3 B1* Tremelimumab + 8 Gy in 1 fraction
4 B2* Tremelimumab + 5 Gy in 5 fractions
5 C1 Durvalumab + Tremelimumab + 8 Gy in 1 fraction
6 C2 Durvalumab + Tremelimumab + 5 Gy in 5 fractions
Subjects in Cohort 1 will be directly assigned to Arms A1, A2, C1, C2 as follows:
xSubjects will initially be enrolled in Arm A1 or A2. Assignment to A1 or A2 is per 
investigator discretion in consultation with multidisciplinary team.
xOnce enrollment to arms A1 and A2 are complete, subjects will be enrolled in Arms C1 and C2, with assignment to C1  or C2 per investigator di scretion in consultation with 
multidisciplinary team.
* With amendment A, the study design was revi sed, Arms B1 and B2 were removed, no subjects 
were assigned to B1 and B2.
2.4 B
ASELINE STUDIES
Tests done at screening do not need to be rep eated on baseline if perfor med in designated time 
frame.If laboratory tests done within 72 hours of Cycle 1 Day 1 they do not need to be repeated on Day 
1.Labs may be performed outside of NIH.Within 28 days prior to study intervention:
xEKG 
xCT scan of chest, abdomen and pelvis and/or MRI
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
30xTumor biopsy
Within 7 days prior to study intervention:
xTumor marker profile: CA 19-9
xPhysical exam with vital signs
Within 72 hours prior to study intervention:
xHematological profile: CBC w ith differential and platelet count, PT, INR, aPTT, 
fibrinogen.
xBiochemical profile: electrolytes, BUN, creatin ine, AST, ALT, total and direct bilirubin, 
calcium, phosphorus, albumin, magn esium, uric acid, amylase.
xThyroid function tests (TSH, T3, T4)
xANA, AMA, Liver autoantibody panel (autoimmune hepatitis)
xImmune monitoring
xSerum or urine pregnancy test for female participants of childbearing age (in the absence 
of prior hysterectomy).
3 STUDY IMPLEMENTATION
3.1 S TUDY DESIGN
The proposed study is a pilot/phase I study of im mune checkpoint inhibition in combination with 
short course radiation therapy in patients with unres ectable pancreatic cancer.
For arms A1 and A2: Durvalumab treatment will continue until off treatment criteria are met 
(Section 3.6.1) (Figure 2 ).
For arms B1 and B2: It was intended for Tremelimumab treatment to continue for a total of 12 months or until confirmed progressive disease (PD; if PD occurs before completion of the 12-month treatment period) a ssessed by irRC criteria. With amendment A, the study design was 
revised and it was decided that we would not  assign subjects into these treatment arms.
For arms C1 and C2: Assignment to arms C1 and C2 will only proceed following 1) NCI IRB approval of updated safety info rmation of ongoing combination therapy studies evaluating
tremelimumab in combination with Durvalumab and 2) submission to the FDA of a revised protocol specifying the selected drug doses and dose schedule.
Patients assigned to arms C1 and C2 will receive 1500 mg durvalumab via IV infusion q4w for 
up to 4 doses/cycles and 75 mg tremelimumab via IV infusion q4w for up to 4 doses/cycles, and 
then continue 1500 mg durvalumab q4w until off treatment criteria are met (Section 3.6.1) (see 
Figure 3 ). Patients with a body weight less than or equal to 30 kg should be dosed using a 
weight-based dosing schedule (i.e. 1mg/kg for tremelimumab and 20mg/kg for durvalumab). Flat weight dosing will be used for all other patients including those who are greater than 75Kg e.g.100-110Kg. Tremelimumab will be administered first. Durvalumab infusion will start approximately 1 hour after the end of tr emelimumab infusion. The duration will be 
approximately 1 hour for each infusion. A 1 hour observation period is required after the first 
infusion of durvalumab and tremelimumab. If no clinically significant infusion reactions are 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
31observed during or after the first cycle, subseq uent infusion observation periods can be at the 
Investigatorâ€™s discretion (suggested 30 minutes  after each durvalumab and tremelimumab 
infusion).
Subjects who permanently discontinue treatment will be followed. All subjects will be followed 
for survival. Follow up details are outlined in Section 3.5.
-The original study design was to have 6 separate treatment arms:
xArms A1 and A2: anti-PDL1 (Durvalumab) in combination with radiation
oArms B1 and B2: anti-CTLA4 (tremelimumab) in combination with radiation(never opened)
xArms C1 and C2: anti-PDL1 (Durvalumab) and anti-CTLA4 (tremelimumab) in combination with radiation.
-Arms differ by the quantity of radiation.
-Arms A1 and C1: 8Gy in 1 fraction (Total = 8Gy) Day 1.
Arms A2 and C2: 5Gy in 5 fractions (Total = 25Gy) for 5 days which will be 
identified as Day -3, Day -2, Day -1, Day 0, Day 1.
-Patient allocation:
xNo randomization will occur.
xThe subjects will be assigned to arms sequentially i.e. A before C (the latter of which will require IRB approval.)
-The radiation schedule the patient receives will be decided through multidisciplinary 
discussion with the radiation oncologist and base d on clinical factors rather than dictated 
purely by sequence based on when the patient happens to be seen. The reason for this is based on our experience thus far where we  commonly encounter one of two specific 
scenarios as follows: A) If a patient has a relatively large pancreatic mass which is causing pain we would like the flexibility to administer the 5x5Gy schedule as this would at least give a good palliative dose of ra diation; B) Some patients have very small 
pancreatic primaries which w ould be more suited to the lower dose of radiation. 
Mandatory baseline and Day 29 tumor biops ies will be obtaine d on all patients.
However, if a patient has technically biopsia ble disease but the interventional radiologist 
has concerns that pursuing the biopsy increases the risk to above average, or if pursuing 
the biopsy creates additional logistical complications (availability, pre-anesthesia requirements, etc.) which causes delays or in convenience to an unreasonable degree, we 
will forgo at investigator discretion.
-Given that the primary aim of this study is to assess safety and feasibility of immune 
checkpoint inhibition in combination with radiation the DLT evaluation period will 
extend for a total of 6 weeks fo llowing completion of radiation.
3.1.1 Arms A1 and A2
Figure 2: Durvalumab in combination with radiation:
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
32Patients with pancreatic cancer who satisfy the eligibility criteria will receive Durvalumab
10mg/kg as an intravenous infusion until off-treatment criteria are met.
Arm Checkpoint inhibitor SBRTa
dose/scheduleN
A1 Durvalumab
10mg/kg/q2w8Gy x 1# 10
A2 Durvalumab10mg/kg/q2w 5Gy x 5# 10
aSBRT= Stereotactic body radiation therapy. 
Timing of checkpoint inhibitor with regard to RT: If RT given for 1 day (Arm A1), 
checkpoint inhibitor given on D1, immediately post RT. If RT given for 5 days (Arm A2), 
checkpoint inhibitor(s) given on the last day of RT immediately post RT and this will be 
identified as D1.
- Initially N=10 patients will be assigned to Arm A1 as per the table. Patients in Arm A1 will 
undergo external beam radiation to the pancrea tic mass comprising 8Gy in a single fraction 
on Day 1.
- The goal will be to evaluate 10 patients in A1 and then 10 in A2, provided that no more 
than 1 of the first 6 in A1 or A2 has a DLT, and that no more than 3 of 10 patients in either 
A1 or A2 has a DLT. If either of these is exceeded, then no further patients would be enrolled in arms A1 and A2.
- Patients in Arm A2 will undergo external beam radiation to the pancre atic mass comprising 
25Gy in 5 fractions (5Gy per fraction) for 5 days, on Day -3, Day -2, Day -1, and Day 0,Day 1.

Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
33- Restaging CT scan (or MR) will be perfo rmed every 8 weeks. RECIST 1.1 and modified
Immune-related RECIST criteria will be applied.
3.1.2 Arms C1 and C2  
Figure 3 :Durvalumab and Tremelimumab in combination with radiation.
Patients with pancreatic cancer  who satisfy the eligibility criteria will receive 1500 mg 
durvalumab via IV infusion q4w for up to 4 doses/cycles and 75 mg tremelimumab via IV 
infusion q4w for up to 4 doses/cycles, and th en continue 1500 mg durvalumab q4w until off-
treatment criteria are met (see graphic above). Tremelimumab will be administered first. Durvalumab infusion will start approximately 1 hour after the end of tremelimumab infusion. 
The duration will be approximately 1 hour for each infusion. A 1 hour observation period is 
required after the first infusion of durvalumab and tremelimumab. If no clinically significant infusion reactions are observed during or after the first cycle, subsequent infusion observation 
periods can be at the Investigatorâ€™s discretion (suggested 30 minutes after each durvalumab and tremelimumab infusion).
Arm Checkpoint inhibitor SBRT
b
dose/scheduleN Start date
C1 Durvalumab 1500mg +
Tremelimumab 75mg8Gy x 1# 10 March
2016
C2 Durvalumab 1500mg +Tremelimumab 75mg5Gy x 5# 20
aSBRT= Stereotactic body radiation therapy. 
Timing of checkpoint inhibitor with regard to RT: If  RT given for 1 day (Arm C1), checkpoint inhibitor 
given on D1, immediately post RT. If RT given for 5 days (Arm C2), checkpoint inhibitor(s) given on the 
last day of RT immediately post RT and this will be identified as D1.

Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
34- The goal will be to evaluate 10 patients in C1 and then 20 in C2, provided that no more 
than 1 of the first 6 in C1 or C2 has a DLT, and that no more than 3 of first 10 patients in 
either C1 or C2 has a DLT. If either of these is exceeded, then no further patients would be enrolled in arms C1 and C2.
- Patients in Arm C2 will undergo external beam ra diation to the pancreatic mass comprising 
25Gy in 5 fractions (5Gy per fraction) for 5 days, on Day -3, Day -2, Day -1, and Day 0,Day 1.
- Restaging CT scan (or MR) will be performed every 8 weeks. RECIST 1.1 and Immune-related RECIST criteria will be applied.
- The decision on which radiation schedule to be employed will be based on technical and 
clinical factors and after disc ussion with and at the discretion of the radiation oncologist.
3.1.3 Protocol Stopping Rules
This study will utilize the Common Terminology Criteria for Adverse Events (CTCAE) version 
4.0 for grading systemic toxicity. For safety reas ons, new subject enrollment will be temporarily 
halted for either of the following events.
xOne occurrence of grade 5 toxicity by the NCI-CTCAE version 4.0 attributable to the treatment regimen.
xTwo occurrences of grade 4 toxicity by the NCI-CTCAE version 4.0 attributable to the 
treatment regimen.
Discussions will be had, if a pplicable, with the NCI IRB and Sponsor regarding necessary 
amendment in order to resume enrollment.
3.1.4 Re-treatment
If patient is taken off treatment for reasons other than disease progression or unacceptable 
toxicity, attributed to Durvalumab, but later, in the opinion of Investigator, can benefit from re-
starting of Durvalumab and meets eligibility criteria, re-treatment with Durvalumab will be initiated (q4w). Screening evaluati ons will be repeated. No research procedures will be done
during re-treatment; however, clinical assessments will be performed per study calendar.
3.2 D
OSE LIMITING TOXICITIES 
3.2.1 Definition of Dose- limiting Toxicities (DLTs):
A DLT will be defined as any Grade 3 or higher treatment-related (related to any investigational 
product) toxicity that occurs during the DLT evaluation period, including:
3.2.1.1 Any Grade 4 immune-mediated AE (imAE)
3.2.1.2 Any Grade 3 im $(WKDWGRHVQRWGRZQJUDGHWRÂ”*UDGHZLWKLQGD\VDIWHURQV HWRI
the event despite maximal supportive care including systemic corticosteroids or 
GRZQJUDGHWRÂ”*UDGH RUEDVHOLQHZLWKLQGD\V
3.2.1.3 Liver transaminase elevation higher than  8 Ã— upper limit of normal (ULN) or total 
bilirubin higher than 5 Ã— ULN
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
353.2.1.4$Q\Â•*UDGHSQHXPRQLWLVWKDWGRHVQRWUHVROYHWRÂ”*UDGHZL WKLQGD\VRIWKH
initiation of maximal supportive care.
3.2.2 Definition of Dose-limiting Toxicities (DLTs) excludes the following conditions:
xGrade 3 asymptomatic elevation of pancreatic enzymes which resolve to grade 1 within 
28 days.
x*UDGHUDVKRUSUXULWXVWKDWGRZQJUDGHVWRÂ”*UDGHZLWKLQ GD\VDIWHURQVHWRIWKH
event with maximal supportive care including systemic corticosteroids or GRZQJUDGHWRÂ”
Grade 1 or baseline (on oral pre dnisone 10mg/day) within 30 days.
xGrade 3 endocrinopathy that is asymptomatic , managed with or without corticosteroid 
therapy and/or hormone repl acement and which downgrades WRÂ”*UDGHRUEDVHOLQH
within 30 days. Grade 3 inflammatory reacti on attributed to a local antitumor response 
(e.g., inflammatory reaction at sites of metastatic disease, lymph nodes, etc.).
xDosing may continue despite concurrent vitiligo and alopecia of any AE grade
xGrade 3 pyrexia, headache, and chills that  are controlled with appropriate supportive 
treatment and do not result in pe rmanent treatment discontinuation 
xGrade 3 nausea, vomiting, or mucositis/esophag itis that is felt to be related to the 
radiation and that responds to maximal supportive care within 3 days
xImmune-related adverse events are defined as  AEs of immune nature  (i.e., inflammatory) 
in the absence of a clear alternative etiol ogy. In the absence of clinical abnormality, 
repeat laboratory testing will be conducted to confirm significant laboratory findings 
prior to designation as a DLT.
3.2.3 Investigational Drug Administration
3.2.3.1 The first day of dosing is considered Day 1. 
3.2.3.2 Tremelimumab IV infusion will be approximately 1 hour  in duration Durvalumab will 
be approximately 1 hour in duration; 
3.2.3.3 For Arms C1 and C2: Tremelimumab will be  administered first. Durvalumab infusion 
will start approximately 1 hour after the end of  tremelimumab infusion.
3.2.3.4 Each dose of investigational product s hould be administered using the following
guidelines: 
1) Investigational product must be administered at room temp erature (25Â°C) by controlled 
infusion at a rate of 250 mL/hr. via an infusi on pump into a peripheral vein. Prior to the 
start of the infusion, ensure that the bag c ontents are at room temperature to avoid an 
infusion reaction due to the administration of the solution at low temperatures.
2) Investigational product must not  be administered via IV push or bolus but as a slow IV 
infusion. The entire content of each IV bag will be infused using an infusion pump. 
3) The infusion lines should be attached only at time of use. Lines used for infusion during 
dose administration will QHHGWREHHTXLSSHGZLWKRUÈPLQ -line filters. 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
364) If there are no requirements to slow, inte rrupt, or permanently stop the infusion, the 
anticipated infusion time to deliver each dose (250 mL) is anticipated to be
approximately 60 minutes.
5) For infusion-related reactions: The infusion rate of Durvalumab or tremelimumab may be 
decreased by 50% or temporarily interrupted until resolution of the event. Acetaminophen and/or antihista mines may be administered pe r institutional standard at 
the discretion of the investigator. Consider premedication prior to subsequent doses.
6) When an IV bag is used for the infusion, the IV line will be flushed with a volume of 
normal saline equal to the priming volume of th e infusion set used after the contents of 
the IV bag are fully administered (unless prohibited by institutional practice). The duration of the investigational product administration will be recorded.
3.2.4 Durvalumab Drug Administration 
Each dose of Durvalumab should be adminis tered using the following guidelines:
1) Durvalumab will be administered as an IV infusion over approximately 60 minutes.
2) When an IV bag is used for the infusion, the IV line will be flushed with a volume of 
normal saline equal to the priming volume of th e infusion set used after the contents of 
the IV bag are fully administered (unless prohibited by institutional practice). 
3) Since the compatibility of Durvalumab with other IV medications and solutions, other 
than normal saline (0.9% [w/v] Sodium Chloride for Injection), is not known, the 
Durvalumab solution should not be infused through an IV line in which other solutions or 
medications are being administered. 
4) The duration of the investigational product administration will be recorded.
3.2.5 Tremelimumab Dose Administration:
Tremelimumab will be administere d as an IV infusion (250 mL) over approximately 1 hour. 
When an IV bag is used for the infusion, the IV line will be flushed with a volume of normal 
saline equal to the priming volume of the infusion set used after the contents of the IV bag are 
fully administered (unless prohibited by institutional practice).
3.2.6 Monitoring of Dose Administration 
Vital signs will be collected within 30 minutes befo re and within 30 minutes after investigational 
product infusion only. Patients will need to stay for one hour post the infusion to assess for any 
delayed reactions for the first infusion. For subse quent infusions patient will be required to stay 
for only 30 minutes or at the discre tion of the Principal Investigator.
As with any antibody, allergic reactions to dose administration are possible. Therefore, 
appropriate drugs and medical equipment to treat acute anaphylactic reactions must be 
immediately available, and study personnel must be trained to recognize and treat anaphylaxis, as per local institutional guidelines.
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
373.3 D OSING DELAYS
The following broad guidelines for dose delivery schedule delays and alternations apply to both 
of the planned dosages of Tremelimumab and Durvalumab and are dependent on the clinical and 
laboratory assessment on the day of dosing. Tremelimumab and Durvalumab can be delivered within 72 hours of planned interval to accommodate scheduling issues/logistics.
3.3.1 Immune-mediated AEs (imAEs)
Based on the mechanism of action of Durvalumab and tremelimumab leading to T-cell activation 
and proliferation, there is the possibility of observing immune-mediated AEs (imAEs) during the conduct of this study. Pote ntial imAEs may be similar to those seen with the use of 
ipilimumab, BMS-936558 (anti-PD -1 mAb), and BMS-936559 (a nti-PD-L1 mAb) and may 
include immune-mediated enterocolitis, dermatitis, hepatitis (hepatotoxicity), and endocrinopathies[ 14,16,44].These AEs are inflammatory in nature and can affect any organ. 
With anti-PD-LI and anti-CTLA-4 combination therapy (arms C1 and C2), the occurrence of overlapping or increasing cumulative toxicities that include imAEs, could potentially occur at higher frequencies than with Durv alumab (arms A1 and A2) monotherapy.
Subjects should be monitored for signs and sympto ms of imAEs. In the absence of an alternate 
etiology (e.g., infection or PD),  an immune-related etiology shoul d be considered for signs or 
symptoms of enterocolitis, de rmatitis, hepatitis, and endocrinopathy. Dosing modification and 
management guidelines for imAEs specified in Appendix D .
3.3.2 Adverse Events of Special Interest
An adverse event of special interest (AESI) is one of scientific and medical interest specific to 
understanding of the Investigational Product and may require close monitoring. An AESI may be serious or non-serious. The rapid reporting of AESI s allows ongoing surveillance of these events 
in order to characterize and understand them in as sociation with the use of this investigational 
product.
xLiver: Immune Checkpoint inhibitors (Tremelimumab and/or Durvalumab) can result in 
severe and fatal inflammation of the liver most commonly manifested as elevation of 
transaminases and hyperbilirubinemia. Liver enzymes and liver function tests (hepatic transaminase and bilirubin levels) will be evaluated and patients assessed for signs and symptoms of hepatitis before each dose of Tremelimumab and Durvalumab. Guidelines for management of subjects with he patic function abnorma lity are outlined in Appendix 
D.
xPneumonitis Adverse events of pneumonitis are also of interest, as pneumonitis has been observed with anti-PD-1 mAbs (but not w ith anti-PD-L1 mAbs). Initial work-up should 
include high-resolution CT scan, ruling out infection, and pulse oximetry. Pulmonary consultation is highly recommended.
xInfusion Reactions. Adverse events of infusion reactions (also termed infusion-related reactions) are of special interest and are defi ned, for the purpose of this protocol, as all 
AEs occurring from the start of the study treatment infusion up to 48 hours after the infusion start time. 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
38xHypersensitivity Reactions: In case of hypersensitivity reactions, the investigator should 
institute treatment measures deemed medically appropriate per institutional guidelines 
-Grade 1 = Transient flushing or rash; drug fever < 38Â°C
-Grade  5DVKIOXVKLQJXUWLFDULD G\VSQHDGUXJIHYHUÂ•Âƒ&
-Grade 3 = Symptomatic bronchospasm with  or without urticaria; parenteral 
medication(s) indicated; allergy-related edema/angioedema; hypotension; anaphylaxis
-Grade 4 = Anaphylaxis
-Grade 5 = Death
3.3.2.1 Autoimmunity
If a subject experience an AE that is though t to be possibly of autoimmune nature (e.g.,
thyroiditis, hepatitis, pa ncreatitis, thrombocytopenia, hypophysitis, diabetes insipidus), the 
investigator should send a blood sample for a ppropriate autoimmune antibody testing and 
immediate consideration of endocri nology consultation. If specific auto-antibodies are present, 
the blood sample taken for storage at baseline can be tested for the presence of auto antibodies. 
Continuation of investig ational product in the presence of immune-mediated events should be 
done by the investigator with cons ideration to risk-benefit analysis.
3.4 S PECIFIC PROCEDURES FOR STEREOTACTIC BODY RADIATION THERAPY (SBRT)
3.4.1 Radiotherapy administration
3.4.1.1 Modality, Fractionation, and Total Dose
Radiation will be delivered with megavoltage exte rnal beam radiation with beam energies of 
6MV or higher. For Arms A1 and C1 treatment will be delivered in 8Gy as a single fraction. For 
Arms A2 and C2 treatment will be delivered in 5Gy fractions for 5 days. The decision on which 
radiation schedule to be employed will be based on technical and clinical factors and after discussion with and at the discretion of the radiation oncologist.
3.4.1.2 Simulation
Patients will be simulated supine with the addi tion of a 4D CT if appr opriate. A stereotactic 
immobilization device with abdominal compression will be used. Oral contrast will be delivered 
approximately one hour prior to simulation to allow opacification of small bowel unless 
contraindicated. IV contrast may be delivered fo r the simulation if deemed necessary by the 
treating radiation oncologist.
3.4.1.3 Volume definitions 
GTV: The gross tumor volume (GTV) will be defined as all gross disease evident on imaging and examination at the site of treatment PTV: The planning target volume will be a 3-5 mm concentric expansion on the GTV. An additional ma rgin of up to 3 mm may be added as needed 
if 4D CT reveals extensive respiratory motion of the target.
3.4.1.4 Target lesions 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
39Target lesions for radiation will be primary or recurrent pancreatic lesions. If there is no 
pancreatic lesion present or in the opinion of the radiation oncologist, there is a more amenable 
lesion outside of the pancreas, this ma y be designated as a target lesion.
3.4.1.5 Dose specification
The PTV doses should meet the following criteria:
1) >93% of the PTV should receive at  least 93% of the prescribed dose.
2) < 5% of the PTV should receive more than 110% of the prescribed dose. Efforts will be 
made to reduce heterogeneity if possible.
Normal Structures The following dose goals will apply for normal tissues:
Kidney: mean dose < 10 Gy (total kidney volume)
Small bowel: maximum 35 Gy, mean <25Gy, V30< 5cc, V35Gy <1cc
Duodenum: maximum 35Gy, mean <25Gy, V30< 5cc, V35Gy <1cc
Stomach: 35 Gy, mean <25Gy, V30< 5cc, V35Gy <1cc
Large bowel: maximum 35Gy, mean <25Gy, V30< 5cc, V35Gy <1cc
Liver: V30<10%
Spinal cord: maximum 20Gy
Daily treatment delivery
Treatment will be delivered at the discretion of the radiation oncologist.Localization will be verified with pretreatment im aging prior to every fraction. Ideally, this will 
include Tomotherapy localization or cone beam  CT, although kV/kV imaging may be used if 
necessary.
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
403.5 S TUDY CALENDAR
Scree
ningBasel
inenC1 C2 C3
D1 of 
every 
subsequ
ent 
cycleEOT
jFU 
k-3 -2 -1 0 1815 22 1 8 15 22 1815 22
DurvalumabaXX X X XX X
Tremelimumabb, oXX X X
SBRTcArms A1, C1 X
SBRTcArms A2, C2 X X X X X
Informed consent X
Medical history X
Concomitant meds X X X X X
Formal adverse event 
evaluation XX X X X X
Physical exam X X X X X X X
Vital Signs X X XiXiXiXiXiXiXX
CBCdX X X X X XXXXX X X X X X X
Hepatitis A, B, C X
PT, INR, PTT,fibrinogen 
dXX X X XpXXpX
TSH, T3, T4dXX X X
Biochemical profiled, eX X X X X XXXXX X X X X X X
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
41Scree
ningBasel
inenC1 C2 C3
D1 of 
every 
subsequ
ent 
cycleEOT
jFU 
k-3 -2 -1 0 1815 22 1 8 15 22 1815 22
Uric acid, amylasedXX X X
pX
pX
pXX
pXpX
pXX
pX
pXpXX
CA 19-9 X X X X X
EKG X X X X X
Restaging radiologic 
EvaluationXX X Xf
Tumor biopsyg, oXX
Immune monitoringoXX X Xh
Pharmacokinetic studies
oXX X X X XhXXm
Immunogenicity(ADA)
oXX XhXXm
ANA, AMA, Liver autoantibody panel (autoimmune hepatitis)
oX Xh
T cell activation/ICOS expression/ functional analyses /immunodiversity (PBMC)
oXX X X X XhX
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
42Scree
ningBasel
inenC1 C2 C3
D1 of 
every 
subsequ
ent 
cycleEOT
jFU 
k-3 -2 -1 0 1815 22 1 8 15 22 1815 22
Plasma-based assays 
for circulating receptors/ligands e.g.,PDL1
oXX X X X XhXXm
Advance Directive lX
Serum or urine pregnancy testXX
Histologic confirmation Xo
aSubjects will receive one dose of Du rvalumab on Days 1 and 15 in Arms A1 and A2 and on Day 1 only in Arms C1 and C2 until off-
treatment criteria are met.
bSubjects will receive 75 mg tremelimumab via IV infusion q4w for up to 4 doses/cycles.
cHypofractionated radiation will be administered to the pancreatic primary tumor OR a lesion noted outside the pancreas per the 
discretion of the radiation oncologist.
dFor all labs a â€˜+/- 72 hr.â€™ window applies, w ith the exception of those needed to deter mine proceeding with treatment. Labs may be 
performed outside of NIH.
eBiochemical profile: electrolytes, BUN, creatinine, AST, ALT,  total and direct bilirubin, calc ium, phosphorus, albumin, magnesi um.
fRestaging CT /MRI scan every 8 weeks (+/- 1 week) to evaluate TTP in target lesion.
gMandatory baseline and post-RT tumor biopsies (D29 approx. (+/- 7 days) will be obtained on all patients.
hRefer to section 5for detailed timing schema
Icollected within 30 minutes before and within 30 minutes after investig ational product infusion.
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
43jEnd Off Treatment Visit: patients will be invited to clinical center approximately 30 days following the last dose of study drug. I f 
patents are not able or not willing to come, they will be asked by phone for performance status, any adverse ev ents and new cance r 
treatment. 
kFU Follow Up: all study subjects will be followed for overall su rvival. Follow-up will be semi-an nual telephone contact to asses s 
survival status. Every attempt will be made to contact patient/subject including: contacting referring physician, contacting eme rgency 
contact patient identified on admission, check ing SSDI (Social Security Death Index).
lFilling out of the Advance Directive will be offered, but obtaining of it is not required. For details see Section 10.3
mDone at day 90 after last dose of drug, but only if patient is willing to come for a visit to NIH
n Tests done at screening do not need to be repeated on baseline if performed in designated time frame.
Owill not be done dur ing re-treatment
p Optional 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
443.6 C RITERIA FOR REMOVAL FROM PROTOCOL THERAPY AND OFF STUDY CRITERIA
Prior to documenting removal from off study, effort must be made to have  all subjects complete 
a safety visit approximately 30 days fo llowing the last dose of study therapy.
3.6.1 Criteria for removal from protocol therapy
xWithdrawal of consent from further tr eatment with inves tigational product 
xUnacceptable Toxicity as defined in section 3.2
xPregnancy or intent to become pregnant
xSubject noncompliance that, in the opinion of the investigator or sponsor, warrants 
withdrawal (e.g., refusal to adhere to scheduled visits)
xInitiation of alternative anticancer therapy including another investigational agent
xProgressive Disease as defined in section 6.2.4. NOTE: While RECIST PD will be noted 
and recorded the immune-related RECIST criteria will be applied to determine discontinuation of study treatment.
xSubject who has received any amount of infliximab or other tumor necrosis factor alpha inhibitor
xIntercurrent illness that prevents further administration of treatment
xInvestigator discretion
3.6.2 Criteria for Removal from Study
xLost to follow-up
Subjects will be considered lost to follow-up only if no contact has been established by the time the study is completed such that there is insufficient information to determine the subjectâ€™s status at that time. Subjects who refuse continuing participation in the study including telephone 
contact should be documented as â€œwithdrawal of  consentâ€ rather than â€œlost to follow-up.â€ 
Investigators should document atte mpts to re-establish contact with missing subjects throughout 
the study period. If contact with a missing subj ect is re-established, th e subject should not be 
considered lost to follow-up and any evaluati ons should resume according to the protocol.
xDeath
xPatient voluntarily chooses to withdraw from the protocol
xInvestigator discretion
xPI decision to close the study
xCompleted study follow-up period
Subjects who permanently discontinue treatment may either be considered to have completed the 
study or not to have completed the study. An individual subject will be considered to have completed the study if the subject was followed through the last protocol-specified visit/assessment (including te lephone contact) regardless of the number of doses of 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
45investigational product that was received. Subjects will be considered not to have completed the 
study if consent was withdrawn or the subject was lost to follow-up.
3.6.3 Off Protocol Therapy and Off Study Procedure
Authorized staff must notify Central Registratio n Office (CRO) when a subject is taken off 
protocol therapy and when a subject is taken off-study. A Participant Status Updates Form from 
the web site ( http://home.ccr.cancer.gov/intra/eligibility/welcome.htm ) main page must be 
completed and sent via encrypted email to: NCI Central Registration Office  
ncicentralregistration-l@mail.nih.gov.
4 CONCOMITANT MEDICATIONS/MEASURES
All routine and appropriate supportive care (inc luding blood products) will be provided during 
this study, as clinically indicated, and in accordance with the standard of care practices. Clinical 
judgment should be utilized in the treatment  of any AE experienced by the patient.
Investigators may prescribe concomitant medications or treatments (e.g., acetaminophen, 
diphenhydramine) deemed necessary to provide adequate prophylactic or supportive care except 
for those medications identified as â€œexcludedâ€ as listed in Section 4.1. Best supportive care 
(including antibiotics, nutritional support, corr ection of metabolic disorders, optimal symptom 
control and pain manage ment [including palliativ e radiotherapy, etc.]) should be used when 
necessary for all subjects. Information on a ll concomitant medicati ons, administered blood 
products, as well as interventions occurring during the study must be recorded on the patientâ€™s eCRF.
4.1 P
ROHIBITED CONCOMITANT MEDICATIONS
Subjects must be instructed not to take any medications, including ove r-the-counter products, 
without first consulting with the investigator.
The following medications are considered exclus ionary during the study. The sponsor must be 
notified if a subject receives any of these during the study.
1. Any investigational anticancer therapy2. Monoclonal antibodies against CTLA-4, PD- 1, or PD-L1 through 90 days post last dose 
during the study
3. Any concurrent chemotherapy, radiotherapy (except palliative radiotherapy), 
immunotherapy, biologic or hormonal therapy for cancer treatment. Concurrent use of 
hormones for noncancer-related conditions (e .g., insulin for diabetes and hormone 
replacement therapy) is acceptable
4. Immunosuppressive medications including, but not limited to systemic corticosteroids at 
doses not exceeding 10 mg/day of prednisone or equivalent, methotrexate, azathioprine, 
and TNF-Ä®EORFNHUV8VHRILPPXQRVXSSUHVVLYHPHGLFDWLRQVIRUWKHPDQDJH PHQWRI
investigational product-re lated AEs or in subjects with cont rast allergies is acceptable. In 
addition, use of inhaled, topical, and intran asal corticosteroids is permitted. Temporary 
uses of corticosteroids for concurrent illnesses (e.g., f ood allergies, CT contrast 
hypersensitivity, etc.) are acceptable.
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
465. Live attenuated vaccines during the study through 180 days after the last dose of both 
investigational products
6. Inactivated vaccinations Â± 30 days around any dose of investigational product.
5 BIOSPECIMEN COLLECTION
5.1 CORRELATIVE STUDIES FOR RESEARCH/PHARMACOKINETIC STUDIES
The correlative studies which we wish to pe rform are outlined below and summarized in the 
table. All samples will be sent to Dr. Figgâ€™s lab for processing and storage until they are 
distributed to Dr. Gretenâ€™s lab or MedImmune for sample analysis as described in the protocol.
A description of each test including a brief statement of rationale and processing information is made below.
Test/assay Volume blood 
(approx.)Type of 
tubeCollection point (+/-
48hrs)Location of 
specimen 
analysis
Immune- monitoring 120 mL (for 
PBMC)EDTA Baseline on day of biopsy,C2D1, C3D1, C4D1Greten Lab
5-10 mL (for 
serum)EDTA
PK 3 mL SST C1D1 (pre- dose and End-
of Infusion (EOI)*) 
C1D8 (local patients only)
C1D15 (local patients 
only)
C2D1 (pre-dose)
C3D1 (pre-dose)
C4D1 (pre-dose)C7D1 (pre-dose and End-
of Infusion(EOI)*)
C10D1 (pre-dose)
C13D1 (pre-dose)
End-of-treatment (EOT), 
and 
90-days post last dose. *End of infusion PK 
samples should be collected within 
approximately 15 minutes. 
C1D1 and C7D1 :pre-MedImmune /Intertek Alta
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
47Test/assay Volume blood 
(approx.)Type of 
tubeCollection point (+/-
48hrs)Location of 
specimen 
analysis
infusion and immediately 
post infusion.
Immunogenicity
(Antidrug antibody 
monitoring) 4m L S S T Pre-dose: C1D1, C2D1, 
C4D1, C7D1, C10D1,
C13D1
End of treatment90-day post last doseMedimmune/PPD
ANA 4 mL SST Baseline and C4D1 CC Department 
of Laboratory 
Medicine (DLM)
AMA & 
Liver/kidney microsomal antibody4 mL SST Baseline and C4D1 CC DLM will send to Mayo Labs
T cell 
activation/ICOS 
expression
(PBMC)12 mL ACD-B (6 
mL 
collection tube)Pre infusion C1D1, C1D8
(local patients only),
C1D15 (local patients 
only), C2D1, C3D1, C5D1, and EOT (end of 
treatment) Medimmune/ 
Quintiles
Plasma-based assays for circulating 
receptors/ligands e.g. 
PDL16m L E D T A C1D1 (pre- dose and End-
of Infusion (EOI)*
C1D8 (local patients only)
C1D15 (local patients 
only)
C2D1 (pre-dose)
C3D1 (pre-dose)
C4D1 (pre-dose)C7D1 (pre-dose and End-
of Infusion(EOI)*)
C10D1 (pre-dose)
C13D1 (pre-dose)
End-of-treatment (EOT), 
and 
90-days post last dose. 
*End of infusion PK Medimmune
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
48Test/assay Volume blood 
(approx.)Type of 
tubeCollection point (+/-
48hrs)Location of 
specimen 
analysis
samples should be 
collected within 
approximately 15 minutes. 
C1D1 and C7D1 :pre-
infusion and immediately 
post infusion.
Mandatory tumor 
biopsyNA NA Baseline + C2D1 Pathology
5.2 NCI CORRELATIVE STUDIES
5.2.1 Immune monitoring (all arms)
We will analyze PBMC for quantitative and functional changes of effector cells as well as 
analyze sera for cytokines and chemokines. The effect on (i) CD4 T cell number and activity, (ii) CD8 T cell number and activity, (iii) NK cell number and activity, (iv) Treg number, (vi) MDSC: frequency + functional assay, (v ii) selected cytokines in serum. 
Patients will undergo blood samplin g (c.120mls blood) on the time points outlined in the table 
(+/- 48 hrs.). Blood will initially be sent to the Figgâ€™s Blood Processing Core (BPC) for barcoding and processing (Section 5.4.1). On certain occasions, the blood may also be brought to 
the Greten lab for processing and analysis. PBMC will be isolated by Ficoll density centrifugation. Aliquots of 1 x 10
7PBMC/tube will be individually frozen â€“ after initial handling 
and processing at the Figg laboratory.
5.2.2 Liver autoantibody panel for autoimmune hepatitis (AIH)
The AIH Diagnostic Panel includes tests for ac tin (smooth muscle) antibody, antinuclear 
antibodies (ANAs), and liver/kidney microsome antibody (LKM-1). ANAs and actin antibody 
are associated with type 1 AIH, the most common form in the United States, while LKM-1
antibody is associated with type 2 AIH, more commonly found in Europe and in some South American countries. The panel also incl udes mitochondrial antibod y, which can help 
differentiate AIH from PBC. Given that autoimmune hepatitis is a potential complication of 
immune checkpoint inhibition we will perform this panel of autoimmune antibodies to 
investigate this. Samples will be collected at baseline and on D85 approximately. These antibody
titers are exploratory and will not be used to guide therapy in the absence of clinical correlation.
5.2.3 Mandatory tumor biopsy
An image guided tumor biopsy will be attempted (if feasible) at baseline and (approx.) D29 (+/-
7 days) for analysis of immune infiltration. Tumor Tissue will be processed by the Department of 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
49Pathology, NCI, NIH (Dr. David Kleiner). Two core biopsies will be the attempted. For each 
specimen obtained the core will be divided in two parts for Surgical Pathology and frozen preservation. If for some reason only one core is ab le to be obtained, the co re will be divided, 
with half submitted to Surgical Pathology and half used for PD studies.
1) Formalin-fixed.
i. The half fixed in 10% formalin will be submitted to Surgical Pathology, 
CCR/NCI (Bldg. 10, 2N212). 
ii. The specimens will have routine H&E stains made as well as 5 additional 
unstained sections. 
2) Frozen-preservation
i. Two 1.5 ml cryogenic vials (obtained from Greten lab) will be  labeled with the 
patientâ€™s name, accession number (HP#) and date using a waterproof sharpie. 
ii. The isotherm flask (Greten lab) will be filled with liquid nitrogen on the morning 
of the procedure and will be available t ogether with the cryogenic vials for pick 
up from there when radiology.
iii. Once the biopsy is ready, the half-core to be cryopreserved will be transferred into 
an empty 1.5-mL cryogenic vial with the use of sterile, pre-chilled (in dry ice) disposable tweezers.
iv. The vial with specimen will be imme diately dropped into liquid nitrogen 
contained in an isotherm flask. 
v. The frozen half will be transferred in th e isotherm flask to th e protocol-specified 
location for that particular analysis. 
5.2.4 Details of Planned Tumor Analysis
We will attempt to perform immunohi stochemically and gene analysis of all tumor biopsies. IHC 
analysis will include characterization of immu ne cell populations - T-cell, MDSC, NK cells, 
macrophages- as well as markers of importance in the microenvironment such as PD-L1/2 
expression. RNA analysis will be performed as follows: RNA will be extracted and sent to Cell Processing 
Section at DTM for microarray analysis using a standard Affymetrix array. Genetic analysis will be on tumor tissue only. No germ line analysis is planned or will be performed without study 
amendment and IRB approval.
5.3 M
EDIMMUNE PLANNED STUDIES
All samples will be processed and cryopreserved in the Figg laboratory. Transfer in batch to 
Medimmune/vendor facilities for further analysis will occur at a later date. Please also seeAppendix B .
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
505.3.1 Pharmacokinetics
The time points for PK sampling are described in  the table in section 5 above. A validated 
enzyme-linked immunosorbent assay (ELISA) will be  used for the quantitative determination of 
Tremelimumab and Durvalumab in human serum.Samples will be collected: Day 1 (pre-dose and End of infusion), Day 8 (pre-dose), Day 15 (pre-
dose in case of q 2weeks regimen), Day 29 (pre-dose), Day 57 (pre-dose), Day 85(pre-dose), 
Day 169 (pre-doe and End of Infusion), Day 253 (pre-dose), Day 337 (pre-dose), End of 
treatment and 90 day post last dose. 
5.3.2 Immunogenicity 
The time points for the assessment of anti-Tr emelimumab and anti-Durvalumab antibodies are 
described in the table in section 5 above .A validated electrochemiluminescence assay (ECLA) 
using a Meso Scale Discovery (MSD) platform will be used for the detection of anti-drug 
antibodies against Tremelimumab and Durvalumab in human serum.
Samples will be collected Pre-dose Day 1, Day 29, Day 85, Day 169, Day 253, Day 337. Additional samples will be collected End of treatment, 90-day post last dose. 
5.3.3 T CELL Activation/ICOS expression
The number and subsets of T cells as well as other immune cells will be evaluated in PBMC by 
flow cytometry. The activation status of T cells will also be assessed in the same study. Whole blood samples will be collected pre-infusion at D1, D8, D15 (in case of q2 regimen), D29, D57,
D113 and EOT. Samples will be pr ocessed to PBMC and stored frozen until time of analysis. 
Additionally, absolute lymphocyte counts at ba seline and in response to Tremelimumab and 
Durvalumab treatment will be evaluated for any relationship with treatment outcome. Isolated PBMCs may be used for additiona l functional analysis or assessment of the diversity of the 
immune cell repertoire
5.3.4 Plasma-based assays for circulat ing receptors/ligands e.g. PDL1 
Plasma samples are to be collected at the time points listed directly into plastic 6 ml lavender
vacutainer tube with EDTA as anticoagulant. 2-3 ml of obtained plasma are to be aliquoted (1 ml 
each) and frozen. Samples may be analyzed for circulating levels of soluble factors such as CRP, cytokines, and chemokines. They may include but are not limited to soluble CTLA-4, soluble PD-L1, soluble B7.1/B7.2, soluble IL-6R, vascular endothelial growth factor, fibroblast growth factor, IL-1 IL-2, IL-4, IL-6, IL-8, IL- 10, cancer biomarkers (alpha fetoprotein, 
carcinoembryonic antigen, cancer antigen 125, pros tate specific antigen, soluble mesothelin-
related protein [SMRP]), granzyme B, IFN, C-X-C motif chemokine 10 (CXCL10), suppressor of cytokine signaling 3 (SOCS3), a prolifer ation inducing ligand, B- cell activating factor, 
insulin-like growth factor (IGF)-1, IGF-2, and autoantibodies to host and tumor antigens and explore their association with Tremelimumab and Durvalumab treatment and clinical outcome.
Samples will be collected: Day 1 (pre-dose and End of infusion), Day 8 (pre-dose), Day 15 (pre-
dose in case of q 2weeks regimen), Day 29 (pre-dose), Day 57 (pre-dose), Day 85(pre-dose), 
Day 169 (pre-dose and End of Infusion), Day 253 (pre-dose), Day 337 (pre-dose), End of treatment and 90 day post last dose. 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
515.4 S AMPLE STORAGE ,TRACKING AND DISPOSITION
Samples will be ordered in CRIS and tracked through a Clinical Trial Data Management system.
Should a CRIS screen not be available, the CR IS downtime procedures  will be followed. All 
samples will be sent to Dr. Figgâ€™s lab for processing and storage until they are distributed to Dr. Gretenâ€™s lab or MedImmune for sample an alysis as described in the protocol.
5.4.1 Samples Managed by Dr. Figgâ€™ s Blood Processing Core (BPC) 
5.4.1.1 BPC contact information 
Please e-mail Julie Barnes at Julie.barnes@nih. gov and Paula Carter pcar tera@mail.nih.gov at 
least 24 hours before transporting samples (the Friday before is preferred).
For sample pickup, page 102-11964.For immediate help, call 240-760-6180 (main blood processing core number) or, if no answer, 
240-760-6190 (main clinical pharmacology lab number).
For questions regarding sample processing, c ontact Julie Barnes by e-mail or at 240-760-6044.
5.4.1.2 Sample Data Collection
All samples sent to the Blood Processing Core  (BPC) will be barcoded, w ith data entered and 
stored in the LABrador (aka LabSamples) utilized by the BPC. This is a secure program, with 
access to LABrador limited to defined Figg la b personnel, who are issued individual user 
accounts. Installation of LABra dor is limited to computers specified by Dr. Figg. These 
computers all have a password re stricted login screen. All Figg  lab personnel with access to 
patient information annually complete the NI H online Protection of Human Subjects course. 
LABrador creates a unique barcode ID for every sample and sample box,  which cannot be traced 
back to patients without LABrador access. Th e data recorded for each sample includes the 
patient ID, name, trial name/protocol number, time drawn, cycle time point, dose, material type, as well as box and freezer location. Patient demogr aphics associated with  the clinical center 
patient number are provided in the system. For each sample, there are notes associated with the processing method (delay in sample proce ssing, storage conditions on the ward, etc.).
5.4.1.3 Sample Storage 
Barcoded samples are stored in barcoded boxes in a locked freezer at either -20 or -80 qC
according to stability requirements. These freezers are located onsite in the BPC and offsite at 
NCI Frederick Central Repository Services in Frederick, MD. Visitors to the laboratory are 
required to be accompanied by laboratory staff at all times. 
Access to stored clinical samples is restricted. Samples will be stored until requested by a
researcher named on the protoc ol. All requests are monitored and tracked in LABrador. All 
researchers are required to sign a form stating that the samples are only to be used for research purposes associated with this trial (as per the IRB approved protocol) and that any unused 
samples must be returned to the BPC. It is the responsibility of the NCI Principal Investigator to 
ensure that the samples requested are being us ed in a manner consistent with IRB approval.
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
525.4.2 Procedures for Storage of Tissue Sp ecimens in the Laboratory of Pathology
Tissues designated for clinical diagnostics are tr ansported to the Laboratory of Pathology (LP) 
where they are examined grossly and relevant portions are fixed, embedded in paraffin and 
sectioned and stained for diagnostic interpretation. Unutilized excess tissue  that is not embedded 
in paraffin is stored in formalin for up to three months, in accordance with College of American Pathologists/Joint Commission on Accreditation of Healthcare Organizations (CAP/JCAHO) guidelines, and then discarded. Following comp letion of the diagnostic workup, the slides and 
tissue blocks are stored indefinitely in the LPâ€™s clinical archives. All specimens are catalogued and retrieved utilizing the clinical laboratory information systems, in accordance with CAP/JCAHO regulations. The use of any stored spec imens for research purposes is only allowed 
when the appropriate IRB approval has been obta ined. In some cases, this approval has been 
obtained via the original protocol on which the patient was enrolled.
5.4.3 Protocol Completion/ Sample Destruction
All specimens obtained in the protocol are used as defined in the protocol. Any specimens that 
are remaining at the completion of the protocol will be stored in the conditions described in 
Section 5.4.1.3. The study will remain open so long as sample or data analysis continues.
Samples from consenting subjects will be stored until they are no longe r of scientific value or if a 
subject withdraws consent for their continued use, at which time they will be destroyed. The PI 
will report any loss or destruction of samples to the NCI IRB as soon as he is made aware of 
such loss. If the patient withdraws consent the participantâ€™s data will be excluded from future distributions, but data that have already been distributed for approved research use will not be able to be retrieved.
xThe PI will report destroyed samples to the IRB if samples become unsalvageable 
because of environmental factors (ex. broken freezer or lack of dry ice in a shipping 
container) or if a patient withdraws consent. Samples will also be reported as lost if they are lost in transit between facilities or misplaced by a researcher. Freezer problems, lost samples or other problems associated with samples will also be reported to the IRB, the NCI Clinical Director, and the office of the CCR, NCI.
6 DATA COLLECTION AND EVALUATION 
6.1 D
ATA COLLECTION
The NCI investigators will be responsible for th e collection, maintenance,  and quality control of 
the study data. Clinical data will be entered into the NCI C3D electronic database at least once 
every two weeks when patients are enrolled on the trial. Protocol-specific eCRFs will be 
developed for this trial in C3D.  All data will be kept secure. The PI will be responsible for 
overseeing entry of data into an in-house password  protected electronic syst em and ensuring data 
accuracy, consistency and timeliness. The principal investigator, associate investigators/research 
nurses and/or a contracted data manager will assist with the data management efforts. All data obtained during the conduct of the pr otocol will be kept in secure  network drives or in approved 
alternative sites that comply with NIH security standards. Primary and final analyzed data will have identifiers so that research data can be attributed to an individual human subject participant.The ICOS/activation PBMC data should be transferred from Quintiles to the Biomarker Data 
Mining System at MedImmune. All analysis done at MedImmune should be shared with NCI.
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
53All adverse events, including clinically signif icant abnormal findings on laboratory evaluations, 
regardless of severity, will be followed until return to baseline or stabilization of event. Patients 
will be followed for adverse events for at least 30 days, after removal from study treatment or until off-study, whichever comes first. 
An abnormal laboratory valu e will be recorded in the database as an AE only if the laboratory 
abnormality is characterized by any of the following:
xResults in discontinuation from the study
xIs associated with clinical signs or symptoms 
xRequires treatment or any other therapeutic intervention
xIs associated with death or another seri ous adverse event, including hospitalization. 
xIs judged by the Investigator to be of significant clinical impact
xIf any abnormal laboratory result is considered clinically significant, the investigator will 
provide details about the action taken with respect to the test  drug and about the patientâ€™s 
outcome.
End of study procedures: Data will be stored according to HHS and, FDA regulations, and NIH 
Intramural Records Retenti on Schedule as applicable. 
Loss or destruction of data: Should we become aware that a majo r breach in our plan to protect 
subject confidentiality and trial data has occurred, the IRB will be notified.
6.2 DATA SHARING PLANS
6.2.1 Human Data Sharing Plan
I will share de-identified human data generated in this research for future research 
in a NIH-funded or approved public repository clinicaltrials.gov
in BTRIS
in publication and/or public presentations
at the time of publication or shortly thereafter.
6.3 R ESPONSE CRITERIA
For the purposes of this study, patients should be  re-evaluated for response every 8 weeks. In 
addition to a baseline scan, c onfirmatory scans should also be obtained 4-8 weeks following 
initial documentation of objective response.
Before stopping the treatment, progressive diseas e should be confirmed by imaging preferably 6 
weeks after progression has been diagnosed according to RECIST 1.1. Treatment may be 
continued despite progression according to RE CIST 1.1 if modified irRC do not match the 
criteria for progression and there are no new tumor-related symptoms or worsening of existing 
symptoms.
Confirmation of progressi on will not be done if in the opinion of Investigator patient has better 
option with another treatment.
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
54Response Evaluation Criteri a in Solid Tumors (RECIST) : Response and progression will be 
evaluated in this study using the new international criteria proposed by the revised Response 
Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1)[ 45]. Changes in the 
largest diameter (unidimensional measurement) of the tumor lesions and the shortest diameter in 
the case of malignant lymph nodes are used in  the RECIST criteria. To assess response, the 
tumor burden at baseline will be estimated also and used for comparison with subsequent measurements. The treatment may continue immune checkpoint inhibitors (Tremelimumab
and/or Durvalumab) and the Subject may remain on study according to the investigatorâ€™s 
decision in case of progressive disease according to RECIST 1.1. For this situation, modified
Immune-Related response criteria (irRC) based on RECIST 1.1 in all subjects without worsening 
of existing symptoms or developing new tumor-related symptoms at the time of progression will be used. Modified Immune-related response criter ia will be primarily used as guidance for 
further clinical care.
Modified immune-related response criteria (irRC): This new classification is based on the 
recent learning from clinical studies with cancer immunotherapies that even if some new lesions 
appear at the beginning of a treatment or if the total tumor burden does not increase substantially, 
tumor regressions or stabilizations might still occur later. The irRC were created using bi-
dimensional measurements (as previously wide ly used in the World Health Organization 
criteria). For this trial, the concepts of the ir RC are combined with RECIST 1.1 to come up with 
the modified irRC. For modified irRC, only target and measurable lesi ons are taken into account. In contrast to the
RECIST 1.1 criteria, the modified irRC criteria (a) require confirmation of both progression and
response by imaging at 6 weeks after initial imaging  (b) do not necessarily score the appearance 
of new lesions as progressive disease if the su m of lesion diameters of target lesions (minimum 
of 10 mm per lesion, maximum of 5 target lesion s, maximum of 2 per or gan) and measurable 
QHZOHVLRQVGRHVQRWLQFUHDVHE\Â•
6.3.1 Definitions
6.3.1.1 Evaluable for toxicity 
All patients will be evaluable for toxicity fr om the time of their first treatment with 
Tremelimumab and Durvalumab.
6.3.1.2 Evaluable for objective response 
Only those patients who have measurable disease pr esent at baseline, have received at least one 
cycle of therapy, and have had their disease re-evaluated will be considered evaluable for 
response. These patients will have their response cl assified according to the definitions stated 
below. (Note: Patients who exhibit objective disease progression prior to the end of cycle 1 will also be considered evaluable.)
6.3.2 Disease Parameters
Measurable disease:
Measurable lesions are defined as those that can be accurately measured in at least one 
dimension (longest diameter to be recorded) as: 
xBy chest x-ray: >20 mm; 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
55xBy CT scan: 
oScan slice thickness 5 mm or under as >10 mm with CT scan
oScan slice thickness >5 mm: double the slice thickness 
xWith calipers on clinical exam: >10 mm.  
All tumor measurements must be recorded in millimeters (or decimal fractions of centimeters).
Malignant lymph nodes 
To be considered pathologically enlarged a nd measurable, a lymph node must be >15 mm in 
short axis when assessed by CT scan (CT sc an slice thickness recommended to be no greater 
than 5 mm). At baseline and in follow-up, only th e short axis will be measured and followed.
Non-measurable disease
All other lesions (or sites of disease), including small lesions (longest diameter <10 mm or 
pathological l \PSKQRGHVZLWKÂ•WRPPVKRUWD[LVDUHFRQVLGHUHGQRQ -measurable 
disease. Bone lesions, leptomeningeal disease, ascites, pleural/pericardial effusions, lymphangitis cutis/pulmonitis, inflammatory breast disease, and abdominal masses (not followed by CT or 
MRI), are considered as non-measurable.
Note: Cystic lesions that meet the criteria for ra diographically defined simple cysts should not be 
considered as malignant lesions (neither meas urable nor non-measurable) since they are, by 
definition, simple cysts.â€˜Cystic lesionsâ€™ thought to represent cystic metastases can be considered as measurable lesions, 
if they meet the definition of measurability desc ribed above. However, if non-cystic lesions are 
present in the same patient, these are preferred for selection as target lesions.
Target lesions
All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in total, 
representative of all involved or gans, should be identified as target lesions and recorded and 
measured at baseline. Target lesions  should be selected on the basis of their size (lesions with the 
longest diameter), be representative of all invol ved organs, but in addition should be those that 
lend themselves to reproducible repeated measurements. It may be the case that, on occasion, the 
largest lesion does not lend itself to reproducible measurement in  which circumstance the next 
largest lesion which can be meas ured reproducibly should be selected. A sum of the diameters 
(longest for non-nodal lesions, short axis for nodal lesions) for all target lesions will be 
calculated and reported as the base line sum of diameters. If lymph nodes are to be included in the 
sum, then only the short axis is added into the sum. The baseline sum of diameters will be used as reference to further characterize any objective tumor regression in the measurable dimension of the disease.
Non-target lesions
All other lesions (or sites of disease) includi ng any measurable lesions over and above the 5 
target lesions should be identified as non-target lesions and should also be recorded at baseline.
Measurements of these lesions are not required, but the presence, absence, or in rare cases 
unequivocal progression of each should be noted throughout follow-up.
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
566.3.3 Methods for Evaluation of Measurable Disease
All measurements should be taken and recorded in  metric notation using a ruler or calipers. All 
baseline evaluations should be performed as closel y as possible to the beginning of treatment and 
never more than 4 weeks before the beginning of the treatment.
The same method of assessment and the same t echnique should be used to characterize each 
identified and reported lesion at baseline and during follo w-up. Imaging-based evaluation is 
preferred to evaluation by clinical examinati on unless the lesion(s) be ing followed cannot be 
imaged but are assessable by clinical exam.
6.3.3.1 Clinical lesions
Clinical lesions will only be considered measurab le when they are superficial (e.g., skin nodules 
and palpable lymph nodes) and t10 mm diameter as assessed using calipers (e.g., skin nodules).
In the case of skin lesions, documentation by co lor photography, including a ruler to estimate the 
size of the lesion, is recommended. 
6.3.3.2 Chest x-ray
Lesions on chest x-ray are acceptable as measurab le lesions when they are clearly defined and
surrounded by aerated lung. However, CT is preferable. 
6.3.3.3 Conventional CT and MRI 
This guideline has defined measurability of lesions on CT scan based on the assumption that CT 
slice thickness is 5 mm or less. If CT scans have slice thickness greater than 5 mm, the minimum size for a measurable lesion should be twice the slice thickness. MRI is also acceptable in certain situations (e.g. for body scans).
Use of MRI remains a complex issue. MRI has excellent contrast, spatial, and temporal 
resolution; however, there are many image acquis ition variables involved in MRI, which greatly 
impact image quality, lesion conspicuity, and measurement. Furthermore, the availability of MRI is variable globally. As with CT, if an MRI is  performed, the technical specifications of the 
scanning sequences used should be optimized for th e evaluation of the type and site of disease.
Furthermore, as with CT, the modality used at  follow-up should be the same as was used at 
baseline and the lesions should be  measured/assessed on the same pulse sequence. It is beyond 
the scope of the RECIST guidelines to prescribe specific MRI pulse sequence parameters for all scanners, body parts, and diseas es. Ideally, the same type of scanner should be used and the 
image acquisition protocol should be followed as closely as possible to prior scans. Body scans should be performed with breath-hold scanning techniques, if possible.
6.3.3.4 Ultrasound
Ultrasound is not useful in assess ment of lesion size and should not be used as a method of 
measurement. Ultrasound examinations cannot be reproduced in their entirety for independent 
review at a later date and, because they are ope rator dependent, it cannot be guaranteed that the 
same technique and measurements will be taken from one assessment to the next. If new lesions are identified by ultrasound in the course of the study, confirmation by CT  or MRI is advised. If 
there is concern about radiation exposure at CT, MRI may be used instead of CT in selected 
instances.
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
576.3.3.5 Endoscopy, Laparoscopy
The utilization of these techniques for objective tumor evaluation is not advised. However, such 
techniques may be useful to confirm complete pathological re sponse when biopsies are obtained 
or to determine relapse in trials where recurrence following complete response (CR) or surgical resection is an endpoint.
6.3.3.6 Cytology, Histology 
These techniques can be used to differentiate between partial responses  (PR) and complete 
responses (CR) in rare cases (e .g., residual lesions in tumor types, such as germ cell tumors, 
where known residual benign tumors can remain).
The cytological confirmation of the neoplastic origin of any effusion that appears or worsens 
during treatment when the measurable tumor has me t criteria for response or stable disease is 
mandatory to differentiate between response or stable  disease (an effusion may be a side effect of 
the treatment) and progressive disease.
6.3.4 Response Criteria
6.3.4.1 Evaluation of Target Lesions
Revised Response Evaluation Criteri a in Solid Tumors (RECIST) 1.1
Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes 
(whether target or non-target) must ha ve reduction in short axis to <10 mm.
Partial Response (PR): At least a 30% decrease in  the sum of the diameters of target lesions, 
taking as reference the baseline sum of diameters.
Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, 
taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions). NOTE: While RECIST PD will be noted and recorded the immune-related RECIST criteria will be applied to determine discontinuati on of study treatment. 
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
6.3.4.2 Evaluation of Non-Target Lesions
Revised Response Evaluation Criteri a in Solid Tumors (RECIST) 1.1
Complete Response (CR): Disappear ance of all non-target lesions  and normalization of tumor 
marker level. All lymph nodes must be non-pathological in size (<10 mm short axis).
Note: If tumor markers are initially above the upper normal limit, they must normalize for a 
patient to be considered in  complete clinical response.
Non-CR/Non-PD: Persistence of one or more non- target lesion(s) and/or  maintenance of tumor 
marker level above the normal limits.
Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal 
progression of existing non-target lesions. Unequivocal progression should not normally trump 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
58target lesion status. It must be representative of overall disease status change, not a single lesion 
increase.
Although a clear progression of â€œnon-targetâ€ lesi ons only is exceptional, the opinion of the 
treating physician should prevail in such circum stances, and the progression status should be 
confirmed at a later time by the review panel (or Principal Investigator).
6.3.4.3 Evaluation of Best Overall Response
The best overall response is the best response recorded from the start of the treatment until 
disease progression/recurrence (taking as reference for progressive disease the smallest 
measurements recorded si nce the treatment started) . The patient's best re sponse assignment will 
depend on the achievement of both m easurement and confirmation criteria.
For Patients with Measurable Disease (i.e., Target Disease)
Target 
LesionsNon-Target 
LesionsNew 
LesionsOverall 
ResponseBest Overall Response when 
Confirmation is Required*
CR CR No CR >4 wks. Confirmation**
CR Non-
CR/Non-PDNo PR
>4 wks. Confirmation**CR Not 
evaluatedNo PR
PR Non-
CR/Non-
PD/not 
evaluatedNo PR
SD Non-
CR/Non-
PD/not 
evaluatedNo SD
Documented at least once >4 
wks. from baseline**
PD Any Yes or 
NoPD
no prior SD, PR or CR Any PD*** Yes or 
NoPD
Any Any Yes PD
* See RECIST 1.1 manuscript for further details.
** Only for non-randomized trials w ith response as primary endpoint.
*** In exceptional circumstances, une quivocal progression in non-target 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
59Target 
LesionsNon-Target 
LesionsNew 
LesionsOverall 
ResponseBest Overall Response when 
Confirmation is Required*
lesions may be accepted as disease progression.
Note: Patients with a global deterior ation of health status requiring 
discontinuation of trea tment without objective evidence of disease 
progression at that time should be reported as â€œ symptomatic 
deterioration.â€ Every effort should be made to document the objective 
progression even after disc ontinuation of treatment.
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
60For Patients with Non-Measurable Disease (i.e., Non-Target Disease)
6.3.5 Duration of Response
6.3.5.1 Duration of overall response
The duration of overall response is measured from  the time measurement criteria are met for CR 
or PR (whichever is first recorded) until the first date that recurrent or progressive disease is 
objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started).
The duration of overall CR is measured from the time measurement criteria are first met for CR 
until the first date that progressive disease is objectively documented.
6.3.5.2 Duration of stable disease 
Stable disease is measured from the start of the treatment until the criteria for progression are met, taking as reference the smallest measurements recorded since the treatment started, including the baseline measurements. 
6.4 M
ODIFIED IMMUNE -RELATED RESPONSE CRITERIA (IRRC)
Modified immune-related response cr iteria (irRC) will also be employed in this study. This new 
classification is based on the re cent learning from clinical st udies with cancer immunotherapies 
that even if some new lesions appear at the beginning of a treatment or if the total tumor burden 
does not increase substantially, tumor regressions or stabilizations might still occur later. The irRC were created using bi-dimensional measuremen ts (as previously widely used in the World 
Health Organization criteria). For this trial, the concepts of the irRC are combined with RECIST 
1.1 to come up with the modified irRC.
6.4.1 The modified irRC based on RECIST 1.1: 
New non-measurable lesions: Do not de fine progression but precludes (irCR).
New measurable lesions: Incorporated into tumor burden.Non-Target Lesions New Lesions Overall Response
CR No CR
Non-CR/non-PD No Non-CR/non-PD*
Not all evaluated No not evaluated
Unequivocal PD Yes or No PD
Any Yes PD
* â€˜Non-CR/non-PDâ€™ is preferred over â€˜stable diseaseâ€™ for non-target disease since 
SD is increasingly used as an endpoint for assessment of efficacy in some trials 
so to assign this category when no le sions can be measured is not advised
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
61Overall irCR: Complete disappearance of all le sions (whether measurable or not) and no new 
lesions. All measurable lymph nodes also must  have a reduction in short axis to 10 mm.
Overall irPR: Sum of the longest diameters of target and new measurable lesions decreases 
Â•
Overall irSD: Sum of the longest diameters of target and new me asurable lesions neither irCR, 
irPR, (compared to baseline) or irPD (compared to nadir).
Overall irPD: Sum of the longest diameters of target and new measurable lesions increase VÂ•
(compared to nadir), confirmed by a repeat, cons ecutive observations at least 4 weeks (normally 
it should be done at 6 weeks) from the date first documented.Please refer to Appendix C .
6.5 T
OXICITY CRITERIA
The following adverse event management guidelines are intended to ensure the safety of each 
patient while on the study. The descriptions and grading scales found in the revised NCI 
Common Terminology Criteria for Adverse Events  (CTCAE) version 4.0 will be utilized for AE 
reporting. All appropriate treatment areas should have access to a copy of the CTCAE version 
4.0. A copy of the CTCAE version 4.0 can be  downloaded from the CTEP web site 
(http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40 ).
7 SAFETY REPORTING REQUIREMENTS/DATA AND SAFETY MONITORING 
PLAN
7.1 D EFINITIONS
7.1.1 Adverse Event
Any untoward medical occurrence in a human subject, including any abnormal sign (for 
example, abnormal physical exam  or laboratory finding), symptom, or disease, temporally 
associated with the subjectâ€™s participation in research, whether or not considered related to the 
subjectâ€™s participation in the research.
7.1.2 Suspected adverse reaction
Suspected adverse reaction means any adverse event for which there is a reasonable possibility 
that the drug caused the adverse event. For th e purposes of IND safety reporting, â€˜reasonable 
possibilityâ€™ means there is evidence to suggest a causal relationship between the drug and the 
adverse event. A suspected adverse reaction implies a lesser degree of certainty about causality than adverse reaction, which means any adverse event caused by a drug.
7.1.3 Unexpected adverse reaction
An adverse event or suspected adverse reaction is  considered â€œunexpectedâ€ if it is not listed in 
the investigator brochure or is not listed at the sp ecificity or severity that  has been observed; or, 
if an investigator brochure is not required or available, is not cons istent with the risk information 
described in the general inve stigational plan or elsewhere in the current application. 
"Unexpectedâ€, also refers to adverse events or suspected adverse reactions that are mentioned in 
the investigator brochure as occurring with a class of drugs or as anticipated from the 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
62pharmacological properties of the drug, but are no t specifically mentioned as occurring with the 
particular drug und er investigation.
7.1.4 Serious 
An Unanticipated Problem or Prot ocol Deviation is serious if it meets the definition of a Serious 
Adverse Event or if it compromises the safety , welfare or rights of subjects or others.
7.1.5 Serious Adverse EventAn adverse event or suspected adverse reaction is considered serious if in the view of the 
investigator or the sponsor, it results in any of the following:
xDeath,
xA life-threatening adverse drug experience
xInpatient hospitalization or prolongation of existing hospitalization
xPersistent or significant incapacity or subs tantial disruption of the ability to conduct 
normal life functions
xA congenital anomaly/birth defect.
xImportant medical events that may not result in death, be life-threatening, or require hospitalization may be considered a serious  adverse drug experience when, based upon 
appropriate medical judgment, they may jeopard ize the patient or subject and may require 
medical or surgical intervention to prevent one of the outcomes listed in this definition.
7.1.6 Disability
A substantial disruption of a personâ€™s  ability to conduct normal life functions.
7.1.7 Life-threatening adverse drug experience
Any adverse event or suspected adverse reaction that  places the patient or subject, in the view of 
the investigator or sponsor, at immediate risk of death from the reaction as it occurred, i.e., it 
does not include a reaction that had it occurred in  a more severe form, might have caused death.
7.1.8 Protocol Deviation (NIH Definition)Any change, divergence, or departure fro m the IRB approved research protocol.
7.1.9 Non-compliance (NIH Definition)The failure to comply with applicable NIH Human Research Protections Program (HRPP) 
policies, IRB requirements, or regulatory requirements for the protection of human research 
subjects.
7.1.10 Unanticipated Problem
Any incident, experience, or outcome that:
xIs unexpected in terms of nature, sev erity, or frequency in relation to 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
63(a) the research risks that are described in the IRB-approved research protocol and informed 
consent document; Investigatorâ€™s Broc hure or other study documents, and
(b) the characteristics of the subject population being studied; AND
xIs related or possibly related to participation in the research; AND
xSuggest that the research places subjects or others at a g reater risk of harm (including 
physical, psychological, economic, or soci al harm) than was previously known or 
recognized.
7.2 NCI-IRB AND CLINICAL DIRECTOR REPORTING
7.2.1 NCI-IRB and NCI CD Expedited Reporting of Unanticipated Problems and Deaths
The Protocol PI will report in the NIH Problem Form to the NCI-IRB and NCI Clinical Director:
xAll deaths, except deaths due to progressive disease 
xAll Protocol Deviations
xAll Unanticipated Problems
xAll non-compliance
Reports must be received within 7 days of PI awareness via iRIS.
7.2.2 NCI-IRB Requirements for PI Reporting at Continuing Review
The protocol PI will report to the NCI-IRB:
1. A summary of all protocol devi ations in a tabular format to include the date the deviation 
occurred, a brief description of the deviation and any corrective action.
2. A summary of any instances of non-compliance
3. A tabular summary of the following adverse events:
xAll Grade 2 unexpected events that are possibly, probably or definitely related to the 
research; 
xAll Grade 3 and 4 events that are possibly,  probably or definitely related to the 
research; 
xAll Grade 5 events regardless of attribution; 
xAll Serious Events regardless of attribution. 
NOTE : Grade 1 events are not required to be reported. 
7.2.3 NCI-IRB Reporting of IND Safety ReportsOnly IND Safety Reports that meet the definition of an unanticipated problem will need to be 
reported to the NCI IRB.
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
647.3 IND S PONSOR REPORTING CRITERIA 
During the first 30 days after the subject receives investigational agent/intervention, the
investigator must immediately report to the s ponsor, using the mandatory MedWatch form 3500a
or equivalent, any serious adverse event, whether or not considered drug related, including those 
listed in the protocol or investigator brochure a nd must include an assessment of whether there is 
a reasonable possibility that the drug caused the event. For serious adverse events that occur more than 30 days after the last administration of investigational agent/intervention, only report those that have an attribution of at least possibly related to the agent/intervention.
Required timing for reporting per the above guideline:
xDeaths (except death due to progressive disease) must be reported via email within 24 
hours. A complete report must be s ubmitted within one business day. 
xOther serious adverse events in cluding deaths due to progressi ve disease must be reported 
within one business day
Events will be submitted to the Center for Cancer Research (CCR) at: CCRsafety@mail.nih.gov
and to the CCR PI and study coordinator.
7.3.1 Reporting Pregnancy
7.3.1.1 Maternal exposure
If a patient becomes pregnant during the course  of the study, the study treatment should be 
discontinued immediately and the pregnancy reported to the Sponsor. The potential risk of 
exposure of the fetus to the investigational ag ent(s) or chemotherapy agents (s) should be 
documented in box B5 of the MedWatch form â€œDescribe Event or Problemâ€.
Pregnancy itself is not regarded as an SAE. However, as patients who become pregnant on study 
risk intrauterine exposure of the fetus to agents which may be teratogenic, the CCR is requesting that pregnancy should be reporte d in an expedited manner as Grade 3 â€œPregnancy, puerperium 
and perinatal conditions -Other (pregnancy) â€ under the Pregnancy, puerperium and perinatal 
conditions SOC. 
Congenital abnormalities or  birth defects and spontaneous mis carriages should be reported and 
handled as SAEs. Elective abortions without comp lications should not be handled as AEs. The 
outcome of all pregnancies (s pontaneous miscarriage, elective termination, ectopic pregnancy, 
normal birth, or congenital abnormality)  should be followed up and documented.
If any pregnancy occurs in the course of the study, then the investigator should inform the Sponsor within 1 day, i.e., immediately, but no later than 24 hours of when he or she becomes 
aware of it.
The designated Sponsor representative will work with the investigator to ensu re that all relevant 
information is provided to the Sponsor within 1 to 5 calendar days for SAEs and within 30 days 
for all other pregnancies.
The same timelines apply when outcome information is available.
7.3.1.2 Paternal exposure
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
65Male patients should refrain from fathering a child or donating sperm during the study and for 90
after the last dose of investigational drug.
Pregnancy of the patientâ€™s partner is not consider ed to be an AE. However, the outcome of all 
pregnancies (spontaneous miscarriage, elective te rmination, ectopic pregnancy, normal birth, or 
congenital abnormality) occurring from the date of the first dose until 90 days after the last dose 
of investigational drug after the last dose should, if possible, be followed up and documented.
7.4 S AFETY REPORTING CRITERIA TO THE PHARMACEUTICAL
COLLABORATORS
All events listed below must be reported in the defined timelines to CCRsafety@mail.nih.gov .
The CCR Office of Regulatory Affairs will send a ll reports to the manufacturer as described 
below.
7.4.1 Reporting of serious adverse events
All SAEs will be reported, whet her or not considered causally related to the investigational 
product, or to the study procedure(s). The repor ting period for SAEs is the period immediately 
following the time that written informed consent is obtained through 90 days after the last dose 
of durvalumab, or durvalumab + tremelimumab or until the initiation of alternative anticancer therapy. The investigator and/ or Sponsor are responsible for informing the Ethics Committee 
and/or the Regulatory Authority of  the SAE as per local requirements.
The investigator and/or sponsor must inform th e FDA, via a MedWatch or equivalent, of any 
serious or unexpected adverse events that occu r in accordance with the reporting obligations of 
21 CFR 312.32, and will concurrently forwar d all such reports to AstraZeneca. 
A copy of the MedWatch report must be send to AstraZeneca at the time the event is reported tothe FDA. It is the responsibility of the sponsor to compile all necessary information and ensure that the FDA receives a report according to th e FDA reporting requirement timelines and to 
ensure that these reports are also sub mitted to AstraZeneca at the above timepoints.
* A cover page should accompany the Me dWatch form indicating the following:
â€¢ â€œNotification from an Investigator Sponsored Studyâ€
â€¢ The investigator IND number assigned by the FDAâ€¢ The investigatorâ€™s  name and address
â€¢ The trial name/title  and AstraZeneca ISS reference number (ESR-16-11987) 
(AstraZeneca only)* Sponsor must also indicate, either in the SAE report or the cover page, the causality of events 
in relation to all study medica tions and if the SAE is related to disease progression, as 
determined by the principal investigator.* Send SAE report and accompanying cover page by way of email to AstraZenecaâ€™s designated 
mailbox: AEMailboxClinicalTrialTCS@astrazeneca.com
If a non-serious AE becomes serious, this and othe r relevant follow-up information must also be 
provided to AstraZeneca and the FDA.
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
667.4.2 Overdose
Any overdose of a study subject with durvalumab or durvalumab + tremelimumab, with or 
without associated AEs/SAEs, is required to be reported within 24 hour s of knowledge of the 
event to the sponsor and AstraZeneca/MedImmune Patient Safety or designee using the designated Safety e-mailbox: AEMailboxClinicalTrialTCS@astrazeneca.com. If the overdose results in an AE, the AE must also be recorded as an AE. Overdose does not automatically make an AE serious, but if the consequences of the overdose are serious, for example death or 
hospitalization, the event is serious and must be recorded and reported as an SAE. There is 
currently no specific treatment in the event of an overdose of durvalumab or tremelimumab. 
The investigator will use clinical judgment to treat any overdose.If the overdose results in an AE or SA E, these should be reported as such.
7.4.3 Hepatic function abnormalityHepatic function abnormality in a study subject, with or without associated clinical 
manifestations, is required to be reported as â€œhepatic functi on abnormalâ€ within 24 hours of 
knowledge of the event to the sponsor and Astr aZeneca/MedImmune Patient Safety using the 
designated Safety e-mailbox: AEMailboxClinicalTrialTCS@astrazeneca.com, unless a definitive underlying diagnosis for the abnormality (e.g., cholelithiasis or bile duct  obstruction) that is 
unrelated to investigationa l product has been confirmed.
If the definitive underlying diagnosis for the abnorm ality has been establishe d and is unrelated to 
investigational product, the decisi on to continue dosing of the st udy subject will be based on the 
clinical judgment of the investigator.
If no definitive underlying diagnosis for the a bnormality is established, dosing of the study 
subject must be interrupted immediately. Follow-up investigations and inquiries must be initiated 
by the investigationa l site without delay.
Each reported event of hepatic  function abnormality will be foll owed by the investigator and 
evaluated by the sponsor and AstraZeneca/MedImmune
7.4.4 Reporting Removal from Prot ocol Therapy and Off Study 
The study drug manufacturer should be notified of  any ongoing AE that may delay treatment or 
necessitate permanent discontinuation of treatment.
7.5 D
ATA AND SAFETY MONITORING PLAN
7.5.1 Principal Investigator/Research Team 
The clinical research team will meet on a regular basis when patients are being actively treated 
on the trial to discuss each patient. Decisions about radiation dose and schedule will be made 
based on the toxicity data from prior patients. 
All data will be collected in a timely manner and reviewed by the principal investigator or a lead 
associate investigator. Adverse events will be reported as requi red above. Any safety concerns, 
new information that might affect either the ethi cal and or scientific c onduct of the trial, or 
protocol deviations will be immediately reported to the IRB using iRIS. 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
67The principal investigator will review adverse event and response data on each patient to ensure 
safety and data accuracy. The principal inves tigator will personally co nduct or supervise the 
investigation and provide appr opriate delegation of responsib ilities to other members of the 
research staff. 
7.5.2 Sponsor Monitoring Plan
As a sponsor for clinical trials, FDA regulations require the CCR to maintain a monitoring 
program. The CCRâ€™s program allows for confirmation of: study data, specifically data that could affect the interpretation of prima ry study endpoints; adherence to  the protocol, regulations, and 
SOPs; and human subjects protection. This is done  through independent verification of study 
data with source documentation focusing on:
xInformed consent process
xEligibility confirmation
xDrug administration and accountability
xAdverse events monitoring
xResponse assessment.
The monitoring program also extends to multi-site research when the CCR is the coordinating center.
This trial will be monitored by personnel employ ed by a CCR contractor. Monitors are qualified 
by training and experience to monitor the progre ss of clinical trials. Pe rsonnel monitoring this 
study will not be affiliated in any way with the trial conduct.
8 STATISTICAL CONSIDERATIONSThe primary objective of this tr ial is to conduct a pilot study of  immune checkpoint inhibition in 
combination with Stereotactic Body Radiation Therapy (SBRT) in patients with advanced 
pancreatic cancer. As such, the main goal is to determine the safety of the proposed combinations of checkpoint inhibitors and SBRT as well as to evaluate if there may be any evidence of acceptable efficacy for any of the treatment combinations as well as whether one 
approach may be considered preferable ove r the others for use in future trials.
With an amendment A the decision has been ma de to not proceed with Arms B1 and B2 and 
move directly from Arms A1 and A2 to Arms C1 and C2. Unfortunately, we have not seen any evidence of clinical activity as of yet. At the time  of study design we did not have any supportive 
safety data for the combination of tremelimumab and durvalumab and that is why a staggered approach was conceived. We now have safety  data for the combina tion of durvalumab and 
tremelimumab and the company has a recommended dose and schedule for the combination of these agents which they are moving forward acro ss all their studies. We originally thought that 
Arms B1 and B2 (Tremelimumab 10mg/kg + SBRT) would provide some safety data to inform Arms C1 and C2, but this is no longer the case as the recommended dosing of Tremelimumab for Arms C1 and C2 is 10mg/kg (i.e., 10% of the dose in Arms B1 and B2).
With amendment I, an additional secondary objec tive has been added to more precisely estimate 
the survival in patients enrolled in Arm C2.
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
68Safety will be evaluated as follows: the trial will be conducted in a sequential manner with 
patients enrolled in the following order: A1, A2, C1, and C2. The goal will be to evaluate 10 
patients in A1 and then 10 in A2, provided that no more than 1 of the first 6 in A1 or A2 has a 
DLT, and that no more than 3 of 10 patients in either A1 or A2 has a DLT. If either of these is exceeded, then no further patients would be enrolled in that particular arm. The same rules apply to C1 and C2, but with all 10 in C1 and the first 10 in C2. Thus, if no safety concerns arise (0-1
of the first 6; 0-3 of 10 have a DLT in each of the 4 arms), then a total of 50 evaluable patients will be enrolled. To allow for a moderate numbe r (30-40%) of inevaluable patients â€“ based on 
disease progression â€“ we will set the accrual ceiling at 70 patients.
Among the initial patients enrolled in C2, there were two patients who have survived to 
approximately one year and bey ond. It will be desirable to have  additional patients enrolled in 
this arm to more precisely estimate its survival. Thus, in amendment I, the accrual to arm C2 will be expanded to a total of 20 evaluable patients to provide a more precise estimate of the patientsâ€™ survival in that arm. The survival of the 20 patients will be determined by a Kaplan-Meier curve 
with 95% two-sided confidence intervals reported primarily at the median, and secondarily at 6 
and 12 months. In addition, as a secondary analysis , the survival of the initial 10 patients treated 
on that arm will be reported separately from that of the second 10 patients treated on that arm, 
and the results will be informally compared to establish the degree of similarity of survival in the earlier and later treated patients.
The median survival in second-line studies in th is patient population is approximately 4 months. 
An important efficacy endpoint will be reached if a given patient is able to survive for 6 months 
or longer.The fraction of such patients will also be eval uated in the following manner, for purposes of 
making decisions about future directions, in addition to the new secondary endpoint focusing on 
C2, which demonstrated some survival advantage based on the first 10 patients:
8.1 C
ROSS -ARM COMPARISON
Evaluation will be performed in combination of  arms: A1+A2 and C1+C2. Within each of arm 
combinations A1+A2 and C1+C2, the 20 total patie nts who are treated in the combination of 
arms (A1+A2) and the total of 30 who are treated in the combination of arms (C1+C2) will be evaluated as a single group and the following objective will be evaluated: For the combination of A1+A2 (n=20), if 3 or more patients out of 20 are able to survive to 6 months, this would be a 
desirable goal, since the probability of observing 3 or more surviving to 6 months is 7.5% if the 
true underlying probability of surviving 6 months is 5% and the probability is 90.9% if the true underlying probability of surviving 6 months is 25%. Thus, 3 or more surviving 6 months or longer is a meaningful goal in a combination of arms of 20 patients. For the combination of C1+C2 (n=30), if 4 or more patients out of 30 can survive to 6 months, this would be a desirable 
goal, since the probability of observing 4 or more  surviving to 6 months is 6.1% if the true 
underlying probability of surviving 6 months is  5% and the probability is 96.3% if the true 
underlying probability of surviving 6 months is 25%. Thus, 4 or more surviving 6 months or longer is a meaningful goal in a combination of arms of 30 patients. Given that there are 2combination of treatment arms to be evaluate d (A1+A2 and C1+C2), the one with the greatest 
fraction of 6-month survivors, provided that the surviving number is 3 or more of 20 patients in 
A1+A2 or 4 or more of 30 patients in C1+C2, will be considered for further evaluation. The 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
69numbers of patients in each combination of ar ms who live to or beyond 6 months who receive 1 
day of SBRT or receive 5 days of SBRT will al so be reported and compar ed informally, and will 
help guide future decisions.
8.2 D URATION OF RADIATION
In addition, the 20 patients who receive 1 day of SBRT and the 30 patients who receive 5 days of 
SBRT will be evaluated via a selection design, although with  the caveat that lack of 
randomization and uneven numbers of patients should be considered when interpreting the results. The 20 or 30-patient SBRT combination of arms with the greatest fraction of survivors to 6 months would be preferentially chosen for furt her study. If there are 20-30 patients in the two 
groups and assuming the true rate s are 15% and 25% in the two groups, the probability of correct 
selection is at least 78%.. Given that the two gr oups of 20 or 30 patients each have subsets of 10
(or 20) patients treated homogeneously, this would also need to be explored within the arms.
Secondary endpoints include evalua tion of clinical endpoints such as response rate, duration of 
response, progression free survival, and overall survival. These will be estimated using confidence intervals for response rates, descriptive statistic for duration of response and Kaplan-Meier curves for PFS and OS. PK parameters will be obtained and results will be estimated and described using standard explor atory and descriptive statistical techniques. Any statistical 
comparisons which may be undertaken will be done using non-parametric te sts, without formal 
correction for multiple comparisons, but interpreted in the context of the secondary nature of the 
tests and the number of such tests performed.
8.3 A
NALYSIS OF IMMUNOGENICITY
Only subjects who receive at least one dos e of both Durvalumab and/or tremelimumab, and
provide the baseline and at least one post-trea tment sample, will be ev aluated. Immunogenicity 
results will be analyzed descriptively by summarizing the number and percentage of subjects 
who develop detectable anti-Durvalumab or anti-tremelimumab antibodies. The immunogenicity 
titer will be reported for samples confirmed positive for the presence of anti-Durvalumab or anti-tremelimumab antibodies. The impact of ADAs on PK will also be assessed if data allow. 
Samples confirmed positive for ADAs may also be evaluated for neutralizing antibody activity.
8.4 A
NALYSIS OF PHARMACOKINETICS
Only subjects who receive at least one dose of Durvalumab and/or tremelimumab, and provide
the baseline and at least one post-treatment sample, will be evaluated. Individual Durvalumaband tremelimumab concentrations will be tabulated by dose arm along with descriptive statistics. The PK of Durvalumab and tremelimumab will be assessed using parameters including Cmax, trough concentration (Cmin), time to peak concentration (Tmax) and AUC after the first dose. Durvalumab and tremelimumab steady-state PK parameters including peak concentration (Cmax,ss), trough concentration (Cmin,ss), and time to peak concentration (Tmax,ss) will be estimated. Accumulation to steady state will be assessed as the ratio of Cmax,ss:Cmax and Cmin,ss:Cmin. All PK paramete rs will be estimated by non-comp artmental analysis. Descriptive 
statistics of non-compartmental PK parameters will be provided.
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
709 COLLABORATIVE AGREEMENTS 
9.1 A GREEMENT TYPE
A CRADA, 02908, is in place between MedImmune, Inc. and CCR, NCI.
10 HUMAN SUBJECTS PROTECTIONS 10.1 R
ATIONALE FOR SUBJECT SELECTION
Subjects treated on this study, will be indivi duals with advanced pancreatic adenocarcinoma,
which is not amenable to potentially curative re section. Individuals of any sex, race or ethnic 
group will be eligible for this study. Eligibility assessment will be based solely on the patientâ€™s 
medical status. Recruitment of patients onto this study will be through standard CCR 
mechanisms. No special recruitment efforts will be conducted.
10.2 P ARTICIPATION OF CHILDREN
Individuals under the age of 18 will not be eligible  to participate in this study because they are 
unlikely to have pancreatic adenocarcinoma, an d because of unknown toxicities in pediatric 
patients.10.3 P
ARTICIPATION OF SUBJECTS UNABLE TO GIVE CONSENT
Adults unable to give consent are excluded from enrolling in the protocol. However re-consent 
may be necessary and there is a possibility, though unlikely, that subjects could become 
decisionally impaired. For this reason and because there is a prospect of direct benefit from 
research participation (section 10.5), all subjects will be offered the opportunity to fill in their 
wishes for research and care, and assign a substitute decision maker on the â€œNIH Advance Directive for Health Care and Medical Research Participationâ€ form so that another person can make decisions about their me dical care in the event that they become incapacitated or 
cognitively impaired during the course of the study. Note: The PI or AI will contact the NIH Ability to Consent Assessment Team (ACAT) for evaluation as needed for the following: an independent assessment of whethe r an individual has the capacity to provide consent; assistance 
in identifying and assessing an appropriate surroga te when indicated; and/or an assessment of the 
capacity to appoint a surrogate. For those subject s that become incapacitated and do not have 
pre-determined substitute decision maker, the procedures described in NIH Policy 87-4 and NIH HRPP SOP 14E for appointing a surrogate deci sion maker for adult subjects who are (a) 
decisionally impaired, and (b) who do not have a legal guardian or durable power of attorney, will be followed.
10.4 E
VALUATION OF BENEFITS AND RISKS/DISCOMFORTS FOR ALL PARTICIPANTS
10.4.1 Risks of exposure to ionizing radiation 
This research study involves exposure to radiation from 2 CT guided biopsies .This radiation 
exposure is not required for medical care and is  for research purposes only. The amount of 
radiation received in this study is 1.6 rem which is below the guideline of 5 rem per year allowed 
for research subjects by the NIH Radiation Safety Committee. The average person in the United States receives a radiation exposure of 0.3 rem pe r year from natural sources, such as the sun, 
outer space, and the earth's air and soil. More in formation about radiation is available in the 
pamphlet, An Introduction to Radi ation for NIH Research Subjects.
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
7110.4.2 Risk of baseline biopsy 
All care will be taken to minimize risks that may be incurred by tumor sampling. However, there 
are procedure-related risks (such as bleeding, infec tion and visceral injury) that will be explained 
fully during informed consent.
10.4.3 Other risks/benefits
The potential benefit to a patient that goes onto study is a reduction in the bulk of their tumor 
which may or may not have favorable impact on symptoms and/or survival. Potential risks 
include the possible occurrence of any of a range of side effects which are listed in the Consent 
Document. The procedure for protecting against or minimizing risks will be to medically evaluate patients on a regul ar basis as described.
10.5 R
ISKS/BENEFITS ANALYSIS
For patients with pancreatic adenocarcinoma cancer, median survival is in the range between 6and 10 months. It is possible that treatment on this protocol may redu ce tumor burden or lessen 
symptoms caused by the cancer. While treatment on this protocol may not individually benefit 
subjects. The knowledge gained from this study may help others in the future who have 
pancreatic adenocarcinoma. Poten tial risks include the possible occurrence of any of a range of 
side effects listed. If patients suffer any physical injury as a result of the biopsies, immediate medical treatment is available at the NIHâ€™s Clinical Center in Bethesda, Maryland. Although no compensation is available, any injury will be fully evaluated and treated in keeping with the benefits or care to wh ich patients are entitled under applicable regulations.
10.6 C
ONSENT PROCESS AND DOCUMENTATION
Patients will meet with an associate or principal investigator on the trial in the GI oncology Clinic, during the initial evaluation for this study. During that meeting, the investigator will inform patients of the purpose, alternatives, tr eatment plan, research objectives and follow-up of 
this trial. The investigator will then provide a copy of the IRB-approved informed consent document that is included in this protocol. The patient will be allowed to take as much time as he wishes, in deciding whether or not he wishes to participate. If a prolonged period of time expires during the decision making process (several weeks, as an example), it may be necessary to reassess the patient for protocol eligibility.
All patients must have a signed informed co nsent form and an on-study (confirmation of 
eligibility) form filled out and signed by a participating investigator before entering on the study.
10.6.1 Reconsent via Telephone
The informed consent document will be sent to the subject. An explanation of the study will be 
provided over the telephone after the subject has had the opportunity  to read the consent form.
The subject will sign and date the informed cons ent. A witness to the subjectâ€™s signature-- -will 
sign and date the consent.
The original informed consent document will be sent back to the consenting investigator who 
will sign and date the consent form with th e date the consent wa s obtained via telephone.
A fully executed copy will be returned via mail for the subjectâ€™s records.
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
72The informed consent process will be documented on a progress note by the consenting
investigator.
10.6.2 Informed Consent of non-English Speaking Subjects
If there is an unexpected enrollment of a research participant for whom there is no translated 
extant IRB approved consent document, the princi pal investigator and/or those authorized to 
obtain informed consent will use the Short Form Oral Consent Process as described in MAS Policy M77-2, OHSRP SOP 12, 45 CFR 46.117 (b) (2), and 21 CFR 50.27 (b) (2). The summary that will be used is the English version of the extant IRB approved consent document. Signed copies of both the English version of the consent and the translated short form will be given to the subject or their legally authorized representative and the signed original will be filed in the medical record.
Unless the PI is fluent in the prospective subjectâ€™s language, an interpreter will be present to 
facilitate the conversation. Preferably someone who is independent of the subject (i.e., not a family member) will assist in presenting information and obtaining consent. Whenever possible, 
interpreters will be provided copies of the relevant consent documents well before the consent 
conversation with the subject (24 to 48 hours if possible). 
We request prospective IRB approval of the use of the short form process for non-English 
speaking subjects and will notify the IRB at the time of continuing review of the frequency of the 
use of the Short Form.
11 PHARMACEUTICAL INFORMATION
11.1 T
REMELIMUMAB 
11.1.1 Source
Tremelimumab will be supp lied by Medimmune, Inc.
11.1.2 Formulation and PreparationTremelimumab is a human IgG2 anti-CTLA-4 mAb.
Investigational Product Manufacturer Concentration and 
Formulation as Supplied 
Tremelimumab MedImmune Formulated at a nominal 
concentration of 20 mg/mL in 
20 mM histidine/histidine hydrochloride, 222 mM trehalose dihydrate, 0.02% (w/v) polysorbate 80, and 0.27mM disodium edetate dihydrate (EDTA), pH 5.5. 
Tremelimumab is supplied as a sterile IV solution, filled in 20 mL clear glass vials with a rubber 
stopper and aluminum seal. Each  vial contains 20 mg/mL (with a nominal fill of 20 mL 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
73accounting to 400 mg/vial) of Tremelimumab, in an  isotonic solution at pH 5.5. Vials containing
Tremelimumab must be stored in the refrigerator at 2-8C. The 20 mg/mL solution will be diluted 
into a saline bag for IV infusion. 
For dose preparation steps, the following ancillary items are required: 
xIV infusion bags of 0.9% sodium chloride injection (250 mL size). Saline bags must be 
latex-free and can be made of polyvinyl  chloride (PVC) or polyolefins (e.g.,
polyethylene), manufactured with bis (2-ethylhexyl) phthalate (DEHP) or DEHP-free. 
xIV infusion lines made of PVC/DEHP or PVC/tri octyl trimellitate (TOTM) or polyethylene or polyurethane. All DEHP-containing or DEHP-free lines are acceptable. /LQHVVKRXOGFRQWDLQDRUÈPLQ -line filter. The in-line filter can be made of 
polyethersulfone (PES) or polyvinylidine fluoride DRF (PVDF) . Lines containing 
cellulose-based filters should not be used with Tremelimumab. 
xCatheters/infusion sets made of polyurethane or fluoropolymer with silicone and stainless 
steel and/or PVC components. 
xSyringes made of polypropylene and latex -free. Polycarbonate syringes should not be 
used with Tremelimumab. 
xNeedles made of stainless steel. 
Tremelimumab does not contain preservatives and any unused portion must be discarded. 
Preparation of Tremelimumab and preparation of the IV bag are to be performed aseptically. Total in-use storage time for the prepared final IV bag should not exceed 24 hours at 2-8Â°C or 4 hours at room temperature (25Â°C). However, it is recommended that the prepared final IV bag be 
stored in the dark at 2-8Â°C until needed. The refrigerated infusion solutions in the prepared final IV bag should be equilibrated at room temperat ure for about 2 hours prior to administration. If 
storage time exceeds these limits, a new dose must be prepared from new vials.
11.1.3 Stability and Storage
Tremelimumab must be stored in the refrigerator at 2-8
0C. The 20 mg/mL solution will be 
diluted into a saline bag for IV infusion. Vials co ntaining Tremelimumab ma y be gently inverted 
for mixing, but should not be shaken.
11.1.4 Administration procedures
Tremelimumab will be administere d as an IV infusion (250 mL) over approximately 1 hour. 
When an IV bag is used for the infusion, the IV line will be flushed with a volume of normal 
saline equal to the priming volume of the infusion set used after the contents of the IV bag are 
fully administered (unless prohibited by institutional practice).
11.1.5 Dose Calculation 
The subjectâ€™s weight (in kilograms) must be m easured prior to each dosing for dose calculation. 
Measurements can be taken in street clothes w ithout shoes and a calibrated scale must be used 
for all measurements. The dose will be calculated at each dosing visit using the following formula: 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
74Tremelimumab: 
The tremelimumab dose will be calculated using the following formula:Arms A1 and A2 only: By weight: Dose (mL) = [subject weight (kg) Ã— dose (mg/kg)]/ 20 
(mg/mL) where 20 mg/mL is tremelimumab concentration.
The corresponding volume of tremelimumab should be rounded to the nearest tenth mL (0.1 
mL). Dose adjustments for each cycle only needed for greater than 10% change in weight.
Each vial contains a small am ount of overage and the overage should be utilized as much as 
possible before using another vial. Arms C1 and C2: Following amendment B, Tremelimumab will be dosed at a flat dose of 75 mg 
via IV infusion q4w for up to 4 doses/cycles). Flat weight dosing will be used for all other patients including those who are greater than 75Kg e.g. 100-110Kg.
11.2 D
URVALUMAB
11.2.1 Source
Durvalumab will be supplied by Meddimmune, Inc.
11.2.2 Formulation and Preparation 
Durvalumab is a human monoclonal antibody of the immunoglobulin G1 kappa (Ig *È›
subclass.
Investigational Product Manufacturer Concentration and 
Formulation as Supplied 
Durvalumab MedImmune Formulated at 50 mg/mL in 26 
mM histidine/histidine-HCl, 275 mM trehalose
dihydrate, 0.02% 
(weight/volume [w/v]) polysorbate 80, pH 6.0.
Durvalumab is supplied is supplied as a white to off-white lyophilized powder in clear 10R glass vials closed with an elastomeri c stopper and a flip-off cap oversea l. Each vial contains 200 mg 
(nominal) of active investigational product. 
For dose preparation steps, the following ancillary items are required: 
xIV infusion bags of 0.9% sodium chloride injection.
xIV infusion lines. All DEHP-containing or DEHP-free lines are acceptable. 
xCatheters/infusion sets made of polyurethane or fluoropolymer with silicone and stainless 
steel and/or PVC components.
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
7511.2.3 Stability
Manufacturer MedImmune
Expiration/Retest Date Expiration/retest dates are documented on the Certificate of
Container Description Type: Material: Size:
Formulation Lyophilized powder cont aining 200 mg Durvalumab. When
reconstituted with 4 mL of WFI, the solution contains 50
mg/mL Durvalumab, 26 mM histidine/histidine -HCl, 275
mM trehalose dih ydrate , 0.02% (weight/volume [w/v])
Active Ingredient Content Mass/Weight: Volume: Concentration:
Storage Conditions +2Â°C to +8Â°C
Stability after reconstitution 24h at +2 -8Â°C and 6h at +25Â°C/ambient
Labeling Product name, lot number,  route of administration, an d
storage conditions
If Durvalumab administration has to be delayed, temporally interrupted or the infusion rate 
decreased, the total time betw een reconstitution and completion of the infusion should not 
exceed 6 hours at room temperature or Total in -use storage time from reconstitution of 
Durvalumab to start of administration should not  exceed 4 hours at room temperature or 24 hours 
at 2 -8 C. If administration time exceeds these limits, a new dose must be prepared from new 
vials. Durvalumab does not contain preservativ es and any unused portion must be discarded.
11.2.4 Storage 
Unopened vials of Durvalumab lyophilized Drug Produc t must be stored at 2Â°C to 8Â°C (36Â°F to 
46Â°F).Protect from light.
11.2.5 Administration procedures
Durvalumab is to be administ ered as an IV solution of 10 mg/kg over approximately 1 hour.
When an IV bag is used for the infusion, the IV line will be flushed with a volume of normal 
saline equal to the priming volume of the infusion set used after the contents of the IV bag are 
fully administered (unless prohibited by institutional practice).
Since the compatibility of Durvalumab with other IV medications and solutions, other than 
normal saline (0.9% [w/v] sodium chloride for in jection), is not known, the Durvalumab solution 
should not be infused through an IV line in wh ich other solutions or medications are being 
administered. The date, start time, interr uption, and completion time of Durvalumab
administration must be recorded in the source documents.
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
76For arms C1 and C2 Durvalumab infusion will st art approximately 1 hour  after the end of 
tremelimumab infusion.
11.2.5.1 Dose Calculation 
11.2.5.1.1 Arms A1 and A2 only
The subjectâ€™s weight (in kilograms) must be measured prior to each dosing for dose calculation. 
Measurements can be taken in street clothes w ithout shoes and a calibrated scale must be used 
for all measurements. The dose of MEDI 4736 will be calculated at each  dosing visit using the following formula: 
By weight:  Dose (mL) = [subject weight (kg) Ã— dose (mg/kg)]/ 50 (mg/mL) where 50 mg/mL is 
Durvalumab concentration after reconstitution. 
The corresponding volume of tremelimumab should be rounded to the nearest tenth mL (0.1 
mL). Dose adjustments for each cycle only needed for greater than 10% change in weight.
Each vial contains a small am ount of overage and the overage should be utilized as much as 
possible before using another vial. 
11.2.5.1.2 Arms C1 and C2
Following amendment B, MEDI 4736 (now called Du rvalumab) will be dosed at a flat dose of 
1500 mg via IV infusion q4w for up to 4 doses/c ycles (in combination with 75 mg tremelimumab 
via IV infusion q4w for up to 4 doses/cycles), and then continue 1500 mg durvalumab q4w (see
Figure 3 ). Patients with a body weight less than or equal to 30 kg should be dosed using a 
weight-based dosing schedule (i.e. 1mg/kg for tremelimumab and 20mg/kg for durvalumab). Flat weight dosing will be used for all other patients including those who are greater than 75Kg e.g.100-110Kg.
11.2.6 Durvalumab Dose Preparation Steps 
11.2.6.1 Durvalumab is formulated at 50 mg/mL in  26 mM histidine/histidine-HCl, 275 mM 
trehalose dihydrate, 0.02% (w/v) polysorbate 80 and is supplied as a lyophilized 
powder in 10R vials 
11.2.6.2 Durvalumab should be reconstituted using aseptic techniques with 4.0 mL sterile 
water for injection (WFI) with the liquid a dded gently to the side of the vial to 
minimize product foaming, to give a final concentration of 50 mg/mL. The reconstituted solution will be diluted with 0.9% (w/v) saline for IV infusion using 
syringes or bags.
11.2.6.3 In arms C1 and C2 Durvalumab infusion will start approximately 1 hour after the end 
of tremelimumab infusion using a 0.2- ÈPLQ -line filter. 
11.2.6.4 Flush the IV line with a volume of normal saline equal to the priming volume of the 
infusion set used after the contents of the IV bag are fully administered, or complete the infusion according to institutional policy to ensure the full dose is administered and document if the line was not flushed.
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
7711.3 I NVESTIGATIONAL PRODUCT PREPARATION STEPS
The investigational prod uct manager or qualified personnel will be responsible for preparing the 
IV doses using the following steps: 
1) Select the IXRS-assigned number of vials of investigational product required to prepare 
the subjectâ€™s dose. 
2) All investigational product vials should be  equilibrated to room temperature for 30 
minutes prior to dose preparation. 
3) To prepare the IV bag, first, calculate  the dose volume of investigational product 
required. Second, remove the volume of 0.9% so dium chloride IV solution equivalent to 
the calculated dose volume of inves tigational product from the IV bag.
4) Lastly, add the calculated dose volume of inve stigational product to the IV bag. Gently 
mix the solution in the bag by inverting up and down. Avoid shaking the IV bag to 
prevent foaming. 
5) Example: A subject weighing 85 kg will re quire 42.5 mL (3 vials) of investigational 
product. Remove 42.5 mL of saline from the commercial IV bag. Add the 42.5 mL of 
investigational product to the IV bag an d gently mix by inverting up and down.
6) Labels will be prepared in accordance  with Good Manufacturing Practice (GMP).
11.4 I NVESTIGATIONAL PRODUCT INSPECTION 
Each vial selected for dose preparation should be inspected. 
If there are any defects noted with the investigat ional product, the investig ator and site monitor 
should be notified immediately. Refe r to the Product Complaint section ( 11.5.1) for further 
instructions. 
During the inspection if the solution is not clear or  any turbidity, discoloration or particulates are 
observed, notify your site monitor and store the vial(s) in QUARANTINE at refrigerated (2-8ÂºC) 
temperature for drug accountabilit y and potential future inspection. 
Notify the IXRS that the unusable vials are damaged. The IXRS will indicate the replacement 
vials. Select appropriate replacement vials for the preparation of the subjectâ€™s dose, and perform the same inspection on the newly selected vials. For accountability, record the total number of vials removed from site inventory. Used vial s should be held for accountability purposes at 
ambient storage temperature.
11.5 I
NVESTIGATIONAL PRODUCT ACCOUNTABILITY 
The investigatorâ€™s or siteâ€™s designated investigational product manager is  required to maintain 
accurate investigational product ac countability records. Upon completion of the study, copies of 
investigational product accountability records will be returned to MedImmune. All unused 
investigational product w ill be returned to a MedImmune-authorized depot or disposed of upon 
authorization by MedImmune.
11.5.1 Reporting Produc t Complaints 
Any defects with the investiga tional product must be reported immediately to the MedImmune 
Product Complaint Depa rtment by the site with further no tification to the site monitor. All 
defects will be communicated to MedImmune and investigated further with the Product 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
78Complaint Department. During the investigation of the product co mplaint, all i nvestigational 
products must be stored at labeled conditions unle ss otherwise instructed. 
Product defects may be re lated to component, product, or packaging and labeling issues. The list 
below includes, but is not limited to, descriptions of product complaints that should be reported. 
Component Issue: Defect in container or dosing mechanis m of the investigational product. The 
component defect may be damaged, missing, or broken. Component examples include vials, 
stoppers, caps, spray barrels, spray nozzles, or plungers. 
Product Issue: Defect in the product itself. The product appearance has visual imperfections 
such as foreign particles, crysta llization, discoloration, turbidity, insufficient volume, or anything 
that does not apply to the product description. 
Packaging/Labeling Issue: Defect in the packaging or labeling of the product. The packaging or 
labeling defects may be damaged or un readable, or the label may be missing. 
When reporting a product complaint, site staff must be prepared to provide the following 
information: 
1) Customer information: reporter name, addr ess, contact number, a nd date of complaint 
2) Product information: product name, packaging kit number or lot number, expiry date, and 
clinical protocol number 3) Complaint information: complaint issue category and description MedImmune contact information for reporting product complaints: 
Email: productcomplaints@medimmune.com Phone: +1-301-398-2105 +1-877-MEDI-411 (+1-877-633-4411) Fax: +1-301-398-8800
Mail: MedImmune, LLC Attn: Product Complaint Department One MedImmune Way, 
Gaithersburg, MD USA 20878
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
7912 REFERENCES 
1. Moore, M.J., et al., Erlotinib plus gemcitabine compar ed with gemcitabine alone in 
patients with advanced pancre atic cancer: a phase III trial of the National Cancer 
Institute of Canada Clinical Trials Group. J Clin Oncol, 2007. 25(15): p. 1960-6.
2. Reyes-Gibby, C.C., et al., Patterns of self-repor ted symptoms in pancreatic cancer 
patients receiving chemoradiation. J Pain Symptom Manage, 2007. 34(3): p. 244-52.
3. Moertel, C.G., et al., Combined 5-fluorouracil and supervoltage radiation therapy of 
locally unresectable gastr ointestinal cancer. Lancet, 1969. 2(7626): p. 865-7.
4. Moertel, C.G., et al., Therapy of locally unresecta ble pancreatic carcinoma: a 
randomized comparison of high dose (6000 rads) radiation alone, moderate dose 
radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The 
Gastrointestinal Tumor Study Group. Cancer, 1981. 48(8): p. 1705-10.
5. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-
modality therapy (chemotherapy plus r adiotherapy) to chemotherapy alone. 
Gastrointestinal Tumor Study Group. J Natl Cancer Inst, 1988. 80(10): p. 751-5.
6. Klaassen, D.J., et al., Treatment of locally unresectable cancer of the stomach and 
pancreas: a randomized comparison of 5-fl uorouracil alone with radiation plus 
concurrent and maintenance 5 -fluorouracil--an Eastern Cooperative Oncology Group 
study. J Clin Oncol, 1985. 3(3): p. 373-8.
7. Chauffert, B., et al., Phase III trial comparing intensive induction chemoradiotherapy (60 
Gy, infusional 5-FU and intermittent cispla tin) followed by maintenance gemcitabine 
with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive 
results of the 2000-01 FFCD/SFRO study. Ann Oncol, 2008.
8. Chauffert, B., et al., Phase III trial comparing initial chemoradiotherapy (intermittent 
cisplatin and infusional 5-FU) followed by gemc itabine vs. gemcitabine alone in patients 
with locally advanced non metastatic pancreatic cancer: A FFCD-SFRO study. J Clin 
Oncol (Meeting Abstracts), 2006. 24(18_suppl): p. 4008-.
9. P. J. Loehrer, M.E.P., H. R. Cardenes, L. Wag ner, J. M. Brell, R. K. Ramanathan, C. H. 
Crane, S. R. Alberts, A. B. Be nson, Eastern Cooperative Oncology Group. A randomized 
phase III study of gemcitabine in combination with radiation therapy versus gemcitabine 
alone in patients with localized, unresectable pancreatic cancer: E4201. in ASCO . 2008. 
Chicago.
10. Huguet, F., et al., Impact of chemoradiotherapy after disease control with chemotherapy 
in locally advanced pancreatic adenocar cinoma in GERCOR phase II and III studies. J
Clin Oncol, 2007. 25(3): p. 326-31.
11. Moureau-Zabotto, L., et al., Concomitant administration of weekly oxaliplatin, 
fluorouracil continuous i
nfusion, and radiothera py after 2 months of gemcitabine and 
oxaliplatin induction in patients with lo cally advanced pancreatic cancer: a Groupe 
Coordinateur Multidisciplinaire en Oncologie phase II study. J Clin Oncol, 2008. 26(7): 
p. 1080-5.
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
8012. Chuong, M.D., et al., Stereotactic body radiation th erapy for locally advanced and 
borderline resectable pancreatic c ancer is effective and well tolerated. Int J Radiat Oncol 
Biol Phys, 2013. 86(3): p. 516-22.
13. Kantoff, P.W., et al., Sipuleucel-T immunotherapy for castration-resistant prostate 
cancer. N Engl J Med, 2010. 363(5): p. 411-22.
14. Hodi, F.S., et al., Improved survival with ipilimumab in patients with metastatic 
melanoma. N Engl J Med, 2010. 363(8): p. 711-23.
15. Robert, C., et al., Ipilimumab plus dacarbazine for previously untreated metastatic 
melanoma. N Engl J Med, 2011. 364(26): p. 2517-26.
16. Brahmer, J.R., et al., Safety and activity of anti-PD-L 1 antibody in patients with 
advanced cancer. N Engl J Med, 2012. 366(26): p. 2455-65.
17. Hanahan, D. and R.A. Weinberg, Hallmarks of cancer: the next generation. Cell, 2011. 
144(5): p. 646-74.
18. Gelao, L., et al., Immune checkpoint blockade in c ancer treatment: a double-edged sword 
cross-targeting the host as an "innocent bystander". Toxins (Basel), 2014. 6(3): p. 914-
33.
19. Postow, M.A., et al., Immunologic correlates of the absc opal effect in a patient with 
melanoma. N Engl J Med. 366(10): p. 925-31.
20. Lee, Y., et al., Therapeutic effects of ablative radi ation on local tumor require CD8+ T 
cells: changing strategies for cancer treatment. Blood, 2009. 114(3): p. 589-95.
21. Blanquicett, C., et al., Antitumor efficacy of capecitabine  and celecoxib in irradiated and 
lead-shielded, contralatera l human BxPC-3 pancreatic cancer xenografts: clinical 
implications of abscopal effects. Clin Cancer Res, 2005. 11(24 Pt 1): p. 8773-81.
22. Camphausen, K., et al., Radiation abscopal antitumor effect is mediated through p53.
Cancer Res, 2003. 63(8): p. 1990-3.
23. Demaria, S., et al., Ionizing radiation inhibition of di stant untreated tumors (abscopal 
effect) is immune mediated. Int J Radiat Oncol Biol Phys, 2004. 58(3): p. 862-70.
24. Reits, E.A., et al., Radiation modulates the peptide repertoire, enhances MHC class I 
expression, and induces successful antitumor immunotherapy. J Exp Med, 2006. 203(5): 
p. 1259-71.
25. Sharma, A., et al., gamma-Radiation promotes immunologi cal recognition of cancer cells 
through increased expression of cancer-testis antigens in vitro and in vivo. PLoS One, 
2011. 6(11): p. e28217.
26. Apetoh, L., et al., T oll-like receptor 4-dependent contribution of the immune system to 
anticancer chemotherapy and radiotherapy. Nat Med, 2007. 13(9): p. 1050-9.
27. Suzuki, Y., et al., Immunogenic tumor cell death induced by chemoradiotherapy in 
patients with esophageal squamous cell carcinoma. Cancer Res, 2012. 72(16): p. 3967-
76.
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
8128. Bramhall, R.J., K. Mahady, and A.H. Peach, Spontaneous regression of metastatic 
melanoma - clinical evidence of the abscopal effect. Eur J Surg Oncol, 2014. 40(1): p. 34-
41.
29. Hiniker, S.M., D.S. Chen, and S.J. Knox, Abscopal effect in a patient with melanoma. N
Engl J Med, 2012. 366(21): p. 2035; author reply 2035-6.
30. Okuma, K., et al., Abscopal effect of radiation on lung metastases of hepatocellular 
carcinoma: a case report. J Med Case Rep, 2011. 5: p. 111.
31. Zeng, J., et al., Anti-PD-1 blockade and stereotactic radiation produce long-term survival 
in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys, 2013. 86(2): p. 343-9.
32. Dewan, M.Z., et al., Fractionated but not single-dose r adiotherapy induces an immune-
mediated abscopal effect when co mbined with anti-CTLA-4 antibody. Clin Cancer Res, 
2009. 15(17): p. 5379-88.
33. Demaria, S., et al., Immune-mediated inhibition of metastases after treatment with local 
radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res, 
2005. 11(2 Pt 1): p. 728-34.
34. McNeel, D.G., et al., Phase I trial of tremelimumab in combination with short-term 
androgen deprivation in patients with  PSA-recurrent prostate cancer. Cancer Immunol 
Immunother, 2012. 61(7): p. 1137-47.
35. Tarhini, A.A., et al., Safety and efficacy of combination immunotherapy with interferon 
alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol, 2012. 
30(3): p. 322-8.
36. Le, D.T., et al., Evaluation of ipilimumab in combina tion with alloge neic pancreatic 
tumor cells transfected with a GM-CSF gene  in previously treated pancreatic cancer. J
Immunother, 2013. 36(7): p. 382-9.
37. Oganesyan, V., et al., Structural characterization of a human Fc fragment engineered for 
lack of effector functions. Acta Crystallographica Section D-Biological Crystallography, 
2008. 64: p. 700-704.
38. Pardoll, D.M., The blockade of immune checkpoi nts in cancer immunotherapy. Nat Rev 
Cancer, 2012. 12(4): p. 252-64.
39. Wang, E., et al., Population pharmacokinetic and pharmacodynamic analysis of 
tremelimumab in patients w ith metastatic melanoma. J Clin Pharmacol, 2014. 54(10): p. 
1108-16.
40. Ng, C.M., et al., Rationale for fixed dosing of pertuzumab in cancer patients based on 
population pharmacokinetic analysis. Pharm Res, 2006. 23(6): p. 1275-84.
41. Wang, D.D., et al., Fixed  dosing versus body size-based  dosing of monoclonal antibodies 
in adult clinical trials. J Clin Pharmacol, 2009. 49(9): p. 1012-24.
42. Zhang, S., et al., Fixed dosing versus body size-based dosing of therapeutic peptides and 
proteins in adults. J Clin Pharmacol, 2012. 52(1): p. 18-28.
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
8243. Narwal, R., L.K. Roskos, and G.J. Robbie, Population pharmacokinetics of sifalimumab, 
an investigational anti-interferon-alpha m onoclonal antibody, in systemic lupus 
erythematosus. Clin Pharmacokinet, 2013. 52(11): p. 1017-27.
44. Topalian, S.L., et al., Safety, activity, and immune correla tes of anti-PD-1 antibody in 
cancer. N Engl J Med, 2012. 366(26): p. 2443-54.
45. Eisenhauer, E.A., et al., New response evaluation criteria in solid tumours: Revised 
RECIST guideline (version 1.1). European Journal of Cancer, 2009. 45(2): p. 228-247.
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
8313 APPENDICES
13.1 A PPENDIX A: P ERFORMANCE STATUS CRITERIA
ECOG Performance Status Scale Karnofsky Performance Scale
Grade Descriptions Percent Description
0Normal activity.  Fully active, 
able to carry on all pre-disease performance without restriction.100Normal, no complaints, no evidence of disease.
90Able to carry on normal activity; minor signs or symptoms of disease.
1Symptoms, but ambulatory.  Restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature (e.g., light housework, office work).80Normal activity with effort; some signs or symptoms of disease.
70Cares for self, unable to carry on normal activity or to do active work.
2In bed <50% of the time.  Ambulatory and capable of all self-care, but unable to carry out any work activities.  Up and about more than 50% of waking hours.60Requires occasional assistance, but is able to care for most of his/her needs.
50Requires considerable assistance and frequent medical care.
3In bed >50% of the time.  Capable of only limited self-care, confined to bed or chair more than 50% of waking hours.40Disabled, requires special care and assistance.
30Severely disabled, hospitalization indicated.  Death not imminent.
4100% bedridden.  Completely disabled.  Cannot carry on any self-care.  Totally confined to bed or chair.20Very sick, hospitalization indicated. Death not imminent.
10Moribund, fatal processes progressing rapidly.
5 Dead. 0 Dead.
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
8413.2 A PPENDIX B: M EDIMMUNE SAMPLE PREPARATION PROCEDURES SERUM - SST T UBE
1. Draw maximum volume of blood into gold top SST tube (s). Record time of collection.
2. Gently invert 5 times.
3. Allow the blood to clot for 30 minutes at room temperature.
4. Centrifuge within 2 hours of collection at 1100 -1300 g for 15 minutes.5. Transfer serum into labeled cryovials. 
6. Immediately freeze the cryovials upright at -20ÂºC or colder.
7. Store at -20ÂºC or colder until shipment on dry ice.
Plasma- K
2EDTA Tube
1. Draw maximum volume of blood into lavender top K 2EDTA tube(s). Record time of 
collection
2. Gently invert 8 to 10 times.
3. Centrifuge within 2 hours of collection at 1100 -1300 g for 10 minutes.
4. Transfer plasma into labeled cryovials.
5. Immediately freeze the cryovials upright at -20ÂºC or colder.
6. Store at -20ÂºC or colder until shipment on dry ice.
Tube Label should include:
1. Patient Identifier 2. Sample ID (Serum 1, Cycle 1, Day 1etc.)3. Sample type (plasma, serum)4. Sample volume 5. Collection time 
6. Barcode (if this system is available)
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
8513.3 A PPENDIX C: M ODIFIED IMMUNE -RELATED RESPONSE CRITERIA (IRRC)
For modified irRC, only target and measurable lesi ons are taken into account. In contrast to the 
RECIST 1.1 criteria, the modified irRC criteria (a) require confirmation of both progression and 
response by imaging at 6 weeks after initial imaging and (b) do not necessarily score the 
appearance of new lesions as progressive disease if the sum of lesion diameters of target lesions 
(minimum of 10 mm per lesion, max imum of 5 target lesions, ma ximum of 2 per organ) and 
PHDVXUDEOHQHZOHVLRQVGRH VQRWLQFUHDVHE\Â•
The same method of assessment a nd the same technique should be used to characterize each 
identified and reported target lesi on(s) at baseline, during the trial,  and at the end of trial visit. 
All measurements should be recorded in metr ic notation. The modified irRC based on RECIST 
1.1 are displayed below. 
Overall Responses Derived from Changes in Index, Non-Inde x, and New Lesions
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
86

Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
8713.4 A PPENDIX D: D OSING MODIFICATION AND TOXICITY MANAGEMENT GUIDELINES FOR IMMUNE -MEDIATED ,INFUSION -
RELATED ,AND NON-IMMUNE â€“MEDIATED REACTIONS (MEDI4736 M ONOTHERAPY OR COMBINATION THERAPY WITH 
TREMELIMUMAB OR TREMELIMUMAB MONOTHERAPY )1N OVEMBER 2017 V ERSION
General Considerations
Dose Modifications Toxicity Management
Drug administration modifications of study  drug/study regimen will be made to 
manage potential immune-related AEs based on severity of treatment-emergent 
toxicities graded per NCI CTCAE v4.03.
In addition to the criteria for permanent discontinuation of study drug/study 
regimen based on CTC grade/severity (table below), permanently discontinue 
study drug/study regimen for the following conditions:
x Inability to reduce corticosteroid to a dose RIÂ” mg of prednisone per 
day (or equivalent) within 12 weeks after last dose of study drug/study 
regimen
x Recurrence of a previously experienced Grade 3 treatment-related AE 
following resumption of dosing
Grade 1 No dose modification
Grade 2 Hold study drug/study regimen dose until Grade 2 resolution to 
*UDGHÂ”
If toxicity worsens, then treat as Grade 3 or Grade 4.
Study drug/study regimen can be resumed once event stabilizes to 
*UDGHÂ”DIWHUFRPSOHWLRQRIVWHURLGWDSHU
Patients with endocrinopathies who may require prolonged or 
continued steroid replacement can be retreated with study 
drug/study regimen on the following conditions:
1. The event stabilizes and is controlled.
2. The patient is clinically stable as per Investigator or treating 
physicianâ€™s clinical judgement.
3.'RVHVRISUHGQLVRQHDUHDWÂ” mg/day or equivalent.It is recommended that management of immune-mediated adverse events (imAEs) 
follows the guidelines presented in this table:
Ã­ It is possible that events with an inflammatory or immune mediated 
mechanism could occur in nearly all organs, some of them not noted 
specifically in these guidelines.
Ã­ Whether specific immune-mediated events (and/or laboratory indicators of 
such events) are noted in these guidelines or not, patients should be 
thoroughly evaluated to rule out any alternative etiology (e.g., disease 
progression, concomitant medications, and infections) to a possible immune-
mediated event. In the absence of a clear alternative etiology, all such events 
should be managed as if they were immune related. General 
recommendations follow.
Ã­ Symptomatic and topical therapy should be considered for low-grade (Grade 
1 or 2, unless otherwise specified) events. 
Ã­ For persistent (>3 to 5 days) low- JUDGH*UDGHRUVHYHUH*UDGHÂ•
events, promptly start prednisone 1 to 2 mg/kg/day PO or IV equivalent.
Ã­ Some events with high likelihood for morbidity and/or mortality â€“ e.g., myo-
carditis, or other similar events even if they are not currently noted in the 
guidelines â€“ should progress rapidly to high dose IV corticosteroids 
(methylprednisolone at 2 to 4 mg/kg/day) even if the event is Grade 2, and if 
clinical suspicion is high and/or there has been clinical confirmation. 
Consider, as necessary, discussing with the study physician, and promptly 
pursue specialist consultation.
Ã­ If symptoms recur or worsen during corticosteroid tapering (28 days of 
taper), increase the corticosteroid dose (prednisone dose [e. g., up to 2 to 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
88General Considerations
Dose Modifications Toxicity Management
Grade 3 Depending on the individual toxicity, study drug/study regimen 
may be permanently discontinued. Please refer to guidelines below.
Grade 4 Permanently discontinue study drug/study regimen.
Note: FRU*UDGHÂ•DV\PSWRPDWLFDP\ODVHRUOLSDVHOHYHOVKROGVWXG\G UXJVWXG\
regimen, and if complete work up shows no evidence of pancreatitis, study 
drug/study regimen may be continued or resumed.
Note: Study drug/study regimen should be permanently discontinued in Grade 3 
events with high likelihood for morbidity and/or mortality â€“ e.g., myocarditis, or 
other similar events even if they are not currently noted in the guidelines. 
Similarly, consider whether study drug/study regimen should be permanently 
discontinued in Grade 2 events with high likelihood for morbidity and/or mortality 
â€“ e.g., myocarditis, or other similar events even if they are not currently noted in 
the guidelines â€“ when they do not rapidly improve to Grade <1 upon treatment 
with systemic steroids and following full taper
Note: There are some exceptions to permanent discontinuation of study drug for 
Grade 4 events (i.e., hyperthyroidism, hy pothyroidism, Type 1 diabetes mellitus). 4 mg/kg/day PO or IV equivalent]) until stabilization or improvement of 
symptoms, then resume corticosteroid tapering at a slower rate (>28 days of 
taper).
Ã­ More potent immunosuppressives such as TNF inhibitors (e.g., infliximab) 
(also refer to the individual sections of the imAEs for specific type of 
immunosuppressive) should be considered for events not responding to 
systemic steroids. Progression to use of more potent immunosuppressives 
should proceed more rapidly in events with high likelihood for morbidity 
and/or mortality â€“ e.g., myocarditis, or other similar events even if they are 
not currently noted in the guidelines â€“ when these events are not responding 
to systemic steroids.
Ã­ With long-term steroid and other immunosuppressive use, consider need for 
Pneumocystis jirovecii pneumonia (PJP, formerly known as Pneumocystis 
carinii pneumonia) prophylaxis, gastrointestinal protection, and glucose 
monitoring.
Ã­ Discontinuation of study drug/study regimen is not mandated for Grade 
3/Grade 4 inflammatory reactions attributed to local tumor response 
(e.g., inflammatory reaction at sites of metastatic disease and lymph nodes). 
Continuation of study drug/study regimen in this situation should be based 
upon a benefit-risk analysis for that patient.
AE Adverse event; CTC Common Toxicity Criteria; CTCAE Common Terminology Criteria for Adverse Events; i mAE immune- mediated adverse event; IV intravenous; NCI 
National Cancer Institute; PO By mouth.
Pediatric Considerations
Dose Modifications Toxicity Management
The criteria for permanent discontinuation of study drug/study regimen based on 
CTC grade/severit y is the same for pediatric patients as it is for adult patients, as Ã­ All recommendations for specialist consultation should occur with a 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
89Pediatric Considerations
Dose Modifications Toxicity Management
well as to permanently discontinue study drug/study regimen if unable to reduce 
FRUWLFRVWHURLGÂ” a dose equivalent to that required for corticosteroid replacement 
therapy within 12 weeks after last dose of study drug/study regimenpediatric specialist in the specialty recommended.
Ã­ The recommendations for dosing of steroids (i.e., mg/kg/day) and for IV IG 
and plasmapheresis that are provided for adult patients should also be used 
for pediatric patients.
Ã­ The infliximab 5 mg/kg IV dose recommended for adults is the same as 
UHFRPPHQGHGIRUSHGLDWULFSDWLHQWVÂ•\HDUVROG)RUGRVLQJLQFKLOGUHQ
younger than 6 years old, consult with a pediatric specialist.
Ã­ For pediatric dosing of mycophenolate mofetil, consult with a pediatric 
specialist.
Ã­ With long-term steroid and other immunosuppressive use, consider need for 
PJP prophylaxis, gastrointestinal protection, and glucose monitoring.
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
90
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
91Specific Immune-Mediated Reactions
Adverse Events Severity Grade of the 
Event (NCI CTCAE 
version 4.03)Dose Modifications Toxicity Management
Pneumonitis/Interstitial 
Lung Disease (ILD)Any Grade General Guidance For Any Grade:
Ã­ Monitor patients for signs and symptoms of pneumonitis or 
ILD (new onset or worsening shortness of breath or cough). 
Patients should be evaluated with imaging and pulmonary 
function tests, including other diagnostic procedures as 
described below.
Ã­ Initial work-up may include clinical evaluation, monitoring of 
oxygenation via pulse oximetry (resting and exertion), 
laboratory work-up, and high- resolution CT scan.
Grade 1
(asymptomatic, clinical 
or diagnostic 
observations only; 
intervention not 
indicated)No dose modifications required. However, 
consider holding study drug/study 
regimen dose as clinically appropriate and 
during diagnostic work-up for other
etiologies.For Grade 1 (radiographic changes only):
Ã­ Monitor and closely follow up in 2 to 4 days for clinical 
symptoms, pulse oximetry (resting and exertion), and 
laboratory work-up and then as clinically indicated.
Ã­ Consider Pulmonary and Infectious disease consult.
Grade 2
(symptomatic; medical 
intervention indicated; 
limiting instrumental 
ADL)Hold study drug/study regimen dose until 
*UDGHUHVROXWLRQWR*UDGHÂ”
x If toxicity worsens, then treat as 
Grade 3 or Grade 4.
x,IWR[LFLW\LPSURYHVWR*UDGHÂ”
then the decision to reinitiate study 
drug/study regimen will be based 
upon treating physicianâ€™s clinical 
judgment and after completion of 
steroid taper.For Grade 2 (mild to moderate new symptoms):
Ã­ Monitor symptoms daily and consider hospitalization.
Ã­ Promptly start systemic steroids (e.g., prednisone 1 to 
2 mg/kg/day PO or IV equivalent).
Ã­ Reimage as clinically indicated.
Ã­ If no improvement within 3 to 5 days, additional workup 
should be considered and prompt treatment with IV 
methylprednisolone 2 to 4 mg/kg/day started
Ã­ If still no improvement within 3 to 5 days despite IV 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
92methylprednisolone at 2 to 4 mg/kg/day, promptly start 
immunosuppressive therapy such as TNF inhibitors 
(e.g., infliximab at 5 mg/kg every 2 weeks). Caution: It is 
important to rule out sepsis and refer to infliximab label for 
general guidance before using infliximab.
Ã­ Once the patient is improving, gradually taper steroids over 
Â•GD\VDQGFRQVLGHUSURSK\ODFWLFDQWLELRWLFVDQWLIXQJDOVRU 
anti-PJP treatment (refer to current NCCN guidelines for 
treatment of cancer-related infections [Category 2B 
recommendation])a
Ã­ Consider pulmonary and infectious disease consult.
Ã­ Consider, as necessary, discussing with study physician.
Grade 3 or 4
(Grade 3: severe 
symptoms; limiting 
self-care ADL; oxygen 
indicated)
(Grade 4: life-
threatening respiratory 
compromise; urgent 
intervention indicated 
[e.g., tracheostomy or 
intubation])Permanently discontinue study drug/study 
regimen.For Grade 3 or 4 (severe or new symptoms, new/worsening hypoxia, 
life-threatening):
Ã­ Promptly initiate empiric IV methylprednisolone 1 to 
4 mg/kg/day or equivalent.
Ã­ Obtain Pulmonary and Infectious disease consult; consider, as 
necessary, discussing with study physician.
Ã­ Hospitalize the patient.
Ã­ Supportive care (e.g., oxygen).
Ã­ If no improvement within 3 to 5 days, additional workup 
should be considered and prompt treatment with additional 
immunosuppressive therapy such as TNF inhibitors 
(e.g., infliximab at 5 mg/kg every 2 weeksâ€™ dose) started. 
Caution: rule out sepsis and refer to infliximab label for general 
guidance before using infliximab.
Ã­ Once the patient is improving, gradually taper steroids over 
Â•GD\VDQGFRQVLGHUSURSK\ODFWLFDQWLELRWLFVDQWLIXQJDOV
and, in particular, anti-PJP treatment (refer to current NCCN 
guidelines for treatment of cancer-related infections [Cate gory 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
932B recommendation]).a
Diarrhea/Colitis Any Grade General Guidance For Any Grade:
Ã­ Monitor for symptoms that may be related to 
diarrhea/enterocolitis (abdominal pain, cramping, or changes in 
bowel habits such as increased frequency over baseline or 
blood in stool) or related to bowel perforation (such as sepsis, 
peritoneal signs, and ileus).
Ã­ Patients should be thoroughly evaluated to rule out any 
alternative etiology (e.g., disease progression, other 
medications, or infections), including testing for clostridium 
difficile toxin, etc.
Ã­ Steroids should be considered in the absence of clear 
alternative etiology, even for low-grade events, in order to 
prevent potential progression to higher grade event.
Ã­ Use analgesics carefully; they can mask symptoms of 
perforation and peritonitis.
Grade 1
(Diarrhea: stool 
frequency of <4 over 
baseline per day)
(Colitis: asymptomatic; 
clinical or diagnostic 
observations only)No dose modifications. For Grade 1:
Ã­ Monitor closely for worsening symptoms.
Ã­ Consider symptomatic treatment, including hydration, 
electrolyte replacement, dietary changes (e.g., American 
Dietetic Association colitis diet), and loperamide. Use 
probiotics as per treating physicianâ€™s clinical judgment.
Grade 2
(Diarrhea: stool 
frequency of 4 to 6 over 
baseline per day) 
(Colitis: abdominal 
pain; mucus or blood in Hold study drug/study regimen until 
UHVROXWLRQWR*UDGHÂ”
x If toxicity worsens, then treat as 
Grade 3 or Grade 4.
x,IWR[LFLW\LPSURYHVWR*UDGHÂ”
then stud y drug/stud y regimen can be For Grade 2:
Ã­ Consider symptomatic treatment, including hydration, 
electrolyte replacement, dietary changes (e.g., American 
Dietetic Association colitis diet), and loperamide and/or 
budesonide.
Ã­ Prom ptly start prednisone 1 to 2 m g/kg/day PO or IV 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
94stool) resumed after completion of steroid 
taper.equivalent.
Ã­ If event is not responsive within  3 to 5 days or worsens despite 
prednisone at 1 to 2 mg/kg/day PO or IV equivalent, GI consult 
should be obtained for consideration of further workup, such as 
imaging and/or colonoscopy, to confirm colitis and rule out 
perforation, and prompt treatment with IV methylprednisolone 
2 to 4 mg/kg/day started.
Ã­ If still no improvement within 3 to 5 days despite 2 to 4 mg/kg 
IV methylprednisolone, promptly start immunosuppressives 
such as infliximab at 5 mg/kg once every 2 weeksa.Caution: it
is important to rule out bowel perforation and refer to 
infliximab label for general guidance before using infliximab.
Ã­ Consider, as necessary, discussing with study physician if no 
UHVROXWLRQWR*UDGHÂ”LQWR days.
Ã­ Once the patient is improving, gradually taper steroids over 
Â•GD\VDQGFRQVLGHUSURSK\ODFWLFDQWLELRWLFVDQWLIXQJDOVDQG
anti-PJP treatment (refer to current NCCN guidelines for 
treatment of cancer-related infections [Category 2B 
recommendation]).a
Grade 3 or 4
(Grade 3 diarrhea: stool 
IUHTXHQF\RIÂ•RYHU
baseline per day;
Grade 4 diarrhea: life 
threatening 
consequences)
(Grade 3 colitis: severe 
abdominal pain, change 
in bowel habits, medi-
cal intervention indi-
cated, peritoneal si gns;Grade 3
Permanently discontinue study drug/study 
regimen for Grade 3 if toxicity does not 
LPSURYHWR*UDGHÂ”ZLWKLQ days; 
study drug/study regimen can be resumed 
after completion of steroid taper.
Grade 4
Permanently discontinue 
study drug/study regimen. For Grade 3 or 4:
Ã­ Promptly initiate empiric IV methylprednisolone 2 to 
4 mg/kg/day or equivalent.
Ã­ Monitor stool frequency and volume and maintain hydration.
Ã­ Urgent GI consult and imaging and/or colonoscopy as 
appropriate.
Ã­ If still no improvement within 3 to 5 days of IV 
methylprednisolone 2 to 4 mg/kg/day or equivalent, promptly 
start further immunosuppressives (e.g., infliximab at 5 mg/kg 
once every 2 weeks). Caution : Ensure GI consult to rule out 
bowel perforation and refer to infliximab label for general 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
95Grade 4 colitis: life-
threatening 
consequences, urgent 
intervention indicated)guidance before using infliximab.
Ã­ Once the patient is improving, gradually taper steroids over 
Â•GD\VDQGFRQVLGHUSURS hylactic antibiotics, antifungals, and 
anti-PJP treatment (refer to current NCCN guidelines for 
treatment of cancer-related infections [Category 2B 
recommendation]).a
Hepatitis 
(elevated LFTs)
Infliximab should not be 
used for management of 
immune-related hepatitis.Any Grade General Guidance For Any Grade:
Ã­ Monitor and evaluate liver function test: AST, ALT, ALP, and 
TB.
Ã­ Evaluate for alternative etiologies (e.g., viral hepatitis, disease 
progression, concomitant medications).
Grade 1
(AST or ALT >ULN 
aQGÂ”Ã®8/1DQGRU
TB > ULN and  
Â”Ã®8/1x No dose modifications.
x If it worsens, then treat as Grade 2 
event.For Grade 1:
Ã­ Continue LFT monitoring per protocol.
Grade 2
(AST or 
ALT >3.0Ã—ULN and 
Â”Ã®8/1DQGRU
TB >1.5Ã—ULN and  
Â”Ã®8/1x Hold study drug/study regimen dose 
XQWLO*UDGHUHVROXWLRQWR*UDGHÂ”
xIf toxicity worsens, then treat as 
Grade 3 or Grade 4.
x,IWR[LFLW\LPSURYHVWR*UDGHÂ”RU
baseline, resume study drug/study 
regimen after completion of steroid 
taper.For Grade 2:
Ã­ Regular and frequent checking of LFTs (e.g., every 1 to 2 days) 
until elevations of these are improving or resolved.
Ã­ ,IQRUHVROXWLRQWR*UDGHÂ”LQWRGD\VFRQVLGHUDV
necessary, discussing with study physician.
Ã­ If event is persistent (>3 to 5 days) or worsens, promptly start 
prednisone 1 to 2 mg/kg/day PO or IV equivalent.
Ã­ If still no improvement within 3 to 5 days despite 1 to 
2 mg/kg/day of prednisone PO or IV equivalent, consider 
additional work up and start prompt treatment with IV 
methylprednisolone 2 to 4 mg/kg/day.
Ã­ If still no improvement within 3 to 5 days despite 2 to 
4mg/kg/day of IV meth ylprednisolone, promptly start PLEASE SEE 
shaded area 
immediately below
this section to findguidance formanagement of
â€œHepatitis (elevated 
LFTS)â€ in HCC patients
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
96immunosuppressives (i.e., mycophenolate mofetil).aDiscuss 
with study physician if mycophenolate mofetil is not available. 
Infliximab should NOT be used.
Ã­ Once the patient is improving, gradually taper steroids over 
Â•GD\VDQGFRQVLGHUSURSK\ODFWLFDQWLELRWLFVDQWLIXQJDOVDQ G
anti-PJP treatment (refer to current NCCN guidelines for 
treatment of cancer-related infections [Category 2B 
recommendation]).a
Grade 3 or 4
(Grade 3: AST or 
ALT >5.0Ã—ULN and 
Â”Ã®8/1DQGRU
TB >3.0Ã—ULN and  
Â”Ã®8/1
(Grade 4: AST or 
ALT >20Ã—ULN and/or 
TB >10Ã—ULN)For Grade 3:
For elevations in transaminases 
Â”Ã— ULN, or elevations in bilirubin 
Â”Ã—U L N :
xHold study drug/study regimen dose 
XQWLOUHVROXWLRQWR*UDGHÂ”RU
baseline
xResume study drug/study regimen if 
HOHYDWLRQVGRZQJUDGHWR*UDGHÂ”RU
baseline within 14 days and after 
completion of steroid taper.
xPermanently discontinue study 
drug/study regimen if the elevations 
GRQRWGRZQJUDGHWR*UDGHÂ”RU
baseline within 14 days
For elevations in transaminases >8 Ã— ULN 
or elevations in bilirubin >5 Ã— ULN, 
discontinue study drug/study regimen.
Permanently discontinue study drug/study 
regimen for any case meeting Hyâ€™s law 
criteria (AST and/or ALT >3 Ã— ULN + 
bilirubin >2 Ã— ULN without initial For Grade 3 or 4:
Ã­ Promptly initiate empiric IV methylprednisolone at 1 to 
4 mg/kg/day or equivalent.
Ã­ If still no improvement within 3 to 5 days despite 1 to 
4 mg/kg/day methylprednisolone IV or equivalent, promptly 
start treatment with immunosuppressive therapy (i.e., 
mycophenolate mofetil). Discuss with study physician if 
mycophenolate is not available. Infliximab should NOT be 
used.
Ã­ Perform hepatology consult, abdominal workup, and imaging 
as appropriate.
Ã­ Once the patient is improving, gradually taper steroids over
Â•GD\VDQGFRQVLGHUSURSK\ODFWLFDQWLELRWLFVDQWLIXQJDOVDQ G
anti-PJP treatment (refer to current NCCN guidelines for 
treatment of cancer-related infections [Category 2B 
recommendation]).a
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
97findings of cholestasis (i.e., elevated 
alkaline P04) and in the absence of any 
alternative cause.b
For Grade 4:
Permanently discontinue study drug/study 
regimen.
Hepatitis 
(elevated LFTs)
Infliximab should not be 
used for management of 
immune-related hepatitis.
See instructions at 
bottom of shaded area 
if transaminase rise is 
not isolated but (at any Any Grade General Guidance For Any Grade:
Ã­ Monitor and evaluate liver function test: AST, ALT, ALP, and 
TB.
Ã­ Evaluate for alternative etiologies (e.g., viral hepatitis, disease 
progression, concomitant medications, worsening of liver 
cirrhosis [e.g., portal vein thrombosis]).
Ã­ For HBV+ patients: evaluate quantitative HBV viral load, 
quantitative HBsAg, or HBeAg
Ã­ For HCV+ patients: evaluate quantitative HCV viral load
Ã­ Consider consulting hepatologist /Infectious disease specialist 
regarding change/implementation in/of antiviral medications 
for any patient with an elevated HBV viral load >2000 IU/ml
Ã­ Consider consulting hepatologist /Infectious disease specialist 
regarding change/implementation in/of antiviral HCV 
medications if HCV viral load increased b \Â•-fold
Ã­ For HCV+ with HBcAB+: Evaluate for both HBV and HCV as THIS shaded area 
is guidance only for
management of â€œHepatitis (elevated 
LFTs)â€ in HCC 
patients
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
98time) occurs in setting 
of either increasing 
bilirubin or signs of 
DILI/liver 
decompensationabove
Grade 1
(Isolated AST or ALT 
!8/1DQGÂ”Ã®8/1
whether normal or 
elevated at baseline) x No dose modifications.
x If ALT/AST elevations represents 
significant worsening based on 
investigator assessment, then treat as 
Grade 2 event.
For all grades, see instructions at bottom 
of shaded area if transaminase rise is not 
isolated but (at any time) occurs in setting 
of either increasing bilirubin or signs of 
DILI/liver decompensation
Grade 2
(Isolated AST or ALT 
>5.0Ã—ULN and 
Â”Ã®8/1LIQRUPDODW
baseline)
(Isolated AST or ALT 
>2.0Ã—baseline and 
Â”Ã®8/1LIHOHYDWHG
>ULN at baseline)x Hold study drug/study regimen dose 
XQWLO*UDGHUHVROXWLRQWR*UDGHÂ”
or baseline.
x If toxicity worsens, then treat as 
Grade 3 or Grade 4.
,IWR[LFLW\LPSURYHVWR*UDGHÂ”RU
baseline, resume study drug/study 
regimen after completion of steroid taper.For Grade 2:
Ã­ Regular and frequent checking of LFTs (e.g., every 1 to 3 days) 
until elevations of these are improving or resolved.
Ã­ Recommend consult hepatologist; consider abdominal 
ultrasound, including Doppler assessment of liver perfusion.
Ã­ Consider, as necessary, discussing with study physician.
Ã­ If event is persistent (>3 to 5 days) or worsens, and investigator 
suspects toxicity to be immune-mediated AE, recommend to 
start prednisone 1 to 2 mg/kg/day PO or IV equivalent.
Ã­ If still no improvement within 3 to 5 days despite 1 to 
2 mg/kg/day of prednisone PO or IV equivalent, consider 
additional workup and treatment with IV methylprednisolone 2 
to 4 mg/kg/day.
Ã­ If still no improvement within 3 to 5 days despite 2 to 
4 mg/kg/day of IV methylprednisolone, consider additional 
abdominal workup (including liver biopsy) and imaging (i.e., 
liver ultrasound ), and consider startin g immunosu ppressives 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
99(i.e., mycophenolate mofetil).aDiscuss with study physician if 
mycophenolate mofetil is not available. Infliximab should 
NOT be used.
Grade 3
(Isolated AST or ALT 
>8.0Ã—ULN and 
Â”Ã®8/1LIQRUPDO
at baseline)
(Isolated AST or ALT 
>12.5Ã—ULN and 
Â”Ã®8/1LI
elevated >ULN at 
baseline)xHold study drug/study regimen dose 
XQWLOUHVROXWLRQWR*UDGHÂ”RU
baseline
xResume study drug/study regimen if
HOHYDWLRQVGRZQJUDGHWR*UDGHÂ”RU
baseline within 14 days and after 
completion of steroid taper.
xPermanently discontinue study 
drug/study regimen if the elevations 
GRQRWGRZQJUDGHWR*UDGHÂ”RU
baseline within 14 days
Permanently discontinue study drug/study 
regimen for any case meeting Hyâ€™s law 
criteria, in the absence of any alternative 
cause.bFor Grade 3:
Ã­ Regular and frequent checking of LFTs (e.g., every 1-2 days) 
until elevations of these are improving or resolved.
Ã­ Consult hepatologist (unless in vestigator is hepatologist); 
obtain abdominal ultrasound, including Doppler assessment of 
liver perfusion; and consider liver biopsy.
Ã­ Consider, as necessary, discussing with study physician.
Ã­ If investigator susp ects toxicity to be immune-mediated, 
promptly initiate empiric IV methylprednisolone at 1 to 
4 mg/kg/day or equivalent.
Ã­ If no improvement within 3 to 5 days despite 1 to 4 mg/kg/day 
methylprednisolone IV or equivalent, obtain liver biopsy (if it 
has not been done already) and promptly start treatment with 
immunosuppressive therapy (mycophenolate mofetil). Discuss 
with study physician if mycophenolate is not available. 
Infliximab should NOT be used.
Ã­ Once the patient is improving, gradually taper steroids over 
Â•GD\VDQGFRQVLGHUSURSK\ODFWLFDQWLELRWLFVDQWLIXQJDOVDQ G
anti-PCP treatment (refer to current NCCN guidelines for 
treatment of cancer-related infections [Category 2B 
recommendation]).a
Grade 4
(Isolated AST or ALT 
>20Ã—ULN,  whether Permanently discontinue study drug/study 
regimen.For Grade 4:
Same as above 
(except would recommend obtaining liver biopsy early)
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
100normal or elevated at 
baseline)
If transaminase rise is not isolated but (at any time) occurs in setting of either increasing WRWDOGLUHFWELOLUXELQÂ•Ã®8/1LIQRUPDODWEDVHOLQHRUÃ®E DVHOLQHLI
>ULN at baseline) or signs of DILI/liver decompensation (e.g., fever, elevated INR):
- Manage dosing for Grade 1 transaminase rise as instructed for Grade 2 transaminase rise
- Manage dosing for Grade 2 transaminase rise as instructed for Grade 3 transaminase rise
- Grade 3-4: Permanently discontinue study drug/study regimen
Nephritis or renal 
dysfunction
(elevated serum 
creatinine)Any Grade General Guidance For Any Grade:
Ã­ Consult with nephrologist.
Ã­ Monitor for signs and symptoms that may be related to changes 
in renal function (e.g., routine urinalysis, elevated serum BUN 
and creatinine, decreased creatinine clearance, electrolyte 
imbalance, decrease in urine output, or proteinuria).
Ã­ Patients should be thoroughly evaluated to rule out any 
alternative etiology (e.g., disease progression or infections).
Ã­ Steroids should be considered in the absence of clear 
alternative etiology even for low-grade events (Grade 2), in 
order to prevent potential progression to higher grade event.
Grade 1
(Serum creatinine > 1
to 1.5 Ã— baseline; > 
ULN to 1.5 Ã— ULN)No dose modifications. For Grade 1:
Ã­ Monitor serum creatinine weekly and any accompanying 
symptoms.
x If creatinine returns to ba seline, resume its regular 
monitoring per study protocol.
x If creatinine worsens, de pendin g on the severit y, treat 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
101as Grade 2, 3, or 4.
Ã­ Consider symptomatic treatment, including hydration, 
electrolyte replacement, and diuretics.
Grade 2
(serum creatinine >1.5 
to 3.0 Ã— baseline; >1.5 
to 3.0 Ã— ULN)Hold study drug/study regimen until 
UHVROXWLRQWR*UDGHÂ”RUEDVHOLQH
xIf toxicity worsens, then treat as 
Grade 3 or 4.
x,IWR[LFLW\LPSURYHVWR*UDGHÂ”RU
baseline, then resume study 
drug/study regimen after completion 
of steroid taper.For Grade 2:
Ã­ Consider symptomatic treatm ent, including hydration, 
electrolyte replacement, and diuretics.
Ã­ Carefully monitor serum creatinine every 2 to 3 days and as 
clinically warranted.
Ã­ Consult nephrologist and consider renal biopsy if clinically 
indicated.
Ã­ If event is persistent (>3 to 5 days) or worsens, promptly start 
prednisone 1 to 2 mg/kg/day PO or IV equivalent.
Ã­ If event is not responsive within  3 to 5 days or worsens despite 
prednisone at 1 to 2 mg/kg/day PO or IV equivalent, additional 
workup should be considered and prompt treatment with IV 
methylprednisolone at 2 to 4 mg/kg/day started.
Ã­ Once the patient is improving, gradually taper steroids over 
Â•GD\VDQGFRQVLGHUSURSK\ODFWLFDQWLELRWLFVDQWLIXQJDOVDQ G
anti-PJP treatment (refer to current NCCN guidelines for 
treatment of cancer-related infections [Category 2B 
recommendation]).a
Ã­ When event returns to baseline, resume study drug/study 
regimen and routine serum creatinine monitoring per study 
protocol.
Grade 3 or 4
(Grade 3: serum 
creatinine 
>3.0 Ã— baseline; >3.0 to 
6.0 Ã— ULN;Permanently discontinue study drug/study 
regimen.For Grade 3 or 4:
Ã­ Carefully monitor serum creatinine on daily basis.
Ã­ Consult nephrologist and consider renal biopsy if clinically 
indicated.
Ã­ Prom ptly start prednisone 1 to 2 m g/kg/day PO or IV 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
102Grade 4: serum 
creatinine >6.0 Ã— ULN)equivalent.
Ã­ If event is not responsive within  3 to 5 days or worsens despite 
prednisone at 1 to 2 mg/kg/day PO or IV equivalent, additional 
workup should be considered and prompt treatment with IV 
methylprednisolone 2 to 4 mg/kg/day started.
Ã­ Once the patient is improving, gradually taper steroids over 
Â•GD\VDQGFRQVLGHUSURSK\ODFWLFDQWLELRWLFVDQWLIXQJDOVDQ G
anti-PJP treatment (refer to current NCCN guidelines for 
treatment of cancer-related infections [Category 2B 
recommendation]).a
Rash
(excluding bullous skin 
formations)Any Grade
(refer to NCI CTCAE 
v 4.03 for definition of 
severity/grade 
depending on type of 
skin rash)General Guidance For Any Grade:
Ã­ Monitor for signs and symptoms of dermatitis (rash and 
pruritus).
Ã­ IF THERE IS ANY BULLOUS FORMATION, THE STUDY 
PHYSICIAN SHOULD BE CONTACTED AND STUDY 
DRUG DISCONTINUED.
Grade 1 No dose modifications. For Grade 1:
Ã­ Consider symptomatic treatment, including oral antipruritics 
(e.g., diphenhydramine or hydroxyzine) and topical therapy 
(e.g., urea cream).
Grade 2 For persistent (>1 to 2 weeks) Grade 2
events, hold scheduled study drug/study 
UHJLPHQXQWLOUHVROXWLRQWR*UDGHÂ”RU
baseline.
x If toxicity worsens, then treat as 
Grade 3.
x,IWR[LFLW\LPSURYHVWR*UDGHÂ”RUFor Grade 2:
Ã­ Obtain dermatology consult.
Ã­ Consider symptomatic treatment, including oral antipruritics 
(e.g., diphenhydramine or hydroxyzine) and topical therapy 
(e.g., urea cream).
Ã­ Consider moderate-strength topical steroid.
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
103baseline, then resume drug/study 
regimen after completion of steroid 
taper.Ã­ If no improvement of rash/skin lesions occurs within 3 to 
5 days or is worsening despite symptomatic treatment and/or 
use of moderate strength topical steroid, consider, as necessary, 
discussing with study physician and promptly start systemic 
steroids such as prednisone 1 to 2 mg/kg/day PO or IV 
equivalent.
Ã­ Consider skin biopsy if the event is persistent for >1 to 2 weeks 
or recurs.
Grade 3 or 4 For Grade 3:
Hold study drug/study regimen until 
UHVROXWLRQWR*UDGHÂ”RUEDVHO ine.
If temporarily holding the study 
drug/study regimen does not provide 
improvement of the Grade 3 skin rash to 
*UDGHÂ”RUEDVHOLQHZLWKLQ days, then 
permanently discontinue study drug/study 
regimen.
For Grade 4:
Permanently discontinue study drug/study 
regimen.For Grade 3 or 4:
Ã­ Consult dermatology.
Ã­ Promptly initiate empiric IV methylprednisolone 1 to 
4 mg/kg/day or equivalent.
Ã­ Consider hospitalization.
Ã­ Monitor extent of rash [Rule of Nines].
Ã­ Consider skin biopsy (preferably more than 1) as clinically 
feasible.
Ã­ Once the patient is improving, gradually taper steroids over 
Â•GD\VDQGFRQVLGHUSURSK\ODFWLFDQWLELRWLFVDQWLIXQJDOVDQG
anti-PJP treatment (refer to current NCCN guidelines for 
treatment of cancer-related infections [Category 2B 
recommendation]).a
Ã­ Consider, as necessary, discussing with study physician.
Endocrinopathy
(e.g., hyperthyroidism, 
hypothyroidism,  Type 1 
diabetes mellitus, 
hypophysitis, Any Grade
(depending on the type 
of endocrinopathy, 
refer to NCI CTCAE 
v4.03 for defining the General Guidance For Any Grade:
Ã­ Consider consulting an endocri nologist for endocrine events.
Ã­ Consider, as necessary, discussing with study physician.
Ã­ Monitor patients for signs and symptoms of endocrinopathies. 
Non-s pecific s ymptoms include headache, fati gue, behavior 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
104hypopituitarism, and 
adrenal insufficiency; 
exocrine event of 
amylase/lipase increased 
also included in this 
section)CTC grade/severity) changes, changed mental status, vertigo, abdominal pain, 
unusual bowel habits, polydipsia, polyuria, hypotension, and 
weakness.
Ã­ Patients should be thoroughly evaluated to rule out any 
alternative etiology (e.g., disease progression including brain 
metastases, or infections).
Ã­ Depending on the suspected endocrinopathy, monitor and 
evaluate thyroid function tests: TSH, free T3 and free T4 and 
other relevant endocrine and related labs (e.g., blood glucose 
and ketone levels, HgA1c).
Ã­ For modest asymptomatic elevations in serum amylase and 
lipase, corticosteroid treatment is  not indicated as long as there 
are no other signs or symptoms of pancreatic inflammation.
Ã­ If a patient experiences an AE that is thought to be possibly of 
autoimmune nature (e.g., thyroiditis, pancreatitis, hypophysitis, 
or diabetes insipidus), the investigator should send a blood 
sample for appropriate autoimmune antibody testing.
Grade 1 No dose modifications. For Grade 1 (including those with asymptomatic TSH elevation):
Ã­ Monitor patient with appropriate endocrine function tests.
Ã­ For suspected hypophysitis/hypopituitarism, consider 
consultation of an endocrinologist to guide assessment of early-
morning ACTH, cortisol, TSH and free T4; also consider 
gonadotropins, sex hormones, and prolactin levels, as well as 
cosyntropin stimulation test (though it may not be useful in 
diagnosing early secondary adrenal insufficiency).
Ã­ If TSH < 0.5 Ã— LLN, or TSH >2 Ã— ULN, or consistently out of 
range in 2 subsequent measurements, include free T4 at 
subsequent cycles as clinically indicated and consider 
consultation of an endocrinologist.
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
105Grade 2 For Grade 2 endocrinopathy other than 
hypothyroidism and Type 1 diabetes 
mellitus, hold study drug/study regimen 
dose until patient is clinically stable.
x If toxicity worsens, then treat as 
Grade 3 or Grade 4.
Study drug/study regimen can be resumed 
once event stabilizes and after completion 
of steroid taper.
Patients with endocrinopathies who may 
require prolonged or continued steroid 
replacement (e.g., adrenal insufficiency) 
can be retreated with study drug/study 
regimen on the following conditions:
1. The event stabilizes and is 
controlled.
2. The patient is clinically stable as per 
investigator or treating physicianâ€™s 
clinical judgement.
3.'RVHVRISUHGQLVRQHDUHÂ” mg/day 
or equivalent.For Grade 2 (including those with symptomatic endocrinopathy):
Ã­ Consult endocrinologist to guide evaluation of endocrine 
function and, as indicated by suspected endocrinopathy and as 
clinically indicated, consider pituitary scan.
Ã­ For all patients with abnormal endocrine work up, except those 
with isolated hypothyroidism or Type 1 DM, and as guided by 
an  endocrinologist, consider short-term corticosteroids (e.g., 1 
to 2 mg/kg/day methylprednisolone or IV equivalent) and 
prompt initiation of treatment with relevant hormone 
replacement (e.g., hydrocortisone, sex hormones).
Ã­ Isolated hypothyroidism may be treated with replacement 
therapy, without study drug/study regimen interruption, and 
without corticosteroids.
Ã­ Isolated Type 1 diabetes mellitus (DM) may be treated with 
appropriate diabetic therapy, without study drug/study regimen 
interruption, and without corticosteroids.
Ã­ Once patients on steroids are improving, gradually taper  
immunosuppressive steroids (as appropriate and with guidance 
of endocrinologist) RYHUÂ•GD\VDQGFRQVLGHUSURSK\ODFWLF
antibiotics, antifungals, and anti-PJP treatment (refer to current 
NCCN guidelines for treatment of cancer-related infections 
[Category 2B recommendation]).a
Ã­ For patients with normal endocrine workup (laboratory 
assessment or MRI scans), repeat laboratory assessments/MRI 
as clinically indicated.
Grade 3 or 4 For Grade 3 or 4 endocrinopathy other 
than hypothyroidism and Type 1 diabetes 
mellitus, hold study drug/study regimen 
dose until endocrinopathy symptom(s) are 
controlled. For Grade 3 or 4:
Ã­ Consult endocrinologist to guide evaluation of endocrine 
function and, as indicated by suspected endocrinopathy and as 
clinically indicated, consider pituitary scan. Hospitalization 
recommended.
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
106Study drug/study regimen can be resumed 
once event stabilizes and after completion 
of steroid taper.
Patients with endocrinopathies who may 
require prolonged or continued steroid 
replacement (e.g., adrenal insufficiency) 
can be retreated with study drug/study 
regimen on the following conditions:
1. The event stabilizes and is 
controlled.
2. The patient is clinically stable as per 
investigator or treating physicianâ€™s 
clinical judgement.
3.'RVHVRISUHGQLVRQHDUHÂ” mg/day 
or equivalent.Ã­ For all patients with abnormal endocrine work up, except those 
with isolated hypothyroidism or Type 1 DM, and as guided by 
an  endocrinologist, promptly initiate empiric IV 
methylprednisolone 1 to 2 mg/kg/day or equivalent, as well as 
relevant hormone replacement (e.g., hydrocortisone, sex 
hormones).
Ã­ For adrenal crisis, severe dehydration, hypotension, or shock, 
immediately initiate IV corticosteroids with mineralocorticoid 
activity.
Ã­ Isolated hypothyroidism may be treated with replacement 
therapy, without study drug/study regimen interruption, and 
without corticosteroids.
Ã­ Isolated Type 1 diabetes mellitus may be treated with 
appropriate diabetic therapy, without study drug/study regimen 
interruption, and without corticosteroids.
Ã­ Once patients on steroids are improving, gradually taper 
immunosuppressive steroids (as appropriate and with guidance 
RIHQGRFULQRORJLVWRYHUÂ•GD\VDQGFRQVLGHUSURSK\ODFWLF
antibiotics, antifungals, and anti-PJP treatment (refer to current 
NCCN guidelines for treatment of cancer-related infections 
[Category 2B recommendation]).a
Neurotoxicity
(to include but not be 
limited to limbic 
encephalitis and 
autonomic neuropathy, 
excluding Myasthenia 
Gravis and Guillain-
Barre)Any Grade
(depending on the type 
of neurotoxicity, refer 
to NCI CTCAE v4.03 
for defining the CTC 
grade/severity)General Guidance For Any Grade:
Ã­ Patients should be evaluated to rule out any alternative etiology 
(e.g., disease progression, infections, metabolic syndromes, or 
medications).
Ã­ Monitor patient for general symptoms (headache, nausea, 
vertigo, behavior change, or weakness).
Ã­ Consider appropriate diagnostic testing (e.g., electromyogram 
and nerve conduction investigations).
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
107Ã­ Perform symptomatic treatment with neurological consult as 
appropriate.
Ã­
Grade 1 No dose modifications. For Grade 1:
Ã­ See â€œAny Gradeâ€ recommendations above.
Grade 2 For acute motor neuropathies or 
neurotoxicity, hold study drug/study 
UHJLPHQGRVHXQWLOUHVROXWLRQWR*UDGHÂ”
For sensory neuropathy/neuropathic pain, 
consider holding study drug/study 
UHJLPHQGRVHXQWLOUHVROXWLRQWR*UDGHÂ”
If toxicity worsens, then treat as 
Grade 3 or 4.
Study drug/study regimen can be resumed 
RQFHHYHQWLPSURYHVWR*UDGHÂ”DQG
after completion of steroid taper.For Grade 2:
Ã­ Consider, as necessary, discussing with the study physician.
Ã­ Obtain neurology consult.
Ã­ Sensory neuropathy/neuropathic pain may be managed by 
appropriate medications (e.g., gabapentin or duloxetine).
Ã­ Promptly start systemic steroids prednisone 1 to 2 mg/kg/day 
PO or IV equivalent.
Ã­ If no improvement within 3 to 5 days despite 1 to 2 mg/kg/day 
prednisone PO or IV equivalent, consider additional workup 
and promptly treat with additional immunosuppressive therapy 
(e.g., IV IG).
Grade 3 or 4 For Grade 3:
Hold study drug/study regimen dose until 
UHVROXWLRQWR*UDGHÂ”
Permanently discontinue study drug/study 
regimen if Grade 3 imAE does not resolve 
WR*UDGHÂ”ZLWKLQGD\V
For Grade 4:
Permanently discontinue study drug/study 
regimen.For Grade 3 or 4:
Ã­ Consider, as necessary, discussing with study physician.
Ã­ Obtain neurology consult.
Ã­ Consider hospitalization.
Ã­ Promptly initiate empiric IV methylprednisolone 1 to 
2 mg/kg/day or equivalent.
Ã­ If no improvement within 3 to 5 days despite IV 
corticosteroids, consider additional workup and promptly treat 
with additional immunosuppressants (e.g., IV IG).
Ã­ 2QFHVWDEOHJUDGXDOO\WDSHUVWHURLGVRYHUÂ•GD\V
Peripheral neuromotor Any Grade General Guidance For Any Grade:
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
108syndromes
(such as Guillain-Barre 
and myasthenia gravis)Ã­ The prompt diagnosis of immune-mediated peripheral 
neuromotor syndromes is important, since certain patients may 
unpredictably experience acute decompensations that can result 
in substantial morbidity or in th e worst case, death. Special care 
should be taken for certain sentinel symptoms that may predict 
a more severe outcome, such as prominent dysphagia, rapidly 
progressive weakness, and signs of respiratory insufficiency or 
autonomic instability.
Ã­ Patients should be evaluated to rule out any alternative etiology 
(e.g., disease progression, infections, metabolic syndromes or 
medications). It should be noted that the diagnosis of immune-
mediated peripheral neuromotor syndromes can be particularly 
challenging in patients with underlying cancer, due to the 
multiple potential confounding effects of cancer (and its 
treatments) throughout the neuraxis. Given the importance of 
prompt and accurate diagnosis, it is essential to have a low 
threshold to obtain a neurological consult.
Ã­ Neurophysiologic diagnostic testing (e.g., electromyogram and 
nerve conduction investigations, and â€œrepetitive stimulationâ€ if 
myasthenia is suspected) are routinely indicated upon suspicion 
of such conditions and may be best facilitated by means of a 
neurology consultation.
Ã­ It is important to consider that the use of steroids as the primary 
treatment of Guillain-Barre is not typically considered 
effective. Patients requiring treatment should be started with IV 
IG and followed by plasmapheresis if not responsive to IV IG.
Grade 1 No dose modifications. For Grade 1:
Ã­ Consider, as necessary, discussing with the study physician.
Ã­ Care should be taken to monitor patients for sentinel s ymptoms 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
109of a potential decompensation as described above.
Ã­ Obtain a neurology consult.
Grade 2 Hold study drug/study regimen dose until 
UHVROXWLRQWR*UDGHÂ”
Permanently discontinue study drug/study 
UHJLPHQLILWGRHVQRWUHVROYHWR*UDGHÂ”
within 30 days or if there are signs of 
respiratory insufficiency or autonomic 
instability.For Grade 2:
Ã­ Consider, as necessary, discussing with the study physician.
Ã­ Care should be taken to monitor patients for sentinel symptoms 
of a potential decompensation as described above.
Ã­ Obtain a neurology consult
Ã­ Sensory neuropathy/neuropathic pain may be managed by 
appropriate medications (e.g., gabapentin or duloxetine).
MYASTHENIA GRAVIS:
o Steroids may be successfully used to treat myasthenia 
gravis. It is important to c onsider that steroid therapy 
(especially with high doses) may result in transient 
worsening of myasthenia and should typically be 
administered in a monitored setting under supervision 
of a consulting neurologist.
o Patients unable to tolerate steroids may be candidates 
for treatment with plasmapheresis or IV IG. Such 
decisions are best made in consultation with a 
neurologist, taking into account the unique needs of 
each patient.
o If myasthenia gravis-like neurotoxicity is present, 
consider starting AChE inhibitor therapy in addition 
to steroids. Such therapy, if successful, can also serve 
to reinforce the diagnosis.
GUILLAIN-BARRE:
o It is important to consider here that the use of steroids 
as the primary treatment of Guillain-Barre is not 
typically considered effective.
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
110o Patients requiring treatment should be started with IV 
IG and followed by plasmapheresis if not responsive 
to IV IG.
Grade 3 or 4 For Grade 3:
Hold study drug/study regimen dose until 
reVROXWLRQWR*UDGHÂ”
Permanently discontinue study drug/study 
regimen if Grade 3 imAE does not resolve 
WR*UDGHÂ”ZLWKLQGD\VRULIWKHUHDUH
signs of respiratory insufficiency or 
autonomic instability.
For Grade 4:
Permanently discontinue study drug/study 
regimen.For Grade 3 or 4 (severe or life-threatening events):
Ã­ Consider, as necessary, discussing with study physician.
Ã­ Recommend hospitalization.
Ã­ Monitor symptoms and obtain neurological consult.
MYASTHENIA GRAVIS:
o Steroids may be successfully used to treat myasthenia 
gravis. They should typically be administered in a 
monitored setting under supervision of a consulting 
neurologist.
o Patients unable to tolerate steroids may be candidates 
for treatment with plasmapheresis or IV IG.
o If myasthenia gravis-like neurotoxicity present, 
consider starting AChE inhibitor therapy in addition 
to steroids. Such therapy, if successful, can also serve 
to reinforce the diagnosis.
GUILLAIN-BARRE:
o It is important to consider here that the use of steroids 
as the primary treatment of Guillain-Barre is not 
typically considered effective.
o Patients requiring treatment should be started with IV 
IG and followed by plasmapheresis if not responsive 
to IV IG.
Myocarditis Any Grade General Guidance For Any Grade:
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
111Discontinue drug permanently if biopsy-
proven immune-mediated myocarditis.Ã­ The prompt diagnosis  of immune-mediated myocarditis is 
important, particularly in patients with baseline 
cardiopulmonary disease and reduced cardiac function. 
Ã­ Consider, as necessary, discussing with the study physician.
Ã­ Monitor patients for signs and symptoms of myocarditis (new 
onset or worsening chest pain, arrhythmia, shortness of breath, 
peripheral edema). As some symptoms can overlap with lung 
toxicities, simultaneously evaluate for and rule out pulmonary 
toxicity as well as other causes (e.g., pulmonary embolism, 
congestive heart failure, malignant pericardial effusion). A 
Cardiology consultation should be obtained early, with prompt 
assessment of whether and when to complete a cardiac biopsy,
including any other diagnostic procedures.
Ã­ Initial work-up should include clinical evaluation, BNP, 
cardiac enzymes, ECG, echocardiogram (ECHO), monitoring 
of oxygenation via pulse oximetry (resting and exertion), and 
additional laboratory work-up as indicated. Spiral CT or 
cardiac MRI can complement ECHO to assess wall motion 
abnormalities when needed.
Ã­ Patients should be thoroughly evaluated to rule out any 
alternative etiology (e.g., disease progression, other 
medications, or infections)
Grade 1
(asymptomatic with 
laboratory (e.g., BNP) 
or cardiac imaging 
abnormalities)No dose modifications required unless 
clinical suspicion is high, in which case 
hold study drug/study regimen dose 
during diagnostic work-up for other 
etiologies. If study drug/study regimen is 
held, resume after complete resolution to 
Grade 0.For Grade 1 (no definitive findings):
- Monitor and closely follow up in 2 to 4 days for clinical 
symptoms,  BNP, cardiac enzymes, ECG, ECHO, pulse 
oximetry (resting and exertion), and laboratory work-up as 
clinically indicated.
- Consider using steroids if clinical suspicion is high.
Grade 2, 3 or 4 - If Grade 2 -- Hold study drug/study For Grade 2-4:
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
112(Grade 2: Symptoms 
with mild to moderate 
activity or exertion)
(Grade 3: Severe with 
symptoms at rest or 
with minimal activity 
or exertion; 
intervention indicated)
(Grade 4: Life-
threatening 
consequences; urgent
intervention indicated 
(e.g., continuous IV 
therapy or mechanical 
hemodynamic support))regimen dose until resolution to 
Grade 0. If toxicity rapidly improves to 
Grade 0, then the decision to reinitiate 
study drug/study regimen will be based 
upon treating physicianâ€™s clinical 
judgment and after completion of 
steroid taper. If toxicity does not 
rapidly improve, permanently. 
discontinue study drug/study regimen.
If Grade 3-4, permanently discontinue 
study drug/study regimen.Ã­ Monitor symptoms daily, hospitalize.
Ã­ Promptly start IV methylprednisolone 2 to 4 mg/kg/day or 
equivalent after Cardiology consultation has determined 
whether and when to complete diagnostic procedures including 
a cardiac biopsy.
Ã­ Supportive care (e.g., oxygen).
Ã­ If no improvement within 3 to 5 days despite IV 
methylprednisolone at 2 to 4 mg/kg/day, promptly start 
immunosuppressive therapy such as TNF inhibitors 
(e.g., infliximab at 5 mg/kg every 2 weeks). Caution: It is 
important to rule out sepsis and refer to infliximab label for 
general guidance before using infliximab.
Ã­ Once the patient is improving, gradually taper steroids over 
Â•GD\VDQGFRQVLGHUSURSK\ODFWLFDQWLELRWLFVD ntifungals, or 
anti-PJP treatment (refer to current NCCN guidelines for 
treatment of cancer-related infections [Category 2B 
recommendation]).a
Myositis/Polymyositis 
(â€œPoly/myositisâ€)Any Grade General Guidance For Any Grade:
Ã­ Monitor patients for signs and symptoms of poly/myositis. 
Typically, muscle weakness/pain occurs in proximal muscles 
including upper arms, thighs, shoulders, hips, neck and back, 
but rarely affects the extremities including hands and fingers; 
also difficulty breathing and/or trouble swallowing can occur 
and progress rapidly. Increased general feelings of tiredness 
and fatigue may occur, and there can be new-onset falling, 
difficulty getting up from a fall, and trouble climbing stairs, 
standing up from a seated pos ition, and/or reaching up.
Ã­ If poly/myositis is suspected, a Neurology consultation should 
be obtained earl y, with prompt guidance on dia gnostic 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
113procedures. Myocarditis may co -occur with poly/myositis; 
refer to guidance under My ocarditis. Given breathing 
complications, refer to guidance under Pneumonitis/ILD. 
Given possibility of an existe nt (but previo usly unknown) 
autoimmune disorder, consider Rheumatology consultation.
Ã­ Consider, as necessary, discussing with the study physician.
Ã­ Initial work-up should include clinical evaluation, creatine 
kinase, aldolase, LDH, BUN/creatinine, erythrocyte 
sedimentation rate or C-reactive protein level, urine myoglobin, 
and additional laboratory work-up as indicated, including a 
number of possible rheumatological/antibody tests (i.e., 
consider whether a rheumatologist consultation is indicated and 
could guide need for rheumatoid factor, antinuclear antibody, 
anti-smooth muscle, antisynthetase [such as anti-Jo-1], and/or 
signal-recognition particle antibodies). Confirmatory testing 
may include electromyography, nerve conduction studies, MRI 
of the muscles, and/or a muscle biopsy. Consider Barium 
swallow for evaluation of dysphagia or dysphonia.
Patients should be thoroughly evaluated to rule out any alternative 
etiology (e.g., disease progression, other medications, or infections).
Grade 1
(mild pain)- No dose modifications. For Grade 1:
Ã­ Monitor and closely follow up in 2 to 4 days for clinical 
symptoms and initiate evaluation as clinically indicated.
Ã­ Consider Neurology consult.
Ã­ Consider, as necessary, discussing with the study physician.
Grade 2
(moderate pain 
associated with 
weakness; pain limiting 
instrumental activities Hold study drug/study regimen dose until 
UHVROXWLRQWR*UDGHÂ”
- Permanently discontinue study 
drug/study regimen if it does not 
UHVROYHWR*UDGHÂ”ZLWKLQGD \VRUFor Grade 2:
Ã­ Monitor symptoms daily and consider hospitalization.
Ã­ Obtain Neurology consult, and initiate evaluation.
Ã­ Consider, as necessary, discussing with the study physician.
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
114of daily living [ADLs]) if there are signs of respiratory 
insufficiency.Ã­ If clinical course is rapidly progressive (particularly if 
difficulty breathing and/or trouble swallowing), promptly start 
IV methylprednisolone 2 to 4 mg/kg/day systemic steroids 
along with receiving input from Neurology consultant 
Ã­ If clinical course is notrapidly progressive, start systemic 
steroids (e.g., prednisone 1 to 2 mg/kg/day PO or IV 
equivalent); if no improvement within 3 to 5 days, continue 
additional work up and start treatment with IV 
methylprednisolone 2 to 4 mg/kg/day
Ã­ If after start of IV methylprednisolone at 2 to 4 mg/kg/day 
there is no improvement within 3 to 5 days, consider start of 
immunosuppressive therapy such as TNF inhibitors 
(e.g., infliximab at 5 mg/kg every 2 weeks). Caution: It is 
important to rule out sepsis and refer to infliximab label for 
general guidance before using infliximab.
Ã­ Once the patient is improving, gradually taper steroids over 
Â•GD\VDQGFRQVLGHUSURSK\ODFWLFDQWLELRWLFVDQWLIXQJDOVRU 
anti-PJP treatment (refer to current NCCN guidelines for 
treatment of cancer-related infections [Category 2B 
recommendation]).a
Grade 3 or 4
(pain associated with 
severe weakness; 
limiting self-care 
ADLs)For Grade 3:
Hold study drug/study regimen dose until 
UHVROXWLRQWR*UDGHÂ”
Permanently discontinue study drug/study 
regimen if Grade 3 imAE does not resolve 
WR*UDGHÂ”ZLWKLQGD\VRULIWKHUHDUH
signs of respiratory insufficiency.
For Grade 4:
- Permanentl y discontinue stud y For Grade 3 or 4 (severe or life-threatening events):
Ã­ Monitor symptoms closely; recommend hospitalization.
Ã­ Obtain Neurology consult, and complete full evaluation.
Ã­ Consider, as necessary, discussing with the study physician.
Ã­ Promptly start IV methylprednisolone 2 to 4 mg/kg/day 
systemic steroids along with receiving input from Neurology 
consultant.
Ã­ If after start of IV methylprednisolone at 2 to 4 mg/kg/day 
there is no improvement within 3 to 5 days, consider start of 
immunosu ppressive thera py such as TNF inhibitors 
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
115aASCO Educational Book 2015 â€œManaging Immune Checkpoint Blocking Antibody Side Effectsâ€ by Michael Postow MD.
bFDA Liver Guidance Document 2009 Guidance for Industry: Drug Induced Liver Injury â€“ Premark eting Clinical Evaluation.
AChE Acetylcholine esterase; ADL Activities of daily living; AE Adverse event; ALP Alkaline phosphatase test; ALT Alanine amino transferase; AST Aspartate aminotransferase; 
BUN Blood urea nitrogen; CT Computed tomography; CTCAE Common Terminology Criteria for Adverse Events; ILD Interstitial lung di sease; imAE immune-mediated 
adverse event; IG Immunoglobulin; IV Intravenous; GI Gastrointe stinal; LFT Liver function tests; LLN Lower limit of normal; MRI   Magnetic resonance imaging; NCI  
National Cancer Institute; NCCN  National Comprehensive Cancer Network; PJP Pneumocystis jirovecii pneumonia (formerly known as Pneumocystis carinii pneumonia); 
PO  By mouth; T3 Triiodothyronine; T4 Thyroxine; TB Total bilir ubin; TNF Tumor necrosis factor; TSH Thyroid-stimulating hormone;  ULN Upper limit of normal.drug/study regimen. (e.g., infliximab at 5 mg/kg every 2 weeks). Caution: It is 
important to rule out sepsis and refer to infliximab label for 
general guidance before using infliximab.
Ã­ Consider whether patient may require IV IG, plasmapheresis.
Ã­ Once the patient is improving, gradually taper steroids over 
Â•GD\VDQGFRQVLGHUSURSK\ODFWLFDQWLELRWLFVDQWLIXQJDOVRU 
anti-PJP treatment (refer to current NCCN guidelines for 
treatment of cancer-related infections [Category 2B 
recommendation]).a
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
116
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
117Infusion-Relat ed Reactions
Severity Grade of the 
Event (NCI CTCAE 
version 4.03)Dose Modifications Toxicity Management
Any Grade General Guidance For Any Grade:
Ã­ Manage per institutional standard at the discretion of investigator.
Ã­ Monitor patients for signs and symptoms of infusion-related 
reactions (e.g., fever and/or shakin g chills, flushing and/or itching, 
alterations in heart rate and blood pressure, dyspnea or chest 
discomfort, or skin rashes) and anaphylaxis (e.g., generalized 
urticaria, angioedema, wheezing, hypotension, or tachycardia).
Grade 1 or 2 For Grade 1:
The infusion rate of study drug/study regimen may be decreased 
by 50% or temporarily interrupted until resolution of the event.
For Grade 2:
The infusion rate of study drug/study regimen may be decreased 
50% or temporarily interrupted until resolution of the event.
Subsequent infusions may be given at 50% of the initial 
infusion rate.For Grade 1 or 2:
Ã­ Acetaminophen and/or antihistamines may be administered per 
institutional standard at the discretion of the investigator.
Ã­ Consider premedication per ins titutional standard prior to 
subsequent doses.
Ã­ 6WHURLGVVKRXOGQRWEHXVHGIRUURXWLQHSUHPHGLFDWLRQRI*UDGH Â”
infusion reactions.
Grade 3 or 4 For Grade 3 or 4:
Permanently discontinue study drug/study regimen.For Grade 3 or 4:
Ã­ Manage severe infusion-related reactions per institutional 
standards (e.g., IM epinephrine, followed by IV diphenhydramine 
and ranitidine, and IV glucocorticoid).
CTCAE Common Terminology Criteria for Adverse Events; IM intr amuscular; IV intravenous; NCI National Cancer Institute.
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
118
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
119Non â€“Immune -Mediated Reactions
Severity Grade of the Event 
(NCI CTCAE version 4.03)Dose Modifications Toxicity Management
Any Grade Note: Dose modifications are not required for AEs not deemed to 
be related to study treatment (i.e., events due to underlying 
disease) or for laboratory abnormalities not deemed to be 
clinically significant.Treat accordingly, as per institutional standard.
Grade 1 No dose modifications. Treat accordin gly, as per institutional standard.
Grade 2 +ROGVWXG\GUXJVWXG\UHJLPHQXQWLOUHVROXWLRQWRÂ”*UDGHRU
baseline.Treat accordingly, as per institutional standard.
Grade 3 +ROGVWXG\GUXJVWXG\UHJLPHQXQWLOUHVROXWLRQWRÂ”*UDGHRU
baseline.
)RU$(VWKDWGRZQJUDGHWRÂ”*UDGHZLWKLQGD\VRUUHVROYHWR
Â”*UDGHRUEDVHOLQHZLWKLQGD\VUHVXPHVWXG\GUXJVWXG\
regimen administration. Otherwise, discontinue study drug/study 
regimen.Treat accordingly, as per institutional standard.
Grade 4 Discontinue study drug/study regimen (Note: For Grade 4 labs, 
decision to discontinue should be based on accompanying 
clinical signs/symptoms, the Inves tigatorâ€™s clinical judgment, and 
consultation with the Sponsor.).Treat accordingly, as per institutional standard.
Note: As applicable, for early phase studies, the following sentence may be added: â€œAny event greater than or equal to Grade 2,  please discuss with Study Physician.â€
AE Adverse event; CTCAE Common Terminology Criteria for Adverse Events; NCI National Cancer Institute.
Abbreviated Title: antiPDL1, antiCTLA4 & radiation
Version Date: 08/24/2018
120